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CELL-TAUGHT GENE THERAPY FOR THE PRESERVATION AND
REGENERATION OF CARDIAC TISSUE FOLLOWING CHRONIC
HEART FAILURE

SRIVIDYA SUNDARARAMAN

ABSTRACT

Heart failure is the primary cause of mortality and morbidity in the Western world.
Although cell therapy has demonstrated improvement in cardiac function, these benefits
are being attributed to the activation of paracrine factors, rather than the differentiation
and integration of the transplanted cells into the host tissue. Based on this knowledge the
focus of this thesis work was to deliver paracrine factors, and evaluate its effect on
cardiac function.

Gene therapy has evolved as a promising option to deliver pro-angiogenic proteins to
infarct zones, thus providing cardiac benefit. This study has identified a gene design
without the use of viral vectors, to deliver transient, yet therapeutic levels of an
angiogenic chemokine, Stromal-Derived-Cell-Factor-1 (SDF-1) in rodents with chronic
heart failure, and has reported significant improvement in cardiac function. The use of
Kozak sequences and translational enhancers helped boost gene expressions which could
be accurately measured using bio-fluorescence imaging techniques. This improvement in
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gene expression was directly proportional to the improvement in cardiac function in
rodents with chronic heart failure.

However effective plasmid delivery, via the systemic route, requires the
encapsulation and targeting of the plasmid to infarct zones. An infarct-specific peptide
was identified with the help of phage panning techniques and nanoparticles, formulated
with poly lactide-co-glycolide (PLGA), were employed to encapsulate a fluorescent dye,
6-Coumarin (6C). Targeted and efficient delivery was achieved by tagging the surface of
the nanoparticles with the targeting peptide. Another aspect of this study was to identify
novel paracrine factors responsible for reverse ventricular remodeling, following the
treatment of chronic heart failure with mesenchymal stem cell (MSC) therapy, using
microarray analysis.

Overall, this study has identified the design and delivery technique for a therapeutic,
cardiac-benefitting gene to the infarct zone, in rodents with heart failure. These results
can be translated to a clinical setting, providing relief to patients with chronic heart
failure. This study has also paved the way for future research in developing novel cardiac
drugs, by identifying cardiac specific genes, responsible for reverse ventricular
remodeling.

vii

TABLE OF CONTENTS
Page
ABSTRACT……………………………………………………………………………..vi
LIST OF TABLES ……………………………………………………………………...xv
LIST OF FIGURES …………………………………………………………………….xvi

CHAPTER
I

INTRODUCTION ............................................................................................................ 1
1.1 Research Interest in Heart Failure ............................................................................ 1
1.2 Chemokine Mediated Repair .................................................................................... 3
1.3 Research Focus .......................................................................................................... 6
1.4 Specific Aims ............................................................................................................ 7

II

BACKGROUND ............................................................................................................ 12
2.1 Cardiovascular Disease ........................................................................................... 12
2.1.1 Myocardial Infarction:................................................................................. 13
2.1.2 Heart Failure ................................................................................................ 14
2.2 Current Treatment Options for Heart Failure ........................................................ 16
2.2.1 Cardiac Devices ........................................................................................... 16
2.2.2 Cell Therapy for Heart Failure.................................................................... 17
2.2.3 Cell Taught Gene Therapy .......................................................................... 20
2.3 Stem Cell Therapy for Cardiac Failure .................................................................. 21
2.3.1 Homing Factors ........................................................................................... 23
2.3.2 Role of SDF-1 in Acute Myocardial Infarction ......................................... 25

viii

2.3.3 Role of SDF-1 in CHF ................................................................................ 27
2.3.4 Molecular Mechanisms Involved in SDF-1 CXCR4 axis ......................... 28
2.4 Overview on Gene Therapy .................................................................................... 29
2.4.1 Gene Therapy in Heart Failure ................................................................... 30
2.4.2 Advantages and Disadvantages of Gene Therapy ..................................... 31
2.4.3 Non Viral verses Viral Constructs .............................................................. 33
2.4.4 Naked Plasmids ........................................................................................... 35
2.4.5 Translational Enhancers .............................................................................. 36
2.4.6 Transfection Agents..................................................................................... 37
2.5 Encapsulation and Systemic Gene Delivery .......................................................... 38
2.5.1 Poly Lactide co Glycolide nanoparticles.................................................... 38
2.5.2 Targeting Factors ......................................................................................... 41
2.6 Phage Panning ......................................................................................................... 44
2.7 Gene Profiles in Tissue Regeneration .................................................................... 46
2.7.1 Whole Genome Analysis............................................................................. 47
2.7.2 Pathway Studies ........................................................................................... 49
III GENERAL METHODS................................................................................................. 50
3.1 Cell Culture.............................................................................................................. 50
3.1.1 Harvesting Rat Mesenchymal Stem Cells .................................................. 50
3.1.2 Isolation of Cardiac Fibroblasts .................................................................. 51
3.1.3 Stem Cell (Mesenchymal Stem Cell) culture............................................. 51
3.1.4 Cardiac Fibroblasts culture ......................................................................... 52
3.1.5 Cell Freezing ................................................................................................ 52

ix

3.2 Plasmid Constructions ............................................................................................ 53
3.2.1 pCMV ........................................................................................................... 53
3.2.2 pCMVe ......................................................................................................... 53
3.2.3 pMHC ........................................................................................................... 54
3.2.4 pMHCe ......................................................................................................... 54
3.2.5 Plasmid Amplification and Validation ....................................................... 55
3.3 Animal Handling ..................................................................................................... 55
3.3.1 LAD Ligations ............................................................................................. 56
3.4 Tissue Fixation and Staining .................................................................................. 57
3.4.1 Harvesting Rodent Organs .......................................................................... 57
3.4.2 Paraffin Embedding ..................................................................................... 57
3.4.3 Embedding in OCT for frozen sections...................................................... 57
3.4.4 Masson’s Trichrome Staining ..................................................................... 58
3.4.5 Immunohistochemistry ................................................................................ 58
3.5 Isolation of total RNA ............................................................................................. 59
3.6 Preparation of cRNA ............................................................................................... 59
3.7 Imaging .................................................................................................................... 60
3.7.1 Xenogen IVIS .............................................................................................. 60
3.7.2 Echocardiography ........................................................................................ 61
3.7.3 Confocal Microscopy Analysis................................................................... 62
3.8 Nanoparticle Formulation ....................................................................................... 62
3.8.1 Conjugation of nanoparticles with RR peptide .......................................... 63
3.8.2 High Performance Liquid Chromatography .............................................. 63

x

3.9 Statistical Analysis .................................................................................................. 64
IV IN VIVO BIO-FLUORESCENCE IMAGING FOR GENE EXPRESSION.............. 65
4.1 Introduction ............................................................................................................. 65
4.2 Methods: .................................................................................................................. 69
4.2.1 Experimental Plan........................................................................................ 69
4.2.2 Optical Imaging System .............................................................................. 69
4.2.3 Image analysis.............................................................................................. 70
4.2.4 Plasmids Used .............................................................................................. 70
4.2.5 In Vitro Expression...................................................................................... 71
4.2.6 In Vivo Expression ...................................................................................... 71
4.3 Results ...................................................................................................................... 71
4.3.1 Plasmid expression in H9C2 cell lines ....................................................... 71
4.3.2 Evaluation of Gene Expression in rodents ................................................. 73
4.3.3 Dose-response of cardiac gene transfer ...................................................... 74
4.3.4 Time course of vector expression in the heart ........................................... 75
4.3.5 Comparison of peak magnitude between the different plasmids .............. 75
4.3.6 Role of promoters and backbones in plasmid design ................................ 76
4.3.7 Role of Transcriptional Enhancers in plasmid design ............................... 77
4.4 Discussion ................................................................................................................ 78
V

SDF-1 GENE TRANSFER FOR HEART FAILURE ................................................. 80
5.1 Introduction ............................................................................................................. 80
5.2 Methods: .................................................................................................................. 83
5.2.1 Experimental Plan........................................................................................ 83

xi

5.2.2 Plasmids Used .............................................................................................. 83
5.2.3 Intramyocardial Gene Delivery .................................................................. 84
5.2.4 Echocardiographic Analysis ....................................................................... 84
5.2.5 Immunohistochemistry ................................................................................ 85
5.2.6 Masson’s Trichrome Staining ..................................................................... 86
5.3 Results: ..................................................................................................................... 86
5.3.1 Intra-myocardial injection of SDF-1 plasmid increased vessel density ... 86
5.3.2 SDF-1 plasmid therapy improves ventricular function in ischemic rats .. 89
5.3.3 SDF-1 gene transfer reduced fibrotic tissue in the infarct zone ............... 92
5.4 Discussion ................................................................................................................ 94
VI IDENTIFICATION OF TARGETING PEPTIDES..................................................... 97
6.1 Introduction ............................................................................................................. 97
6.1.1 Mechanism of phage panning ................................................................... 100
6.2 Methods: ................................................................................................................ 101
6.2.1 Phage Panning............................................................................................ 101
6.2.2 Peptide Synthesis and Analysis ................................................................ 102
6.2.3 Immunohistochemistry .............................................................................. 102
6.3 Results .................................................................................................................... 103
6.3.1 Identification of targeting peptide ............................................................ 103
6.3.2 Synthetic Peptide Formulation and Analysis ........................................... 104
6.3.3 In Vivo Expression Profile of the RR peptide .......................................... 105
6.3.4 BLAST Analysis of the targeting peptide ................................................ 106
6.4 Discussion .............................................................................................................. 108

xii

VII NANOPARTICLES AS CARRIERS FOR SYSTEMIC DELIVERY .................... 110
7.1 Introduction ........................................................................................................... 110
7.2 Methods ................................................................................................................. 113
7.2.1 Materials ..................................................................................................... 113
7.2.2 Formulation of 6C loaded PLGA nanoparticles ...................................... 114
7.2.3 Conjugation of targeting peptide: ............................................................. 115
7.2.4 Nanoparticle characterization ................................................................... 116
7.2.5 In vitro expression and uptake of 6-coumarin ......................................... 116
7.2.6 Extraction and quantitation of 6C fluorescence in cells .......................... 117
7.2.7 Confocal Microscopy Analysis................................................................. 117
7.2.8 In vivo Expression Analysis ...................................................................... 118
7.2.9 HPLC Analysis .......................................................................................... 118
7.3 Results .................................................................................................................... 119
7.3.1 Formulation of Nanoparticles ................................................................... 119
7.3.2 Particle Size Analysis and Zeta Potential................................................. 119
7.3.3 In vitro Expression Analysis ..................................................................... 120
7.3.4 Time for Uptake ......................................................................................... 122
7.3.5 HPLC Analysis with in vitro particle study ............................................. 124
7.3.6 In vivo nanoparticle uptake in rodents...................................................... 126
7.4 Discussion .............................................................................................................. 128
VIII IDENTIFYING CARDIAC PATHWAYS INVOLVED IN REVERSE
VENTRICULAR REMODELING ............................................................................. 131
8.1 Introduction ........................................................................................................... 131

xiii

8.2 Methods ................................................................................................................. 134
8.2.1 Experimental Plan...................................................................................... 134
8.2.2 Isolation of MSCs ...................................................................................... 135
8.2.3 Isolation of Cardiac Fibroblasts ................................................................ 135
8.2.4 Transfection of Cardiac Fibroblasts with MCP-3.................................... 136
8.2.5 Experimental animals ................................................................................ 136
8.2.6 Intramyocardial Cardiac Fibroblast delivery ........................................... 136
8.2.7 Infusion of Mesenchymal Stem Cells ...................................................... 137
8.2.8 Isolation of total RNA ............................................................................... 137
8.2.9 Preparation of cRNA ................................................................................. 138
8.2.10 Affymetrix Analysis .................................................................................. 138
8.3 Results .................................................................................................................... 139
8.3.1 Stem cell therapy improves cardiac function in chronic heart failure ....139
8.3.2 Identification of pathways and genes involved in cardiac repair ...........140
8.3.3 RT PCR Analysis for individual paracrine factors .................................. 142
8.3.4 Pathway Analysis with Ingenuity Pathway Analysis Software ..............143
8.4 Discussion .............................................................................................................. 158
IX SUMMARY AND CONCLUSIONS ......................................................................... 161
BIBLIOGRAPHY ................................................................................................................ 167

xiv

LIST OF TABLES

Table 2-1: Comparison between viral and plasmid vectors for gene delivery ................... 35
Table 2-2: Various parameters involved in gene delivery .................................................. 36
Table 4-1 : Comparison of maximum expression time between the plasmids. .................. 75
Table 8-1 : Animal groups involved in stem cell therapy ................................................. 134
Table 8-2 : Genes of secreted proteins involved in cardiac repair with MSC therapy ....142
Table 8-3 : Genes associated with cardiac function ........................................................... 158

xv

LIST OF FIGURES

Figure 2-1: Role of SDF-1 in AMI as a homing factor for stem cells ................................ 25
Figure 2-2 : Schematic of the encapsulation of DNA within PLGA nanoparticles ........... 42
Figure 2-3 : Schematic of a microarray chip ........................................................................ 48
Figure 4-1 : Illustration of the mechanism involved in bioluminescent imaging. ............. 68
Figure 4-2: Plasmid design and in vitro expression profile. ................................................ 72
Figure 4-3 : Gene expression in vivo in 8 week old rodents................................................ 73
Figure 4-4 : Dose curve to determine optimal amount of plasmid in vivo ......................... 74
Figure 4-5 : Expression profile between various plasmid designs in vivo ......................... 76
Figure 4-6 : Peak expression profile between various plasmids in vivo ............................. 78
Figure 5-1: Vessel density count (vessels / mm2) in rodents that received SDF-1 gene ... 88
Figure 5-2 : Increase in blood vessels following SDF-1 gene therapy ............................... 88
Figure 5-3 : Actin staining to determine the vessels to be arterioles .................................. 89
Figure 5-4 : Functional benefit observed in vivo with SDF-1 plasmid treatment .............. 91
Figure 5-5 : Sustenance of benefit for 8 weeks post treatment ........................................... 91
Figure 5-6 : Other physiological parameters associated with benefit ................................. 92
Figure 5-7 : Masson’s Trichrome staining to determine infarct sizes in vivo .................... 93
Figure 5-8 : Decrease in fibrotic scar following SDF-1 treatment...................................... 93
Figure 6-1 : Mechanism of in vivo phage panning technique in rodents. ......................... 101
Figure 6-2 : Phage panning to determine a targeting sequence to the ischemic heart .....104
Figure 6-3 : Specificity of peptide interaction with heart tissues ...................................... 106
Figure 6-4 : BLAST Analysis of the peptide sequence with other known proteins ........107

xvi

Figure 7-1 : Dose response with un-conjugated nanoparticles encapsulating 6C............121
Figure 7-2 : Time response with un-conjugated nanoparticles encapsulating 6C............123
Figure 7-3 : Time response of nanoparticles with 6C conjugated with RR peptide ........124
Figure 7-4 : In vitro HPLC analysis to determine amount of 6C in cardiac fibroblasts ..125
Figure 7-5 : In vivo HPLC analysis between infarct and healthy regions of the heart ....127
Figure 7-6 : Difference in uptake in infarcted tissue with conjugation of nanoparticles 127
Figure 8-1 : Change in cardiac function with MSC therapy in vivo ................................. 140

xvii

CHAPTER I

INTRODUCTION

1

1.1

INTRODUCTION

Research Interest in Heart Failure

Heart failure is a major cause of morbidity and mortality in the modern world. The
conventional therapies involve a replacement of the tissue, either by designing total
artificial hearts made with the use of biocompatible metals, or using a xenogenic
transplant. However, the number of patients who die every year, or who are at risk has
increased dramatically, leading researchers to focus on preventing the occurrence of an
acute myocardial infarction, or to repair the tissue and thus provide relief to the chronic
conditions associated with it and improving the quality of life.

Ischemic heart disease, caused by reduced blood supply in the heart and thus the
damage associated with it, is a leading cause for heart failure. Current therapies involve
preventive measures in order to stop cardiac myocyte loss in an acute stage, or to
1

optimize the reversal of ventricular remodeling in a chronic condition. The heart is a
highly aerobic organ requiring a constant supply of oxygen in order to continue its
function. The cells of the heart, specially the muscle cells or myocytes, are terminally
differentiated and thus do not repair themselves following damage. A reduction in
oxygen, due to reduced blood supply, can lead to the death of the cells in that tissue,
almost immediately.

This damage elicits an inflammatory process where the dead muscle cells are
replaced by a scar region, which is not an ideal replacement to the loss in function. This
action, then leads to a cascade of lower cardiac output and the compensation mechanisms
caused henceforth. The combination of ventricular fibrosis, muscle cell hypertrophy,
dilation of the ventricle, thickening of the ventricular wall, and thinning of the scar tissue
is termed ventricular remodeling. These pathological conditions are symptomatic of a
more progressive condition known as chronic heart failure.

Current research is now focused on reversing this ventricular remodeling, by
inducing angiogenesis in the infarct region, thus providing oxygen to injured myocardium
in the infarct border zones, or in triggering a cascade of pathways that can provide the
right signals to regenerate the myocardium either with the concomitant use of stem cells
or without.

2

1.2

Chemokine Mediated Repair

Cell therapy has evolved as a promising option for cardiac repair for more than a
decade. Pre-clinical and clinical studies have demonstrated the potential of skeletal
myoblasts, multiple autologous or syngeneic stem cell populations, including
Hematopoietic (HSC), Mesenchymal (MSC) Stem Cells, and Multipotent Adult
Progenitor Cells (MAPC) to improve cardiac function when delivered in the peri-infarct
period in animal models as well as human trials. For cell therapy to provide substantial
clinical impact, the cells transplanted should be able to survive in a hypoxic environment
and must protect themselves from being degraded by the host’s immune system. The
other option for successful cell therapy is to use multipotent stem cells, capable of
differentiating to the cells of the cardiac lineage and then engrafting into the host tissue to
replace the damaged or dying cells.

Although cell therapy has shown to provide cardiac functional benefit by improving
the cardiac output, there is limited evidence that point to the improvement as arising from
the differentiation of these cells to cardiac myocytes. This has led to the belief that the
improvement in cardiac function is not due to regeneration of the myocardium but rather
due to the paracrine effects which then help improve angiogenesis, matrix remodeling,
cell signaling to help stem cells from the bone marrow to home to the ischemic
myocardium, and cell survival to name a few.

3

Consistent with this hypothesis are recent studies by us and others, demonstrating
that the benefit of stem cell therapy is increased by the over-expression of specific factors,
namely Stromal Derived Cell factor -1 (SDF-1), Monocyte Chemoattractant Protein-3
(MCP-3), and others.

The over-expression of SDF-1, in ischemic tissue, leads to

increased stem cell homing, neovascularization, and preservation of cardiac myocytes
due to the binding of SDF-1 to its receptor CXCR4, which is present on the cell surface
of hematopoietic cell populations. Although SDF-1 is shown to be elevated in injured
tissue; the naturally occurring transient increase of this chemokine, is not sufficient to
provide a significant improvement in cardiac function.

Other studies in our laboratory have demonstrated that MSC home to myocardial
tissue in response to MCP-3 when transfected a month after inducing myocardial
infarction in rodents, and that re-establishment of MCP-3 weeks after AMI re-establishes
MSC homing to the heart leading to ventricular remodeling and improved function.
However the pathways that mediate the benefits associated with cardiac remodeling are
poorly defined. Similar results are obtained from varied stem cell sources with limited
evidence that these different cell types actually differentiate into cardiac myocytes. The
conclusion that the majority of the improvement observed is not due to the regeneration
of cardiac myocytes, but rather due to the paracrine factors released by the engrafted stem
cells, has led to growing number of research in identifying these paracrine factors.

Sophisticated software is currently available to analyze and identify the changes in
gene expression following cell therapy. The use of whole genome analysis is made
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possible with the help of Affymetrix’s and Ilumina’s software systems, that can identify
changes in gene behavior, whether it is differential or not. Other software, such as
DAVID and Ingenuity Pathway Analysis, provide effective techniques in order to
decipher the information present in the large datasets.

Gene therapy has provided an efficient method of expressing these chemokines in
vivo and assessing their effects in animal models. In cardiac applications, this method has
evolved as a potential target for encoding angiogenic proteins which lead to repair of the
myocardium, following a promotion of blood vessel growth in the injured area, which
helps revive the hibernating myocardium. Although, this is a promising field and the
expectation is that it can provide functional benefit, there are no clinically approved gene
therapy treatment options available today. One reason is that most gene therapy trials use
viral techniques, which pose a serious threat to the life of the patient due to
immunological reactions, and tumor developing potentials.

The alternative method is to use naked plasmid or DNA which then has a drawback
of having low transcription efficiencies, and the potential to degrade in the host
environment. In order to bridge this gap between low transcription and immunological
reactions, it is necessary to understand mechanisms which will provide a platform for
high transcriptions and not pose a risk towards pathological damage. Another concern to
be addressed with gene therapy is to avoid the degradation of these genes in the host
tissue when delivered systemically. The use of polymeric devices has gained popularity

5

in order to optimize the delivery of plasmids to specific organs with the focus being on
safety and efficacy.

1.3

Research Focus

Our overall goal with this thesis is to determine a gene therapy based approach to
provide benefit to myocardium with chronic heart failure, stemming from ischemic injury.
We would like to develop and optimize a gene drug, which effectively translates to a
cardiac benefiting protein and can provide significant improvements in cardiac function.
Towards this main goal of designing and delivering a cardiac benefiting gene drug, we
would like to optimize the delivery of this drug by understanding the principles required
to systemically deliver this to the injured cardiac tissue. Having done that, we would have
developed a drug, capable to providing cardiac relief that can be delivered systemically to
patients, thus minimizing the trauma associated with multiple surgeries.

However, the need for more efficient drugs to support the prevention and
regeneration of cardiac tissue, and reverse the remodeling caused by ischemic injury,
leads us to focus on other cardiac pathways, responsible for this remodeling, following
treatment with mesenchymal stem cells. This will provide us with leads to follow, in
future, for other candidates that may be able to provide a better benefit to the
myocardium and improve quality of life in patients.

6

1.4

Specific Aims

Hypothesis 1

Adult stem cell therapy for preventing and treating cardiac dysfunction is due to
paracrine factors; therefore, the results of cell therapy can be achieved by gene transfer.
To effectively design a gene it is necessary to manipulate the gene expression in vivo. A
bioluminescent reporter can be used as a method to determine real time information on
gene expression for plasmid profiling. This reporter will utilize optical imaging in order
to determine changes in expression of a plasmid with the reporter gene and other
enhancer elements.

Specific Aim 1

The goal of this study was to determine if re-establishing myocardial plasmid SDF-1
expression without the concomitant delivery of cells would provide a significant benefit
in cardiac function by increasing myocardial vascular density in an ischemic
cardiomyopathy condition. This study aimed to design and monitor the expression of the
naked plasmid for effective gene therapy capable of expressing and sustaining expression
in rodent hearts. We also wanted to evaluate if optical imaging could provide detailed
information about changes in gene expression, with modifications to the plasmid design.
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Therefore, the primary focus of this study was to investigate the role of naked SDF-1
gene when delivered in chronic ischemic hearts in vivo. Transient expressions of the
naked SDF-1 plasmids were monitored for corresponding functional responses mediated
in rodent ischemic hearts. To manipulate gene expressions, our secondary focus was to
identify a gene design for efficient delivery of the SDF-1 gene into the ischemic
myocardium. We investigated the role of transcription enhancers, Kozak sequences, and
cardiac specific promoters for this purpose.

Hypothesis 2

A safe, effective and targeted delivery of naked plasmid to the heart, without having
to reopen the chest, is important for targeted, systemic delivery of drugs to the
myocardium. Infusion of phage display libraries within M13 bacteriophage may be useful
in identifying specific targeting ligands in the infarct region of the heart.

Poly lactide co glycolide (PLGA) derived polymeric devices may be able to
encapsulate drugs and deliver them safely to tissues via the systemic circulation. The
targeting peptide when tagged to the polymeric complex, may be viable and in its active
form, and will be able to direct the polymeric complex to the injured myocardium. The
PLGA polymer will then be able to release the encapsulated material into the area of
injury.
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Specific Aim 2

The main focus with this aim was to engineer a targeted delivery carrier for gene
drugs into the ischemic myocardium. The delivery of genes involves two complicated
aspects: the targeting of the gene into the region of interest, and carriers for the
maintenance and delivery of the gene in vivo without degrading it. Our primary focus was
divided into two secondary focuses, a) To identify a peptide sequence, via phage panning
to target the genes to the ischemic myocardium when injected intra-venously, b) to utilize
nanoparticles for the encapsulation of the naked genes to prevent degradation of the DNA
and tagging targeting peptides to the surface of these devices to mediate effective
delivery of the DNA.

We wanted to identify one or a few ligands that have a high affinity for infarct tissue
and are specific to the heart. This can then be used to tag polymeric devices to infuse
therapeutic genes to the ischemic myocardium. Our goal then, was to design a
nanoparticlulate carrier capable of encapsulating a fluorescent dye, and delivering it to
the myocardium, with the help of a tagging peptide. The uptake and in vivo trafficking
will be monitored to determine the dose, time, and other aspects associated with this
delivery system.
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Hypothesis 3

Recruitment of stem cells mediated improvement, in ventricular function is due to
reverse ventricular remodeling. In previous studies, we have shown that Monocyte
Chemoattractant Protein -3 (MCP-3) based recruitment of mesenchymal stem cell therapy
leads to the expression of paracrine factors capable of improved ventricular function
without the differentiation of cardiac myocytes, or blood vessel growth in the
microenvironment. This reverse ventricular remodeling is attributed to paracrine factors
secreted in the microenvironment.

Whole genome analysis provides sophisticated, yet specific information on all genes
in the genome that are affected as a result of the application of therapy. Therefore whole
genome analysis would be a viable option to identify pathways associated in the changes
that lead to functional improvement thereby leading us to paracrine factors associated
with this improvement.

Specific Aim 3

The primary focus of this aim is to identify cardiac pathways associated with
reversing ventricular remodeling, following therapy with mesenchymal stem cells and
then identifying proteins associated with ischemic disease and repair.
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The goal is to identify candidate proteins responsible for the improvement in cardiac
function when mesenchymal stem cells are recruited to the injured heart tissue due to
MCP-3 over-expression. To understand and identify these proteins and pathways we shall
employ whole genome analysis and back that with pathway analysis studies. Important
aspects of genome wide experiments will be the large number of genes assessed and the
high sensitivity of this approach.

11

CHAPTER II

BACKGROUND

2

2.1

BACKGROUND

Cardiovascular Disease

Cardiovascular disease ranks among the leading causes of morbidity and mortality in
the world today with more than 80 million people who suffer from one or more forms of
it, just in the United States. Cardiovascular disease is a pathological condition affecting
the normal functioning of the heart due to an injured or overworked heart muscle, or an
electrical imbalance determining the rhythm. These fall under a general umbrella of four
types; dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy
and arrhythmogenic cardiomyopathy. The causes for any of these forms can be due to
bacterial or viral infections, genetic mutations and predispositions, the growth and build
up of fatty components in the arteries and heart walls, abuse of cardio toxic substances,
like caffeine and alcohol, or a secondary symptom of other chronic conditions, such as
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hypertension and diabetes. Any or all of these forms have the potential to develop into a
more progressive heart failure. While each of these conditions can cause a clinically
significant cardiomyopathy, the focus of this work is primarily on ischemic
cardiomyopathy.

2.1.1

Myocardial Infarction:

One of the more common types of cardiovascular diseases is Myocardial Infarction
(or Acute Heart Attack) which occurs when there is a lack of blood supply to the heart.
This condition affects more than 8 million people in the United States with 1.1 more
being added each year.1

The most common cause is due to a coronary artery disease

(CAD); when a plaque ruptures and causes intra coronary thrombosis and disrupt blood
flow, distal to thrombosis. The extent of damage to the heart depends on the duration of
ischemia, and can lead to permanent damage if not treated immediately.

The cells of the heart tissue are terminally differentiated and thus do not repair
themselves following damage. Following lack of blood supply, the myocytes, endothelial
cells, nerves and fibroblasts die by a process called necrosis. This is then followed by an
influx

of inflammatory

components,

including

macrophages,

neutrophils and

granulocytes that replace the viable muscle with a dead scar region, which is not an ideal
replacement to the loss in function. The ventricular wall with a scar tissue lining which is
unable to contract during the pumping action of the heart is not able to provide the same
cardiac output as a healthy, viable wall. To compensate for this loss in output the
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ventricle enlarges by either hypertrophy of the cardiac cells or by increase in ventricular
volume, corresponding to thinning of the scar tissue. These conditions lead to a
progressive heart failure condition.2, 3

Damaged heart, incapable of pumping the right amount of blood, can also lead to a
life threatening condition, cardiac arrhythmia. Cardiac arrhythmias are conditions when
the heart is unable to synchronize its pumping action thus causing abnormal beats or
rhythms. Often times this leads to insufficient supply of blood pumped from the heart and
may lead to cardiac arrest.4

2.1.2

Heart Failure

The combination of ventricular fibrosis, muscle cell hypertrophy, dilation of the
ventricle, thickening of the ventricular wall, and thinning of the scar tissue is termed
ventricular remodeling. These pathological conditions are symptomatic of a more
progressive condition known as chronic heart failure.3, 5

Heart failure is among the leading causes of morbidity in the Western world, with a
prevalence of 5.4 million Americans and an incidence of 690,000 cases being added each
year. Coronary Artery Disease leading to Acute MI is the most common cause for heart
failure. Other causes may be due to some or various forms of cardiomyopathy, attributed
by genetic dispositions, personal lifestyles, cardio toxic abuse, pregnancy, radiation, and
other chronic conditions such as diabetes, hypertension etc.
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As heart failure is a progressive condition, the diseased state is classified into various
classes based on the quality of life, class 1 for patients who are least affected physically
by the condition and class 4 for those who are severely limited in their day to day activity
and class 2 and 3 in between these two. Pathologically, the disease is classified based on
the condition of the heart muscle, Stage 1 is a classification for patients at risk for heart
disease, due to lifestyle choices, or secondary conditions but with no cardiac tissue
compromise. Stage 4 is assigned to patients with structural heart disease and previous
symptoms of heart failure.3, 6

The same pathways that are triggered as a response to acute cardiac injury, when
sustained for longer periods of time, lead to a progression of events causing chronic heart
failure.

Some of these are mediators present in the circulatory system, such as

angiotensin II,7, 8 which is released as a result of low cardiac output can lead to increase
in cardiac hypertrophy, others such as norepinephrine, cause cardiotoxicity and
arrhythmias,9 and TNF-α which decrease contractility.10 A family of peptides, also used
as a diagnostic tool, is β-natriuretic peptides that are released as a response to increased
ventricular pressure, can cause vasodilation.11 These cytokines released in response to
myocardial injury, can worsen cardiac and endothelial dysfunction with the progression
to heart failure.
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2.2

Current Treatment Options for Heart Failure

Heart failure is not an isolated event that can be controlled or reversed after its
occurrence. The current treatment options involve alleviating the symptoms associated
with it and preventing a worsening of the condition. There are currently no available
options to entirely cure a person of this condition. For patients without any structural
damage or physical limitations, the simplest solution is to prevent the occurrence for one.
This involves a few drugs that can help prevent the damages caused by secondary
components. However, these are not sufficient for patients dealing with advanced stages
of heart failure thus a number of other treatment options have been developed in the last
few decades that support the heart from assistance to total replacement.

2.2.1

Cardiac Devices

Implantable cardiac defibrillators (ICDs) are devices that are connected to the heart
tissues via electrodes. When the leads detect an abnormality in the beating action, e.g.
tachycardia or fibrillation, they send a signal to the pulse generator, stored in the upper
chest under the skin, which then sends a pulse or a shock to the heart thus setting the
rhythm back for the pumping to continue. Cardiac Resynchronization is a technique by
which electrical leads are placed on the atria and ventricles and these are then connected
to a small battery operated device placed under the skin. The device sends electrical
pulses routinely to the atria and ventricles which then contract in tandem. Such a
procedure allows for effective ventricle ejection, reduction in ventricular size, and
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improvement in cardiac function. A Left Ventricular Assist Device (LVAD) or a Total
Artificial Heart (TAH) is used in patients with hearts that have completely lost the
capability to function. Revascularization of the ventricle is a viable option when the left
ventricle may be capable of functioning again. The myocardium may either be ischemic,
infracted, stunned, or hibernating. Ischemic myocardium is one where the supply of
blood to it, has been disrupted. The flow of blood back to it will repair the damage done
relatively quickly. Stunned myocardium is one, where there is muscular dysfunction due
to prolonged ischemia.12 Revascularization will benefit the patient over a period of time.
Hibernating myocardium is one where revascularization may or may not respond to
revascularization, although revascularization coupled with other forms of functional
assistance may provide benefit. Infarcted tissue is one where scar tissue has progressed
with the lack of myocytes in the region. Revascularization may not provide any benefit in
such situations.3, 12

2.2.2

Cell Therapy for Heart Failure

Cell Therapy has evolved as a promising mechanism for cardiac repair for more than
a decade. The potential of several different populations of cells, including fetal
cardiomyocytes, skeletal myoblasts, bone marrow derived progenitor cells, and
embryonic stem cells has been studied in animal models and clinical populations in an
attempt to repair the damage in ischemic cardiac tissue.13-15 Ideally, the right type of cell
should be able to survive in a hypoxic environment, with reduced angiogenesis, and
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should be able to interact with the host cardiac tissue and integrate with it in order to
facilitate contraction of the tissue, synchronous with existing heartbeats.

The first studies used fetal cardiomyocytes, which retain the potential to grow as
they possess the required growth factors and signals necessary to do so. Leor et al studied
the ability of human and rat fetal cardiomyocytes to engraft in ischemic rat myocardium
following coronary ligation.16 These cells engrafted and survived for up to 2 months post
transplantation. Similar results were observed with cells encapsulated within
bioengineered grafts with improved vasculogenesis in the graft tissue and improved LV
function.17,18 The improvement in LV function is due to improved morphological
engraftment, coupled with the improvement of electrical conduction and rhythmic
contractions of the ventricle.19,20 Fetal cardiomyocytes have been shown to couple and
integrate with host cardiomyocytes through gap junction proteins, such as N cadherins
and connexin-43.19

Although fetal cardiomyocytes successfully engrafted with the host tissue, a scar
region differentiated the newly formed myocardium and the host myocardium. Similar
results with xenogenic neonatal and fetal cardiomyocytes have showed significant
engraftment to host tissue and improvement in cardiac function in larger animals.13 In
spite of increasing evidence, proving successful transplantation of fetal cardiomyocytes,
the use of these cells in treating patients leads to ethical concerns. The use of xenogenic
cells is accompanied by immunological concerns and its clinical significance has not
been tested.21
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Skeletal myoblasts are rapidly mobilized following injury and have the potential to
proliferate in ischemic conditions. Also, they are not stem cells therefore can retain their
lineage, thus reduce the risk for uncontrolled proliferation into various cell types and are
autologous, thus eliminating the need for xenogenic transplantation. The first studies
were performed in rabbits with cryoinjured myocardiums.22,23 Transplantation of
autologous skeletal myoblasts, have since shown a trend towards engraftment to host
tissue and improved cardiac function capable of being taken to larger animals and
towards a clinical perspective.24-26 This engraftment is not coupled to the host tissue via
the gap junction proteins, nor does it trans-differentiate to cardiac cells, but occupies the
scar zone as multinucleated striated cells and improvement in function is only detectable
in these pockets of striated myotubes directly proportional to the number of cells
injected.22, 27 This has led researchers to believe that the cardiotropic benefit attained by
skeletal myoblast transplantation is due to paracrine factors released by these cells and
the cardiac tissue, but these factors have been ill defined.28, 29 Also, the engraftment is
independent of the host cardiac cells and thus may lead to ventricular arrhythmias.

Bone marrow derived cells include whole bone marrow preparations,30,31
hematopoietic bone marrow stem cells (HSC),32, 33 mesenchymal stem cells (MSC),34, 35
multipotent adult progenitor cells (MAPC),36 and endogenous cardiac stem cells
populations,37 all of which have been shown to improve cardiac function in animal
models and clinical perspectives. These cells can be modified to change their phenotype
in vitro in order to differentiate into cells of the cardiac lineage before they are
transplanted into the ischemic myocardium, or are transplanted into the myocardium and
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are transdifferentiated in vivo or elicit paracrine factors that assist in the improvement in
cardiac function due to the activation of other survival and angiogenic pathways.
Embryonic stem cells and induced pluripotent stem cells have recently become more
attractive options due to their totipotency, thus the ability to differentiate into
cardiomyocytes.14, 38, 39

However, from a clinical perspective, there a many challenges involved, apart from
the regulatory and ethical concerns. Embryonic stem cells are limited in the purification
of specific lineages, concerns regarding the formation of teratomas, in vitro
differentiation and in vivo engraftment into host tissues. Induced pluripotent stem cells
can overcome the graft rejection and ethical concerns but the risk of teratoma formation
still exists.

2.2.3

Cell Taught Gene Therapy

While there is clearly emerging evidence that future cell based therapies will
ultimately yield clinical benefit, it is also becoming clear that, in the absence of
embryonic or induced pluripotent stem cells, the benefits achieved may be in the absence
of myocardial regeneration. Rather, the benefits of adult stem cell based therapies appear
to be due to paracrine effects delivered following cellular homing and engraftment in the
injured myocardium. If paracrine effects dominate the benefits of adult cell based
therapies, then one could postulate that adult stem cell based therapies will evolve into a
new wave of gene therapies.40 This new wave of gene therapy will not be based on gene
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product that we believe the normal myocardium should have; but rather will be based on
gene targets that cell therapy would have taught us that benefit the myocardium in an
injured state.

The primary genes of interest were the vascular endothelial growth factor (VEGF)
gene family, as well as fibroblasts growth factor (FGF). These gene products were
demonstrated in studies in vitro to induce endothelial and smooth muscle cell
proliferation. In preclinical studies, in the absence of atherosclerosis, the administration
of VEGF or FGF protein or gene transfer led to significant capillary and arteriolar blood
vessel growth.37,41, 42 While no clinical product has evolved from these studies to date,
significant advances in know-how and knowledge in the field of myocardial gene therapy
were achieved by providing a better understanding of vectors, doses, and backbones that
help design it.

2.3

Stem Cell Therapy for Cardiac Failure

Using cell therapy as means for providing cardiac benefit was developed because
having a viable tissue was better than a collagenous scar tissue in the myocardium. Initial
studies were performed with skeletal myoblasts and when that led to engraftment led
arrhythmias, researchers moved to more versatile forms of bone marrow derived
pluripotent cells.43 Stem cell therapy began with the hope of differentiating these cells,
either in vivo or in vitro to replace the lost or damaged cardiac cells.
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Early studies with hematopoietic cells showed great improvements in cardiac benefit by
myogenesis following transplantation of ckit+ cells.44 This study further led to clinical
trials, but the earlier studies representing myocardial differentiation of hematopoietic
cells have not been corroborated by subsequent studies.15 Instead the improvement in
function was attributed to increase in angiogenesis and arteriogenesis.45,46 Moreover,
unknown parameters such as timing of delivery, methods of purification and storage of a
single cell population, selection of patient population and techniques for cell delivery
have limited the clinical trials giving rise to heterogeneity within the trials themselves.47

Other cell populations, including mesenchymal stem cells, and multipotent adult
progenitor cell, have been shown to improve cardiac function in animal models but most
theories regarding the differentiation of these cells to cardiomyocytes have been limited
and not unanimous. In fact, MSCs have been exploited as the more attractive option for
cell delivery as they can be easily proliferated in vitro, they secrete a variety of growth
hormones, such as IGF, HGF, VEGF etc,48-50 elicit paracrine factors, in vivo, such as
sfrp2, SDF-1, MCP-3 etc,51-54 and thereby are able to provide repair in more than one
aspect of tissue damage. Currently, the focus of research has shifted from myogenic
differentiation to peripheral parameters that improve the environment around the infarct
zone to provide for cardiac benefit.
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2.3.1

Homing Factors

The first few steps required for efficient cardiac tissue repair with stem cell therapy
is the need for targeting the cells to the area of injury and to engraft it there. Traditionally,
homing occurs as a stress response, when certain factors are released by cells, following
injury, as a signal to recruit either stem cells from the bone marrow and inflammatory
cells in order to begin the repair process.

One such chemokine is SDF-1 which is shown to be elevated in an injured
myocardium and recruits stem cells to the area providing cardiac benefit.55 We, in our lab
have also shown that MSCs infused intravenously home to the heart one day post MI but
not when infused 14 days after MI. This is attributed to the fact that SDF-1 peaks one day
post MI and drops by 7 days. Moreover, plasma elevation of SDF-1 induces
hematopoietic stem cell and platelet migration to the area of injury.56 Apart from adult
tissue, stem cell homing has been shown to be critical in mice fetuses, where the
elimination of either the homing factor (SDF-1) or its receptor, CXCR4, is fatal for
development due to the lack of homing of the essential cells to the interstitial space to
form blood vessels.57, 58

The homing of mesenchymal stem cells is a slightly more complicated process, as
the molecular mechanisms that define these are not completely understood. Mesenchymal
Stem Cells possess the CXCR4 receptors on its surface and therefore migrate towards the
SDF-1 chemotactic gradient. However, the amount of CXCR4 receptors are limited and
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this limits the amount of MSC migration leading to limited tissue benefit. Endothelial
progenitor cells, precursors to blood vessels, respond to IL-8, released in injured tissues,
and prevent apoptosis.59,60 However, these cells are not capable of angiogenesis, probably
due to reduced function in a hypoxic environment. In our lab, we have demonstrated the
homing of MSCs as a response to Monocyte Chemoattractant Protein -3 (MCP-3).52 LAD
ligated rodents were infused with MSCs and Cardiac Fibroblasts to show that only MSCs
migrated to the myocardium and cardiac fibroblasts did not. Using a DNA assay,
monocyte chemoattractant protein was identified to be a myocardial homing factor for
stem cells.

Transplanting cardiac fibroblasts over expressing MCP-3 in the myocardium we
have been able to show an elevation in MSC homing to the heart immediately after MI,
and late after MI. Reestablishing the homing factors can lead to reestablishing homing of
stem cells. We also observed that the over expression of SDF-1 immediately after AMI,
leads to the recruitment of cardiac stem cell like cells to the area of injury. Interestingly,
although these cells are positive for cardiac myosin, they are not differentiated cardiac
myocytes. These cells also possess CXCR4 on their cell surfaces thus determining their
lineage to be cardiac stem cells. Also, optical mapping studies demonstrated that these
cells are capable of de-polarizing in vivo, therefore may possess the ability to contract.
The recruitment of cardiac stem cell like population into the infarct zone can alter
electrical activity and may have a significant impact on the electrical functions of the
myocardium.61
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Figure 2-1: Role of SDF-1 in AMI as a homing factor for stem cells

2.3.2

Role of SDF-1 in Acute Myocardial Infarction

It has been established that CD34+ cells home to the infarct zone, following Acute
Myocardial Infarction (AMI). To understand the triggers signaling the targeting of these
cells from the bone marrow to the heart, initial studies were performed to determine the
levels of mobilizing cytokines in the serum plasma. The increase in the amount of CD34+
cells correlated to the increase in levels of G-CSF (Granulocyte colony stimulating factor)
and an increase in SDF-1 (Stromal derived cell factor-1).62

To understand the role of G-CSF and SDF-1 in promoting homing in AMI, rodents
were injected with G-CSF in the presence and absence of cells over expressing SDF-1,
transplanted in the cardiac tissue. G-CSF was not sufficient to mobilize the bone marrow
derived cells, establishing the role of SDF-1 as the homing agent.55 Further studies
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identifying the role of SDF-1 in mobilization of CD34+ cells was demonstrated with
emphasis on the SDF-1 CXCR4 axis playing a pivotal role, in the homing of stem cells.63
Stem cells, positive for the CD34 marker, in the bone marrow possess the receptor
CXCR4. An increase in SDF-1, a ligand for CXCR4, in the plasma leads to the targeting
of the CD34+ cells.

This homing is prevalent in the first 12 hours following injury and then drops
significantly over a week. Furthermore, the levels of the stress cytokines are proportional
to this homing effect, where levels of VEGF and SDF-1 increase following AMI after the
first day, and continue to increase for 3 days following injury.64 The levels then start
dropping to normal levels by the end of a 7 day follow up.55 The initial theory regarding
the trans-differentiation of these early cardiac marker cells, following the homing to
ischemic tissue was refuted in a study from our lab, to identify trophic factors to be the
cause of the repair mechanism.

Rodents with AMI were treated with infusions of

mesenchymal stem cells over expressing SDF-1, and showed great improvements in
cardiac function. This improvement was attributed to a decrease in apoptotic nuclei, a
decrease in scar tissue formation and a significant improvement in vessel density in the
infarct zone.35

Subsequent studies have followed regarding the use of SDF-1 without the
concomitant use of cells, to over-express SDF-1 in infarcted regions to understand the
improvement in cardiac functions thereafter. SDF-1 protein injections was the most
straightforward of these and injecting SDF-1 directly into the center of an infarct
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demonstrated improved cardiac benefit by increased neovascularization in infarct zones
and reduction in scar sizes, but the effect was short lived and failed to provide clinically
relevant results.33, 65, 66 To prolong the effect of SDF-1, controlled release of the protein
was then studied. SDF-1 protein encapsulated within nanofibers, when injected
immediately after coronary ligation, has shown to provide improvement in cardiac
function coupled with increase in vascular density.67 A controlled release of SDF-1
provided by a PEGylated fibrin patch when placed in situ after coronary ligation in mice,
showed a marked improvement in cardiac function following recruitment of CD34+ cells.
The improvement was more prominent after 2 weeks and was sustained at 4 weeks.68
SDF-1 promotes cell survival immediately after MI and also helps reverse ventricular
remodeling and prevents heart failure.

2.3.3

Role of SDF-1 in CHF

As established earlier, our lab has also shown that MSCs infused intravenously home
to the heart one day post MI but not when infused 14 days after MI.69 This is attributed
to the fact that SDF-1 peaks one day post MI and drops by 7 days. To determine if the
homing reaction produced by SDF-1 could elicit a meaningful response late after injury,
rodents were infarcted via LAD ligation, and were allowed to develop a chronic heart
failure model for 2 months. In this time, the ventricular cavity had dilated, the scar tissue
had developed and viable myocardium in the ischemic region had died due to apoptosis.
8 weeks after ligation, control fibroblasts, or those over-expressing SDF-1 were
transplanted into the ischemic myocardium. Animals that received the SDF-1 expressing
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cardiac fibroblasts, had a greater number of proliferating cells, including, CD117+
(hematopoietic stem cells), CD45+ (leukocytes), CD34+ (hematopoietic stem cells,
endothelial progenitor cells) and vWF + (endothelial cells) cells in their heart tissues.
Apart from acting as a homing factor for these cells, the presence of the angioblasts and
paracrine factors released by the recruited cells, led to a significant improvement in
cardiac function, as determined by their fractional shortening.69

2.3.4

Molecular Mechanisms Involved in SDF-1 CXCR4 axis

CXCR4 is present in CD34+ cells, such as hematopoietic stem cells, endothelial
progenitor cells, and cardiac stem cells.64,70-72 Following myocardial infarction, the
mRNA expressions of SDF-1 has been shown to be elevated in the left ventricular
anterior and posterior walls in animal studies.55, 69 Cells with the CXCR4 receptor, stem
cells, now migrate towards a SDF-1 chemotactic gradient and thus home towards the
ischemic myocardium. SDF-1 present in systemic circulation is sufficient to mediate this
recruitment.61,70 When SDF-1 binds to its receptor CXCR4 it leads to the activation of
other paracrine factors such as P selectin ligand, E selectin ligand,73 Very late antigen
VLA4, VLA5 etc, on the surface of hematopoietic stem cells.74 These ligands bind to the
receptors P selectin, E selectin, Intracellular Adhesion Molecule (ICAM) on endothelial
cells and allow them to roll over the endothelial cell layer allowing for transmigration
along the cell layer thus recruiting cells to the area of injury.74-76
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The interaction of SDF-1 ligand with the G-protein coupled receptor, CXCR4
triggers intracellular pathways involving Akt phosphorylation, Ca2+ influx, mitogenactivated protein kinases (MAPKs) phosphorylation, activation of PI3 Kinases, and JAK
STAT pathway activation.77

Following SDF-1 up regulation in the infarct zone,

phosphorylation of Akt and up regulation of VEGF are observed which leads to cell
preservation.53, 78 Cell survival can also be attributed to downstream signaling of Akt
involving BAD, NF-kB, and NO from e NOS.79 Also, SDF1 CXCR4 coupling activate
both PI-PLC and PI3K, which activates PKC.80 PKC activation induces Pyk2 and ERK
activation, leading to adhesion and chemotaxis as well as gene transcription via MAPK
activation. MAPKs are a family of protein kinases that consist of ERKs, p38, MAPK and
JNK which mediate apoptosis. PKC also mediates the activation of NF-kB which in turn
mediates MMP-9 production allowing for matrix remodeling and reducing the scar tissue
which in turn allows for reverse ventricular remodeling.81, 82

2.4

Overview on Gene Therapy

Gene therapy involves the manipulation of nucleotide sequences involving the
recognition, selection and integration of the desired genes in a chromosome. Since early
1990’s up to now, more than 900 clinical trials involving gene therapy in various disease
conditions, such as cancer, monogeneic diseases, vascular diseases, immunogenic
diseases, etc have been carried out.83, 84 The most evident application of gene therapy is to
replace a defective/abnormal gene by its normal counterpart in order to benefit the
organism, by supporting normal functioning. This replacement is preferred to be a stable,
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safe and permanent one, in order to constitutively provide normalcy in the organ. Another
application of gene therapy involves suppressing an unwanted reaction by the organ, such
as in cancerous tissue, in order to prevent the growth of tumors. Genes can also be used
as a drug or a prodrug, which encodes for an enzyme or a protein that can act as a
cytotoxic drug to eliminate the tumor and its environment. This application of genes as
prodrugs can also be used to promote the growth of certain growth factors or enzymes
that may help provide relief to repair injured tissues or organs.

2.4.1

Gene Therapy in Heart Failure

Significant pioneering work was done in the 1990’s in the field of cardiovascular
gene therapy. Gene therapy was involved not only in therapeutic purposes, but played a
significant role in diagnosis of key participants in the heart failure process. Multiple
studies regarding the apoptosis of cardiac myocytes following ischemia have been
reported, and the role of TNF-α in cardiac dilation, procaspase-8 in dilated
cardiomyopathy, and gp180 molecules in cardiac apoptosis following pressure overload
have been elucidated.10, 85, 86

As therapeutic options in cardiac applications, gene therapy studies are responsible
for preventing apoptosis and promoting survival signaling. The members of the PI-3
kinase pathway also include Akt phosphorylation that leads to survival and growth of
myocytes, as seen in the prenatal heart.87, 88 Insulin Like Growth Factor-1 is another pro
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survival protein that prevents naturally occurring apoptosis.89 SDF-1 has been shown to
prevent apoptosis, and induce the growth of vessels in ischemic zones. 66

However, in a heart failure condition the focus is on inducing angiogenesis in an
attempt to treat “no option” patients who are presented with diffuse coronary artery
disease and chronic ischemia. The genes of interest could be characterized as those that
investigators believed would benefit the myocardium, not necessarily those that were
inherently needed by the heart. These genes would provide peripheral support to the
ischemic tissue, by enriching the environment thus promoting cardiac benefit. The
primary genes of interest are those of the vascular endothelial growth factor (VEGF) gene
family, as well as fibroblasts growth factor (FGF).90, 91 In a protein form, these factors
were not sufficient to elicit any clinically meaningful results.92,93 Growth factors have
short half lives, and thus it was hypothesized that a gene therapy approach would allow
for prolonged sustenance and effect. These gene products were demonstrated in studies in
vitro to induce endothelial and smooth muscle cell proliferation.94-96 In preclinical studies,
in the absence of atherosclerosis, the administration of VEGF or FGF gene transfer led to
significant capillary and arteriolar blood vessel growth.97, 98 However, none of these gene
therapy products have been approved for clinical use in cardiovascular patients yet.

2.4.2

Advantages and Disadvantages of Gene Therapy

Initial studies regarding transplantation of skeletal myoblasts in ischemic regions in
the heart have not been able to provide enough functional benefit in the heart. Moreover,
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this effect was lost in a 4 month follow up.27 More concerning, is the fact that this celltherapy treatment may lead ventricular arrhythmias.25 Gene therapy is a more straight
forward approach where the ultimate goal is either to over-express a gene such as to
achieve therapeutic levels of cardioprotective protein, or the knocking-down of genes that
may lead to cardiotoxicity. However, the first clinical study with gene therapy led to the
death of a patient, due to immune toxicity. Gene therapy has to battle a few factors that
lead to its inefficacy in clinical trials.84, 99

Transient Expression: It is undesirable to let genes integrate into the host genome
such as to provide this constitutive effect for future generations. However, it is necessary
to have a transient supply of the therapeutic DNA for a clinically relevant period of time.
The cells that inherit the DNA must also be able to proliferate, survive and stably express
this DNA for the same period of time. This will prevent the need for patients to undergo
multiple rounds of the therapy in order to sustain the therapeutic level of benefit.
Furthermore, the level of proteins translated directly relate to the amount of DNA
injected into the patient. However, the corollary may also pose a risk, where unregulated
gene expression leading to unchecked protein levels may have detrimental effects.

Immunotoxicity: For an effective, stable DNA expression, these plasmids are
packaged into viral vectors and then introduced into the patient. The main advantage of
viral vectors is that it yields very high transfection efficiencies. However, viral vectors
pose numerous safety and efficacy issues, ranging from toxicity and immune and
inflammatory responses, to gene control and targeting issues. The presence of such
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foreign bodies can lead to an enhanced immune reaction by the body, hoping to destroy
this foreign object, thus reducing the effectiveness of the enhanced gene. This can further
lead to the immune system attacking healthy tissues and can pose a high risk to the organ.
Furthermore, the immune system's enhanced response to invaders it has encountered
before makes it difficult for gene therapy to be repeated in patients.

Cardiovascular Applications: Unlike single gene mutation disorders, where the
defective gene can be replaced by the normal gene sequence, cardiovascular diseases
come with multiple symptoms, from loss of contractility, loss of blood vessels, loss of
growth factors, increased inflammatory reactions, deposition of collagenous scar etc.
Treating such conditions with gene therapy will only be possible with treating it early and
before the tissues are beyond repair. In chronic heart failure, although there may be
methods of providing cardiac benefit and an improved life style for the patient, it is
difficult to bring the heart back to a normal healthy tissue.

2.4.3

Non Viral verses Viral Constructs

Delivering the genetic material into a host cell involves the use of vectors, which
could either be viral or non viral. Direct injection of naked DNA is widely employed in
gene transfer studies as it is relatively safe, is cost effective and can be produced in large
quantities in bacteria and can also be manipulated by standard recombinant techniques.100
Moreover, it possesses low immunological toxicity, is water soluble and heat stable. In
earlier cardiovascular diseases, this method was widely used for the same reasons. On the
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other hand, naked DNA has low transfection efficiencies, can be degraded rapidly and
generally needs targeting or condensing agents to penetrate the cell wall. 101

It has been seen in the past that transfection decreases with increase in animal size.102
Expression levels are slightly lower in rats than mice and significantly decrease with
rabbits and pigs which make it unsuitable for large animal studies.102,103 Greater
expression of the gene can be achieved by complexing the DNA with compounds such as
cationic polymers,104 lipopolymers,105 PEI,106 and liposomes.107 Such compounds not
only protect the DNA from degradation but also condense them into smaller sizes so that
it can mediate uptake by the cell. Despite alternative approaches, non viral delivery
methods yield transient and non site specific expressions, which make it non feasible for
conditions that require long lasting expressions such as cardiomyopathies.

The major advantage of viral vectors is that its yields very high transfection
efficiencies. The difference between viral transduction efficiencies and non viral ones are
due to the difference in uptake mechanisms between the two. In contrast to non viral
vectors, which may get degraded in the presence of lysosomes, viral vectors are readily
bound to cell surface receptors, which prevent native degradation of the virus.108
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Advantages

Naked
plasmid

Adenovirus

Adeno
associated
virus

Lentivirus

Disadvantages

Safe
Cost effective
Bulk processing available
Low toxicity
Water soluble
Heat stable
High transfection efficiency
Can be taken up by all cell
types
Easy to produce
Tropism for multiple cell types
Non pathogenic vectors
Long term expression patterns
High transduction efficiency
Can be taken up by all cell
types
Low immune responses
Long term expression patterns
Can integrate into all cell types
Can be driven by various
promoters

Low transfection efficiency
Transient expression

Adverse immunological
responses
Transient expression patterns
High toxicity
Limited transgene capacities
Difficult to produce in large
quantities

Safety issues
Difficult to produce in large
quantities
Low transduction efficiency

Table 2-1: Comparison between viral and plasmid vectors for gene delivery

2.4.4

Naked Plasmids

Most commonly, non viral delivery techniques involve the use of naked plasmid
alone, or naked DNA either encapsulated within polymeric delivery systems or liposomes
in order to protect DNA from degradation and to allow for a consistent expression over
time.109, 110 The use of non viral vectors can circumvent most issues associated with viral
vectors, mainly safety associated with immunotoxicity. On the other hand,
unencapsulated DNA can be modified, with the help of transcriptional and translational
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enhancers, in order to achieve similar benefits. Other aspects that affect the transfections
involved with naked plasmid delivery are based on technical details such as the number
of injections, the time of delivery, the amount of DNA used, site of injection and so forth
as described in the table below.96, 102, 107

Dose

Needle

20 μg /
100 μl of
saline
15 μg /
200 μl of
sucrose
500 μg /
150 μl of
saline

Curved
30 gauge

60 μg /
100 μl of
saline
50 μg /
100 μl of
saline

30 gauge

30 gauge

24 gauge

30 gauge

Area

Number of
injections

Time of
injection

Treatment

Infarct
border
zone
Infarcted
area

4 to 5

1 week after
infarct

Naked with bFGF
and PGDF

1

2 weeks
after infarct

HVJ liposome
method

Left
anterior
border
zone
border
zone

1

24-50 days
after infarct

phVEGF

1

1 week after
infarct

phVEGF and
adVEGF

Left
anterior
free wall

1

At the time
of infarct

HIF1 and VP16;
phVEGF

Table 2-2: Various parameters involved in gene delivery

2.4.5

Translational Enhancers

Enhancers are a short sequence of nucleotides either present upstream or downstream
to the transcription activator site, or the start codon and can boost the transcription or
translation of the RNA to protein. A Kozak sequence is a short sequence present
upstream of the transcription activation site and generally contains the full consensus
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sequence, GCC GCC A/T CC ATG G, three bases before the start codon. The Kozak
sequence slows the rate of ribosomal scanning and thereby improves the chance of
translation by ensuring that the start codon is recognized.111 Similarly, the 5’ untranslated
region (UTR) can affect the translation of mRNA, by either inhibiting or enhancing
translation. If the untranslated region has more number of AU rich regions and is poorly
structured, it allows for easy ribosomal scanning and thus helps the ribosomes to
recognize the translation initiation codon.112 The UTR of the human t cell leukemia virus
(HTLV) conforms to this poor structure and thus enhances translation when present
upstream to the activation site.113

2.4.6

Transfection Agents

Transfection agents prevent the degradation of naked plasmid by encapsulating them
and then releasing them into the cell. These encapsulating agents can either be polymeric
or liposomes. These are either made of polymers, proteins or lipids and coat the DNA
such that they allow for timed release and also protect the DNA from being damaged.
Moreover, they condense the DNA to smaller sizes to mediate better uptake by the cell.
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2.5

Encapsulation and Systemic Gene Delivery

2.5.1

Poly Lactide co Glycolide nanoparticles

Research involving the delivery of DNA or plasmids as therapeutic agents has grown
rapidly. The need to safely and efficiently deliver these genes to the tissue of interest has
resulted in a rapid growth of research in the use of polymeric nanoparticles as delivery
vehicles for these transiently expressing, easily degradable therapeutic agents. Although,
recent advances have led to almost 100 clinical trials with nanoparticles as carriers for
drugs, there is no drug loaded within nanoparticles which has been approved for human
use yet. This is partly due to the fact that the targeting of nanoparticles to cells has been a
challenge.114

DNA plasmids have a polynucleotide structure and thus are negatively charged
which poses a challenge for traversing the tissue layers, and they are easily degraded in
the system. In order to overcome this, genes need to be properly condensed to a size that
can be taken up by cells. Once they are taken up by cells, the plasmid may be lost due to
endosomal sequestration of the nanoparticle, loss of nanoparticle by exocytosis, or
lysosomal degradation of the nanoparticle in the cytoplasm. Therefore, an efficient
delivery of plasmid DNA to the cell nucleus requires the condensation of the plasmid to
allow encapsulation within the nanoparticle, stability during formulation and in vivo,
ability to target the tissue or cells of choice by either a surface ligand or by possessing a
specific promoter element in the plasmid, or both, capability of release from the
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nanoparticle following endocytosis into the cell, and ability to be taken up by the nucleus
in its active form.

Polymeric nanoparticles are being widely used as delivery agents for plasmids
because of their stability,115 ability to bind targeting ligands to the surface,116 regulated
control over the release kinetics of the encapsulated plasmid in the cytoplasm, ability to
be degraded in vivo,117-119 following the release of the plasmid, and are approved for use
in human trials by the FDA.120

Generally, nanoparticles encapsulating plasmids are formulated using a variety of
techniques such as; double emulsion solvent evaporation technique,121 salting out,122 nano
precipitation,123 cross flow filtration,124 or emulsion diffusion technique.125 The most
common of these techniques is the double emulsion method where the hydrophilic
plasmid is dissolved in an aqueous solution with sucrose or albumin as stabilizing agents
and the polymer is dissolved in an organic phase. A primary, water in oil, emulsion is
formulated between the aqueous phase and the organic solvent. This is then added drop
wise to another aqueous phase with a polymeric surface activator, poly vinyl alcohol
(PVA), to formulate a secondary, oil in water, emulsion.126 This is then allowed to
evaporate slowly to remove all the organic solvents, and form hydrophobic nanoparticles
encapsulating the hydrophilic plasmid, with surface activators that alter the
hydrophobicity of this complex.127
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The surface activation is a key step in this process, since the surface comes in contact
with cell membranes, and thus is the determining factor for the internalization of the
nanoparticle in the cell. PLGA nanoparticles enter into the cell by endocytosis partially
by pinocytosis and partially by receptor mediated endocytosis and this process is
concentration and time dependent.127 Other factors, such as size of the nanoparticle,
affect cell internalization, with smaller size of the nanoparticle facilitating easier uptake
than larger ones.119 Nanoparticles escape the endo lysosomes and enter into the
cytoplasm immediately after, within the first 10 minutes. However, some studies have
demonstrated that a significant amount of these nanoparticles escape the cells via
exocytosis and only about 15% of the nanoparticles remain in the cytoplasm.127

Some factors that affect the release of nanoparticles in the cytoplasm are dependent
on the surface characteristics, such as the zeta potential, hydrophilicity and surface charge,
all governed by the surface activator, poly vinyl alcohol (PVA). An excess of PVA on the
surface, if not removed completely during formulation alters a process called surface
charge reversal. In an acidic lysosome, the nanoparticles change their surface charge from
anionic to cationic, destabilize the vesicle membrane, and get released from them into the
cytoplasm. An excess PVA prevents this occurrence and the nanoparticles do not release
from the lysosomes and exit the cells via exocytosis.120

This portion of released nanoparticles degrades slowly and releases the encapsulated
plasmid over a controlled period of time. The release of plasmid in the cytoplasm can be
altered by varying formulation parameters, such as polymer to plasmid ratio or molecular
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weight and composition of the polymer used. Higher molecular weight polymers allow
for more plasmid loading within the nanoparticles and thus release more plasmid per
nanoparticle, facilitating greater gene transfections. Other factors, such as higher
viscosity, better emulsifying properties also allow for greater loading and smaller
nanoparticle sizes, thus greater uptake and release of more DNA into the cells. The
hydrophobicity of polymers affects loading and release, with less hydrophobic particles
providing better release. Surface activators also help in altering the hydrophobicity.121, 128

Formulations of the polymer complex with the plasmid, involving the type of
polymer, the method of formulation, surface activators, size of the resulting nanoparticles
and zeta potentials (surface charge of the particles) all have an effect on encapsulation
and delivery of the plasmid and can be modulated to provide the required results.

2.5.2

Targeting Factors

Targeting ligands aid nanocarriers to effectively direct them to a specific cell or
tissue type to maximize efficacy of the encapsulated plasmid or drug in the specific
tissue.129 Initial targeting studies were used for tumors, in order to prevent angiogenesis,
and thus prevent the growth of tumor cells, but leave the healthy tissue around it intact.130
These ligands exclusively bind to specific receptors on the cell surface with high affinity.
Some of the common ligands that have been studied are peptides, antibodies, sugars,
vitamins and certain chemical compounds. Once these ligands bind to the cell surface, the
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uptake occurs by a receptor mediated endocytosis, via clathrin dependent or independent
pathway.127, 131

To formulate a ligand tethered polymer/DNA complex, the ligand molecule is either
linked directly or via a linker polymer to covalently bind to the surface of the polymer
complex.

Figure 2-2 : Schematic of the encapsulation of DNA within PLGA nanoparticles

There is a lot of research involving the receptors on cell surface that target these
homing ligands. A great body of research is dedicated to looking at integrin based
members of cell adhesion receptors. Proteins of the extra cellular matrix such as
fibronectin bind to a three amino acid sequence peptide commonly known as RGD, for
Arg-Gly-Asp132,133 on specific integrins over expressed in angiogenic endothelial cells of
tumor tissues.134,135 This led researchers to tap this targeting moiety to deliver siRNAs
and other inhibitor drugs to these tissues to hamper its growth and block blood flow to
this region, resulting in targeted tumor tissue damage.136
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Other peptide sequences such as the Luteinizing Hormone - Releasing Hormone
(LHRH) is also a tumor targeting ligand as its receptor is commonly found in various
tumor (breast, ovarian) tissues.137 Certain iron binding ligands, such as transferrin and
lactoferrin, are common receptor binding proteins specially used for lung targeting and
traversing the blood brain barrier in the brain,138,139 although in gene transfections studies,
lactoferrin mediated delivery demonstrated a greater transfections efficiency as compared
to transferrin mediated delivery.140 A similar ligand protein is epidermal growth factor
(EGF) that binds to the EGF receptor (EGF-R).141,142 Another similar ligand protein is the
Receptor associated protein (RAP) that binds to low density lipopolysaccharides (LDL)
on the cell surface.143 Several sugars, such as galactose, mannose, and folates bind to
specific moieties on the cell surfaces such as asialoglycoprotein receptors on
hepatocytes,144 mannose receptors on macrophages, and dendritic cells,145 and folate
receptors on tumor cells.146

Other technologies involve combinatorial libraries, such as RNA display, yeast
display or bacterial display to identify certain small peptide molecules that target specific
cell types.147 A novel yet powerful strategy that is being used nowadays is called in vivo
phage panning using a phage display library.148 Phages are screened by allowing them to
bind to specific cell receptors in the tissue of interest. After several rounds of screening
followed by purification and amplification of the primary candidates, a robust and highly
specific ligand-receptor binding target is identified.
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2.6

Phage Panning

Bacteriophages or phages are viruses to bacteria that can replicate their DNA in a
bacterial cell. Generally phages have a single stranded DNA in them, and can infect E
coli. A phage clone has a foreign gene introduced into a phagemid vector, such that it
possesses the phage and a replication plasmid to enhance transformations. A phage
display library has multiple copies of various clones, with sequences for a number of
known and unknown peptides attached to the fusion coat protein plasmid in the M13
genome of phagemid vectors.149 The peptides are comprised of 7 amino acids, formed
from all possible permutations from the genome sequence of the organism. When these
phage particles enter into a bacterial cell, the genome is now released from inside the
phage vector and is displayed on the surface, while the coat protein remains attached to
the phage vector. On identifying a receptor to these peptides, the ligand binds to the
receptor tagging the phage with it. Phage panning studies with specific epitopes (receptor)
or the tissue with the epitope employs this specificity to identify the phage that binds to it,
which is then isolated, amplified, and sequenced to reveal the peptide sequence that binds
to the epitope of interest.

The principle behind phage panning is to identify the clone that binds to an epitope
with the affinity and selectivity that other clones do not bind to or do so with poor affinity.
To achieve this, multiple rounds (or pans) of binding the phage to the epitope, identifying
the bound phage, eluting the unbound phage, amplifying it and sequencing the bound
phage are carried out. For in vivo identification of ligands specific to receptors, animals
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are infused with multiple copies of phages expressing a library. This is allowed to
circulate for 2 hours, to ascertain the removal of unbound phage from the tissues (organs
and tumors). Residual phages still bound to the target organs are harvested. This residual
phage is purified, amplified and infused into the animal for a second round. After
multiple rounds, it will now be possible that very few phages express specificity to the
tissue.150

Several studies with this principle has led to specific ligands for traversing the
intestinal mucosa and targeting the goblet cells,151 traversing layers of the skin to deliver
drugs intradermally,152 targeting pancreatic cells,153 tumor cells,154 lymph channels,155
and vascular endothelium.156

In vitro affinity binding to identify targets for these antigens have been tapped for
tumor targeting ligand selections. Certain antigens, specific for tumor cells such as
urokinase plasminogen activator (uPA), epidermal growth factor receptor (EGF-R),
Thomsen Friedenreich tumor associated antigen etc, are plated on a dish and phages are
allowed to bind to them. Unbound phage is eluted and the bound phage is amplified and
sequenced, after multiple rounds, to identify targets to these receptors.157

Although phage display seems to be able to provide crucial information regarding
targeting ligands which can then be synthesized chemically, and tagged with photo or
radio labels to help imaging, or be tagged to liposomes and polymeric gene carriers to
deliver encapsulated drugs to organs, it has some serious drawbacks. First of all, in vivo
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screening can be done only in animal models which limit translating this information to
humans, if the targets that bind these 7-mers are not identified. In such scenarios, it may
or may not be useful to use these ligands to target or image tissues in humans. This
extrapolation might also lead to secondary organ damage.158 In recent times, human
panning for identifying targeting ligands are being performed but this is limited in the
number of subjects that can be used for this study, as organs need to be excised following
phage injections.159 However ex vivo screenings on intact organs can be used to
determine targeting peptides in human organs.160

Other smaller drawbacks are based on the size of the phage particles, thus the
vascular space and mostly the endothelial layer are targeted for receptors. Secondly, the
affinity to certain receptors may be due to the large copies of libraries infused into the
organ rather than a specific affinity of the peptide in itself, which is revealed by low
affinities seen with mono copies. Thus there is a great deal of work to be done in
optimizing this system towards ideal screening platforms.161

2.7

Gene Profiles in Tissue Regeneration

Following the human genome project, that has identified the sequences to all genes
in the human body, researchers began to study how these genes affect each other. Gene
expression profiling is a tool used to study the expression of multiple, or in some cases,
all genes at the same time. Following treatment, a gene expression profile would help
understand how all genes respond to the therapy.162,163 The ones that are closely
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associated with the damaged organ, will have significant changes in expression as a
response to therapy, and genes that are not affected will have no change in expression as
a response to the therapy. Monitoring the changes in gene expression for multiple genes
at one time will provide a comprehensive knowledge of many genes that may be
associated with the disease state. During the early part of this century, following the
human genome project, studying the effect of all the genes in response to therapy would
require hours of labor but today, the same study, identifying the same data can be done in
a few hours due to advances in chip technology and fluorescence detection. Several
studies have identified novel pathways and peptides associated with cardiac tissue
damage using genome wide studies. The role of chronic Akt mediated hypertrophy and
heart failure was established.164 Novel paracrine factors associated with tissue repair,
following Akt- modified stem cell transplantation has been attributed to a secreted
frizzled related protein 2 (sfrp 2) that mediates myocardial survival and tissue repair.54

2.7.1

Whole Genome Analysis

A gene chip is a matrix of sequence specific oligonucleotides, arranged in a specific
order, and bound to a solid surface (quartz) at the bottom. This system is known as a
microarray chip. One company that has revolutionized the microarray chip with
providing comprehensive data and easy experimentation is Affymetrix.165 The affymetrix
chip has about 16 to 20 probe pairs for each gene. Each probe pair consists of a perfect
match to the gene of interest, and a mismatch to the same gene. The difference in
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intensity between this perfect match and mismatch is what will be provided at the end of
the analysis.

The degree of discrimination, R, which determines the ratio of the difference
between the perfect and mismatch to the sum of the two will be calculated. R= PM-MM
/PM+MM. An increase in gene expression would be determined by an R value of 1 or
close to 1.

Figure 2-3 : Schematic of a microarray chip

According to the Wilcoxon signed rank test, two parameters are analyzed a) change
in gene expression (up or down regulation) and b) the p value. If the p value is greater
than 0.05, the gene will be excluded from the list. The fold changes between the control
and sample genes will be measured and based on these results, a new set of genes, with
highest fold changes, will be identified. The chip is normalized using the Robust Multi
Averaging (RMA) software.166,167 This software allows users to normalize the

48

background and also negate misidentified mismatch data and also determine fold changes
between the original gene and the up regulated or down regulated gene.

2.7.2

Pathway Studies

Pathway analysis tools help in searching and exploring the relationships between
genes that are associated in any given pathological condition. The relationships then help
researchers understand the functionality associated with these genes. These tools are
structured in order to define the location of these genes in the cellular compartments.
Moreover they define the interactions between genes to endogenous chemicals, drug
targets and other genes within their network. This then provides a mechanistic
understanding of all genes and their targets, thus illustrating the pathways that are
involved in the given process. These networks and pathways are mostly pre defined and
provide comprehensive information to the researcher. The Ingenuity Pathway Analysis
software is a tool to understand the various pathways involved in the genes that have
changed after the treatment process.163 It can provide information on the signaling
pathway involved in the whole process. Other software, such as Spotfire, helps cluster the
genes and thus form groups which helps in gene profiling.
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CHAPTER III

GENERAL METHODS

3

GENERAL METHODS

3.1

Cell Culture

3.1.1

Harvesting Rat Mesenchymal Stem Cells

Rat bone marrow was isolated by flushing rat femurs and tibias with 0.6 ml DMEM
repeatedly until all of it is extracted. Clumps of bone marrow were gently minced using a
20 gauge needle and a 10 ml syringe. Cells were then be removed by Percoll density
gradient. This bone marrow was then washed with PBS three times to remove all debris
and then plated in a dish with MSC media, comprising 10% FBS and 1% antibiotic in
low glucose DMEM, and incubated at 37ºC for three days.
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The mesenchymal stem cells adhere to the plate leaving the endothelial cells in
suspension. The floating endothelial cells were removed and the media was changed in
order to obtain a pure population of MSC cells. After four passages, this culture was then
sorted negatively for CD45 and CD34, by magnetic cell sorting to remove endothelial
cell types and in order to obtain a double purified population of MSCs.

3.1.2

Isolation of Cardiac Fibroblasts

The left ventricles of 3 to 5 rats were pooled together, minced and placed in 100
U/ml of collagenase XI and trypsin at 37 ºC for 10 minutes in a shaking incubator. The
cell suspension was filtered out using gauze filtration and minced tissue was collected.
The cell suspension was centrifuged at 2000 rpm for 10 minutes to sediment the cells.
The cells were seeded in Ham’s modified DME medium supplemented with 10 % FBS
and 1% antibiotic containing Penicillin and Streptomycin. Non adherent cells were
removed after 2 hours of incubation and the adherent cells were washed twice with
phosphate buffered solution (PBS). The resulting adherent fibroblasts were cultured in
Ham’s modified DMEM medium supplemented with 10% FBS and 1% antibiotic
containing Penicillin and Streptomycin on T75 flasks and incubated in 37ºC and 5% CO2.

3.1.3

Stem Cell (Mesenchymal Stem Cell) culture

Harvested mesenchymal stem cells were cultured on tissue culture plates. Cells were
added to media comprising Dulbecco’s minimum essential medium supplemented with
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10% fetal bovine serum and 1% antibiotic of penicillin and streptomycin. Cells were
allowed to adhere to the bottom of the plate and proliferate in a 5% CO 2 and 37° C.
Media was changed every 2 days. When the plate was confluent, cells were detached
from the bottom of the plate by washing twice with Phosphate buffered solution, and then
incubated for 5’ at 37°C with trypsin EDTA. Cells were pipetted to break down clumps
mechanically and then re-plated at a concentration of 1 million cells per plate in the
specific medium.

3.1.4

Cardiac Fibroblasts culture

Cardiac fibroblasts were cultured on tissue culture plates in a similar fashion as
described for mesenchymal stem cells but with a specific cardiac fibroblasts media
comprising equal parts of Dulbecco’s minimum essential medium and F12 medium
supplemented with 10% fetal bovine serum, 1% antibiotic solution with penicillin and
streptomycin, and 1% L-glutamine.

3.1.5

Cell Freezing

Cells were detached from the tissue culture plate using Trypsin-EDTA. A pellet of 1
million cells was collected by centrifuging the cell solution (Cells in Trypsin) at 2000
rpm for 5 minutes. Each cell pellet was dissolved in 1 ml of DMSO (dimethyl sulfoxide)
and Fetal Bovine Serum at a ratio of 6:4 (600 µl of DMSO and 400µl of FBS). These
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were then transferred to a Nunc cryovial and slowly frozen at -80°C for 1 week and then
in liquid nitrogen for long term storage.

3.2

Plasmid Constructions

3.2.1

pCMV

The pCMV Luc plasmid was generated by digesting the Luciferase gene from a
pGL3 vector (Promega), using the following primers: Forward: 5’- GAATTCGTCG
ACTATGGAAGACGCCAAAAACATAAAGAAAGGC-3’; Reverse: 5’-TCTAGAAAG
CTTTTACACGGCGATCTTTCCGCCCT TC-3’, and subsequently ligating it onto a
pcDNA3.1 vector (Invitrogen, Carlsbad, CA). The Forward Primer has the restriction
enzymes EcoRI & SalI; the Reverse Primer has HinDIII and XbaI. The resulting PCR
product was digested with EcoRI and XbaI, gel-purified and ligated into an EcoRI-XbaI
digested pcDNA3.1+ (Invitrogen) backbone.

3.2.2

pCMVe

The pCMVe Luc vector was a kind gift from Copernicus. This plasmid was
generated by ligating a Luc gene onto a pcDNA3.1 vector with a Kozak sequence and an
RU5 sequence at the 5’ end of the plasmid, followed by a polyA tail.
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3.2.3

pMHC

The luciferase gene from pCMV vector was digested and ligated into a pBSK.αMHC
vector (a kind gift from Jeffery Robbins Lab at the University of Cincinnati Medical
Center, Children’s Hospital Medical Center) to generate the pMHC Luc vector. The
MHC promoter is a mouse alpha myosin heavy chain promoter in pBluescript SK (+)
vector (Stratagene, Agilent Technologies, La Jolla, CA) with a 23bp linker region and a
Human Growth Hormone Poly A tail (hGH).

3.2.4

pMHCe

This plasmid was generated by ligating a Luc gene onto an αMHC vector with a
Kozak sequence and an RU5 sequence at the 5’ end of the plasmid, followed by a polyA
tail.

The Luc gene was sub cloned out of the vector and the SDF-1 cDNA was inserted to
generate the pCMV SDF-1, pCMVe SDF-1 and the pMHC SDF-1 vectors respectively.
For the SDF-1 plasmids, the hSDF-1 gene was cloned from the mRNA of human foreskin
fibroblasts

using

the

primers,

Forward:

5’-

GCTAGCGTCGACATGAACGC

CAAGGTCGTGGTCGTGCTGGTC-3’; Reverse: 5’-AAGCTTTTACTTGTTTAAGGC
TTTCTCCAGGTAC TCCTGAAT-3’.
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3.2.5

Plasmid Amplification and Validation

The DNA was amplified using 250mL of LB Broth (Ampicillin) resistance and 50uL
of the frozen bacteria plasmid stock. It was cultured overnight in a shaking incubator at
37oC at 225rpm. The DNA was isolated from the bacterial prep using the PureLink
HiPure Plasmid Filter Maxiprep Kit (Invitrogen, Carlsbad, CA) as per the manufacturer’s
instructions. The DNA was then measured at 260/280nm for concentration using a
Nanodrop 3000 fluorospectrometer (Thermo Fischer Scientific, Waltham, MA).

The CMV driven Luc plasmids, pCMV-Luc and pCMVe Luc were transfected onto
293FT cells and the αMHC driven Luc plasmids, pMHC Luc were transfected onto H9C2
cardiomyoblasts at 50% confluence at 300,000 cells per well in a 6 well plate using the
FUGENE Transfection kit (Roche Basel, Switzerland) as per the manufacturer’s
instructions. The cells were exposed to luciferin at 10µg per ml of PBS per well and the
chemiluminescence emitted was quantified using a cooled couple device camera from the
Xenogen Imaging Systems.

3.3

Animal Handling

All animals were maintained in the AAALAC approved rodent facility of the
Cleveland Clinic Foundation that is staffed by a full time veterinarian and trained
technicians.

The Animal Research Committee of the Cleveland Clinic Foundation

reviews and approves all protocols.

All animals were maintained under sodium
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pentobarbital anesthesia by i.p. injection during the surgical procedures. Once surgery is
complete, bupivacaine (0.5%), a local anesthetic was injected along the sternal wound
which provided analgesia for ~18 hours. The animals were treated with Buprenorphine
after the procedure at a concentration of 0.3 mg/kg up to 3 days after surgery. For
euthanizations, the animals were treated with an overdose of sodium pentobarbital at the
time of sacrifice. This mode of euthanasia is consistent with the recommendations of the
Panel on Euthanasia of the AVMA. We routinely use Buprenorphine as an analgesic in
our protocols.

All animal experiments were approved by the Institutional Animal Care and Use
Committee and we followed the guidelines provided by them. All animals were 8 week
old, weighing 200-225 grams, Lewis rats (Jackson Laboratories Bar Harbor, ME) for the
chronic heart failure study.

3.3.1

LAD Ligations

Briefly, LAD ligation was performed in rats anesthetized with sodium pentobarbital,
50 mg/kg. Animals were intubated and ventilated with room air at 100 breaths per
minute using a rodent ventilator (Harvard Apparatus Holliston MA). The chest was
sterilized with ethanol, and a sternotomy was performed. The left atrium was retracted
and the proximal LAD was identified visually. The proximal LAD was ligated using 6-0
prolene. We were able to verify ligation of the LAD by blanching and dysfunction of the
anterior wall. The sternum and then skin was closed with 4-0 prolene with interrupted
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sutures. Any residual pneumothrorax was reduced using negative pressure generated by
a 20G needle placed in the closed chest, attached to a 10 ml syringe. The rat was then
weaned from the ventilator over the next 10-15 minutes.

3.4

Tissue Fixation and Staining

3.4.1

Harvesting Rodent Organs

At the time of necropsy, the animals were perfused with saline to remove all residual
blood from their circulation and histochoice to fix the tissues immediately. The hearts
were harvested and again fixed in histochoice for 7 days.

3.4.2

Paraffin Embedding

Harvested tissues were then processed by a series of dehydration steps and then
washed in hot paraffin. Plastic labeled blocks were filled with hot paraffin and the tissues
were embedded into them. This was allowed to cool at 4°C for a couple days.

3.4.3

Embedding in OCT for frozen sections

At the time of necropsy, animals are perfused with saline alone, and then organs are
harvested. The tissues are again washed three times in ice cold PBS and then embedded
in the OCT (Optimum Cutting Temperature) compound and placed on dry ice. This is a
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gel at room temperature but freezes on dry ice. This snap frozen tissue, embedded in
OCT is stored at -20°C for a week.

3.4.4

Masson’s Trichrome Staining

Tissues embedded in paraffin blocks are cut into 5 micron slices using a microtome.
These slices are then mounted on transparent slides and stained with the Masson’s
Trichrome dye in a series of steps involving dehydration and staining with the dye for
collagen and heart muscle. Mason’s trichrome is used to quantitate the collagen content.
Fibrosis size or scar tissue was deduced by the percentage of area with collagen as
compared to the total area.

3.4.5

Immunohistochemistry

Tissues were fixed in formalin and embedded in paraffin blocks according to
established protocols. Antigen retrieval was performed using 10 mM sodium citrate
buffer (pH 6.0) and heat at 95°C for 5 min. The buffer was replaced with fresh buffer and
reheated for an additional 5 min, then cooled for 20 min. The slides were washed in
deionized water three times for 2 min each. Specimens were then incubated with 1%
normal blocking serum with goat and donkey serum in PBS for 60 min to suppress
nonspecific binding of IgG. Slides were then incubated for 60 min with the primary
antibody at a dilution specified by the manufacturer in blocking buffer with serum. Slides
were then washed with phosphate-buffered saline (PBS) and incubated for 45 min, with

58

secondary antibody at a dilution specified by the manufacturer in blocking buffer with
serum in a dark chamber. After washing extensively with PBS, coverslips were mounted
with aqueous mounting medium. (Vectashield Mounting Medium with DAPI, H-1200;
Vector Laboratories, Burlingame, CA, USA).

3.5

Isolation of total RNA

RNA from tissue samples were isolated using the Trizol reagents. Briefly, the tissues
were homogenized in Trizol in dry ice and chloroform was added to this. The aqueous
phase obtained was collected and mixed with isopropanol and centrifuged to collect the
samples. RNAgents denaturing solution (Qiagen, Hilden, Germany) was then added to
this to dissolve the pellet. Samples were again collected with isopropanol and are
centrifuged. This sample was further treated with 75% ethanol and centrifuged to collect
samples. The supernatant was discarded without disturbing the pellet and the pellet is
dissolved in DEPC water for future use. Further clean up of the RNA was done with the
use of the Qiagen kit as per the manufacturer’s instructions.

3.6

Preparation of cRNA

First-strand cDNA was synthesized using Oligo dT and Superscript II RT (Invitrogen,
Grand Island, NY). Alternatively, cDNA can be prepared using OVATION RNA
Amplification System (NuGen Technologies, Inc., San Carlos, CA). cDNA amplification
products were fragmented and chemically-labeled with biotin to generate biotinylated
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cDNA targets. Each Affymetrix gene chip for rat genome was hybridized with
fragmented and biotin-labeled target (2.5 μg) in 200 μl of hybridization cocktail. Target
denaturation was performed at 99°C for 2 minutes, followed by hybridization for 18
hours. Arrays were washed and stained using Genechip Fluidic Station 450, and
hybridization signals were amplified using antibody amplification with goat IgG (SigmaAldrich) and anti-streptavidin biotinylated antibody (Vector Laboratories, Burlingame,
CA).

3.7

Imaging

3.7.1

Xenogen IVIS

The animals were routinely measured for luciferase expression using a cooled
coupled device camera from the Xenogen Imaging Systems. The animals were
anesthetized using 2% isofluorane. Luciferin was injected intra peritoneally at a
concentration of 125 mg/kg of the animal. As Luciferin is light sensitive, care was taken
to minimize the amount of light in the room. After 10 minutes, within which time the
luciferin would have been flushed to all parts of the body, real time images were obtained
to determine the luciferase expression of the gene, as expressed by a chemiluminescence
emitted by the luciferase protein in the presence of luciferin.
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3.7.2

Echocardiography

We performed 2D-echocardiography on rats using a 15-MHz linear array transducer
interfaced with a Acuson Sequoia C256 (Siemens, Munich, Germany). The animals were
sedated with ketamine, the chest was shaved, and the sedated animal maintained in a
supine position. For quantification of LV dimensions and wall thickness, we digitally
record 2D clips and m-mode images in a short axis view from the mid-LV just below the
papillary muscles.

This anatomical location was chosen to consistently obtain

measurements from the same anatomical location in different mice. Measurements were
made offline using ProSolv (Indianapolis, IN). Each measurement in each animal was
made 6 times, from 3 randomly chosen m-mode clips out of 5.
As a measure of left ventricular functions, shortening fractions was calculated from
M mode studies.
Shortening fraction: (LVEDD-LVESD)/LVEDD *100 where,
LVEDD: Left ventricular end diastolic dimension
LVESD: Left ventricular end systolic dimension
Dimensions were measured between the anterior and the posterior walls from short axis
view just below the papillary muscle. Left ventricular mass was calculated by
Left Ventricular Mass = 1.05 * ((Anterior Wall Thickness+LVEDD+Posterior Wall
Thickness)3 –LVEDD3)
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3.7.3

Confocal Microscopy Analysis

Tissues were analyzed using an upright spectral laser scanning confocal microscope
(Model TCS-SP; Leica Microsystems Heidelberg, Germany) equipped with blue argon
(for DAPI), green argon (for Alexa Fluor 488), and red krypton (for Alexa Fluor 594)
lasers. Data were collected by sequential excitation to minimize “bleed-through.” Image
processing, analysis, and the extent of co-localization were evaluated using the Leica
Confocal software. Optical sectioning was averaged over four frames, and the image size
was set at 1,024 x 1,024 pixels. No digital adjustments were made to the images.

3.8

Nanoparticle Formulation

Nanoparticles containing BSA and 6-coumarin were formulated using a double
emulsion-solvent evaporation technique. An aqueous solution of BSA (60 mg/ml, 1 ml)
was emulsified in a PLGA solution (180 mg in 6ml chloroform) containing 6-coumarin
(100µg) using a probe sonicator (55W for 2 min) (Sonicator® XL, Misonix, NY). The
water-in-oil emulsion formed was further emulsified into 50 ml of 2.5% w/v aqueous
solution of PVA by sonication (55W for 5 min) to form a multiple water-in-oil-in-water
emulsion. The multiple emulsion was stirred for ~18 h at room temperature followed by
for 1 h in a desiccator under vacuum to remove the residual chloroform. Nanoparticles
were recovered by ultracentrifugation (35,000 rpm for 20 min at 4°C, OptimaTM LE80K, Beckman, Palo Alta, CA), washed two times with distilled water to remove PVA,
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un-entrapped BSA and 6-coumarin, and then lyophilized (−80°C and <10µm mercury
pressure, SentryTM, Virtis, Gardiner, NY) for 48 h to obtain a dry powder.

3.8.1

Conjugation of nanoparticles with RR peptide

Nanoparticle surface was activated by the epoxy compound, Denacol® , followed by
conjugation of the activated NPs to RR-peptide in the second step. Briefly, 60 mg of NPs
were sonicated in 4 mL of borate buffer (50 mM, pH 5.0) for 30 s on an ice-bath. This
was followed by the addition of 40 mg of Denacol® that was also dissolved in an equal
volume of buffer and the reaction was allowed to take place for 30 min at 37 °C with
gentle stirring in the presence of 50 mg of zinc tetrahydrofluroborate hydrate, which
acted as a catalyst. NPs were separated by ultracentrifugation at 30,000 rpm at 4 °C for
20 min followed by three washings with borate buffer to remove any unreacted Denacol®.
To conjugate RR-peptide, epoxy activated NPs were resuspended in 4 mL of borate
buffer and mixed with a solution containing 200 μg of RR peptide in the same buffer. The
reaction was allowed to proceed at 37 °C for 2 h with constant stirring. The unreacted
peptide was then removed by ultracentrifugation as discussed above; the final NP
suspension was lyophilized for 48 h to obtain a dry powder.

3.8.2

High Performance Liquid Chromatography

The mobile phase used for the HPLC analysis was acetonitrile water solution at a
ratio of 65:35 supplemented with 0.005M n-heptane sulfonic acid salt. The column used
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was a C8 column (Waters Technologies). The mobile phase was allowed to circulate
through the column and the samples were dissolved in 100% methanol. Samples were
allowed to pass through the column at a rate of 0.8 ml/minute for 5 minutes. All samples
were in triplicates. Standard curves were generated with increasing concentrations of 6
Coumarin extracted with methanol overnight. Excitation and emission wavelengths were
at 420 and 490 nm.

3.9

Statistical Analysis

All results are expressed as mean + s.e.m. Statistical analysis was performed using
the Students t-test.
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CHAPTER IV

IN VIVO BIO-FLUORESCENCE IMAGING FOR GENE
EXPRESSION

4

4.1

IN VIVO BIO-FLUORESCENCE IMAGING FOR GENE EXPRESSION

Introduction

Gene therapy has evolved as a viable method to deliver therapeutic genes, such as
VEGF, FGF to ischemic myocardium following myocardial infarction. However, this is
limited in its approach as there are not enough bio assays that can quantify the amount or
the presence of these proteins in the injured tissue. Moreover, the expression of these
plasmids is mostly studied ex vivo, wherein the tissue is excised and the level of reporter
molecules are identified via various assays, such as optical microscopy (confocal), PCR
analysis, flow cytometry, microarray analysis, and others. However, this method provides
information for a single time point and for temporal analysis several animals are used,
with one group of animals being sacrificed for each time point. These studies also vary
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between animal groups, and have discordance due to technical errors generated during
intra myocardial injections. A real time in vivo quantification of gene expression can
provide a more cost effective and more accurate data between animal groups.

Several sophisticated imaging modalities can be used to detect physiological changes,
as a response to gene therapy, including magnetic resonance imaging MRI, positron
emission tomography PET, single photon emission computed tomography SPECT and
others.168, 169 However these modalities are extremely complicated, are not well suited for
small animals, and are highly expensive and thus non feasible for initial studies.

Bioluminescent reporters, however, can be used as a tool to determine real time
information on gene expression for plasmid expression studies. Bioluminescent reporters
can provide real time, in vivo monitoring data for gene expression by emitting
chemiluminescence at particular wavelengths. In the past, such studies were only possible
with transparent or translucent objects, however, recent studies using a firefly Luciferase
gene has been shown to provide non invasive quantification of expression due to its
bioluminescent light source internally.170

Luciferase, derived from the firefly, is a

photoprotein used in several molecular biology studies, including in vitro in cells studies,
tumor studies, and gene expression studies.171-173

This study aimed to design and validate a plasmid for effective gene therapy capable
of expressing and sustaining expression in rodent hearts. We wanted to evaluate if optical
imaging could provide detailed information about changes in gene expression, with
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modifications to the plasmid design. Therefore, we designed a plasmid that encoded for
the gene, Luciferase. This protein generates bioluminescence via a reaction in the
presence of a substrate luciferin and oxygen, in order to produce photons of light. Light
thus produced can be imaged via a sensitive detector present in a cooled coupled camera
device.

We injected plasmids encoding Luciferase into rats that had chronic heart failure. We
then serially measured the light emitted from it in the presence of an i.p. injection of
luciferin. This was quantified and analyzed in order to understand the gene expression
profile of this plasmid. We noticed that this profile changed when the gene was enhanced
with transcriptional enhancers boosting the amount of light and the duration that the light
was emitted. Utilizing a cooled camera to detect bioluminescence can help understand the
gene expression profile in gene therapy and eliminate the need for complicated bioassays.
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Mechanism of Biofluorescence Imaging using the IVIS 100

Figure 4-1 : Illustration of the mechanism involved in bioluminescent imaging.
Adapted from www.caliperls.com

When the luciferin protein interacts with oxygen it emits light but this process is
extremely slow. In the presence of oxidative Luciferase, this reaction occurs almost
immediately allowing this light to be quantified. The animal or cells that possess the
Luciferase (Luc) gene are placed in a light tight box. An i.p. injection of luciferin is
administered and this is allowed to circulate through the body. When luciferin interacts
with oxygen in the presence of Luciferase, it emits chemiluminescence, which is captured
by a highly sensitive charged cooled camera device. The signal here needs to be adjusted
for autoluminescence and scattered luminescence.

68

4.2

Methods:

4.2.1

Experimental Plan

1 month (CHF)
Rats are
infarcted

Chest is reopened
Luciferin injected
intra peritoneally
Plasmid of choice
is injected
100µg / site * 4 sites
In the border zone

Imaged using
Xenogen cooled
camera device

Rats were infarcted via LAD ligation and the hearts were allowed to modify to a
chronic heart failure stage. 4 weeks after LAD ligation, the chests were re-opened in
order to inject the plasmid into the border zone of the left ventricle. Rats were imaged
using the IVIS system (Xenogen, CA) in the presence of an i.p. injection of luciferin
serially till no chemiluminescent image was observed for three days in a row.

4.2.2

Optical Imaging System

All studies were performed using the IVIS 50 small animal scanner (Xenogen,
Alemeda, CA) using the Luciferase filter set to match the emission characteristics of the
chemiluminescence emitted from the Luciferase Luciferin reaction. Acquisitions were
performed 10 minutes after an i.p. injection of luciferin to allow for maximum circulation.
Illumination parameters (exposure time of 1 minute, medium lamp voltage = medium,
f/stop of 2, and binning of 2) were selected for each acquisition. For in vitro studies, cell
samples were placed in a black bottomed 6 well plate. Whole-body real-time scans of
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anesthetized rats were acquired in prone and supine position, every day following
myocardial injection of the Luciferase gene.

4.2.3

Image analysis

Images were acquired and analyzed using Living Image 2.5 software (Xenogen,
Alameda, CA, SA) integrated with Igorpro (Wavemetrics, Lake Oswego, OR, USA). The
digitized image intensity is expressed in arbitrary units.

For the in vitro experiments, image analysis involved the designation of regions-of
interest (ROI) as the circular area of the well containing the cell concentrations to extract
the average intensity (sum of the intensity of all pixels within this ROI divided by the
number of pixels). For the in vivo experiments, image analysis involved the definition of
the ROI in each location of enhanced fluorescence as the area having intensity larger than
50% of the peak signal intensity. This ROI was manually selected.

4.2.4

Plasmids Used

The pCMV, pCMVe and pMHC plasmids expressing the Luc gene was used for this
study. Detailed descriptions of these plasmids are described above. (Chapter 3)
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4.2.5

In Vitro Expression

Plasmids were transfected into HEK293A cells or H9C2 cardiomyoblasts at 50%
confluence at 300,000 cells per well in a 6 well plate using the FUGENE Transfection kit
(Roche Basel, Switzerland) as per the manufacturer’s instructions. The cells were
exposed to luciferin at 10 µg per ml of PBS per well and the chemiluminescence emitted
was quantified using a cooled coupled device camera from the Xenogen Imaging Systems.

4.2.6

In Vivo Expression

8 week old male Lewis rats weighing 225-250 grams underwent LAD ligation, as
previously described. 4 weeks later, the chests were re opened and the plasmid was
injected, intra myocardial at 100 µg / 100 µl of plasmid in phosphate buffered solution
(PBS) at 4 sites in the border zone of the infarct using a 30 gauge needle. Animals were
imaged serially, one day post surgery, using the IVIS system. Five animals were used per
group for each plasmid type.

4.3

Results

4.3.1

Plasmid expression in H9C2 cell lines

The inefficiency of physical delivery of non-viral plasmid DNA to cells has been
well documented. One of the strategies employed to circumvent low transfection
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efficiencies has been to identify vector components that yield either high levels of protein
expression or enable target specific expression using tissue-specific promoters. We tested
three different plasmids in the H9C2 myoblast cell line to identify a vector that would
produce sufficient cardiac cell expression over approximately two weeks. Plasmids were
constructed with either the ubiquitous CMV promoter or cardiac-specific αMHC
promoter and the luciferase reporter gene (pCMV, pMHC and pCMVe, Figure 4-2A). We
observed that CMV-driven promoters (pCMV and pCMVe) exhibited higher luciferase
expression (1.3x107 arb units and 2.3x107 arb units) compared to the cardiac-specific
αMHC-driven plasmid (pMHC, and pMHCe at 1.1x106 and 9.2x106 arb units). As
expected, the RU5 translational enhancer in pCMVe increased expression over pCMV
and pMHC plasmids (Figure 4-2B).

Figure 4-2: Plasmid design and in vitro expression profile.
A) A schematic of the gene design is shown here. The promoters, a ubiquitous CMV, or a
cardiac specific αMHC present in the 5’ region are used to drive the gene expression.
Transcriptional enhancers, such as Kozak sequences and RU5 regions are used to boost
the gene expression by multiple folds. B) The in vitro expression of luciferase activity is
shown here. H9C2 cells were transfected with CMV and αMHC driven plasmids at
300,000 cells per well. Transcriptional enhancers, such as Kozak sequences and RU5
regions increase gene expression by multiple folds.
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4.3.2

Evaluation of Gene Expression in rodents

We assessed in vivo vector expression in adult Lewis rats infarcted via a left anterior
descending artery (LAD) ligation followed by direct cardiac injection with 100 µl of 1
mg/ml pCMV, pMHC or pCMVe-luc in saline into the border zone of the infarcted
myocardium at the time of infarct. Control rats were injected with saline. Gene
expression was quantified by measuring chemiluminescence following i.p. injection of
luciferin three days after direct cardiac injection (Figure 4-3). The presence of the signal
in the heart alone, rules out the possibility of the naked plasmid being flushed into the
liver, or being washed away into the circulatory system

Figure 4-3 : Gene expression in vivo in 8 week old rodents
Animals were injected with CMV αMHC plasmids expressing the Luc gene and the
images were obtained after 3 days. The luciferase gene expresses the protein which emits
chemiluminescence in the presence of an i.p. injection of luciferin. This intensity is
measured using a cooled coupled camera device. The greatest intensity was obtained with
the gene vector with transcriptional enhancers.
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4.3.3

Dose-response of cardiac gene transfer

To determine the optimal plasmid dose required for efficient myocardial transfection,
we injected naked plasmid encoding luciferase (pCMV-luc) immediately after ligation of
the LAD in Lewis rats at doses ranging from 0 to 500 μg in 100 μl PBS. A dose-response
curve was generated for vector expression. The peak expression increased up to a dose of
100 µg and saturated at higher doses (Figure 4-4). Therefore, a dose of 100 μg was used
in all subsequent experiments.

Figure 4-4 : Dose curve to determine optimal amount of plasmid in vivo
Infarct model of rodents were injected with CMV pcDNA3.1 Luc at varying doses of 0
µg to 500 µg in the border zone. The chemiluminescence emitted was measured every
day for 5 days after the injection. The gene expression saturated at 100ug. n=3
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4.3.4

Time course of vector expression in the heart

Next we determined duration of expression after cardiac gene transfer with pCMV,
pCMVe and pMHC vectors. All plasmids expressed luciferase in infarcted cardiac tissue.
Expression from the CMV based plasmids expressed for a short period of 5 days,
whereas plasmid pMHC expressed for a longer period of 32 days. Adding elements to
increase transcriptional and translational efficiency significantly affected the expression
profile, with pCMVe expression lasting 15 days. Changing the promoter or adding
elements to increase translational efficiency significantly affected the duration of
expression (Table 4-1).

Promoter
αMHC
αMHC
CMV
CMV

Backbone
pBS
pBS
pCDNA 3.1
pCDNA 3.1

Model
Infarcted rats
Infarcted rats
Infarcted rats
Infarcted rats

Days of expression
32
40
5
16

Table 4-1 : Comparison of maximum expression time between the plasmids.
CMV and αMHC plasmids exhibited different expression profiles when injected in
rodents. CMV plasmids had shorter expression time as compared to αMHC plasmids.
Translational enhancers boosted expression time.

4.3.5

Comparison of peak magnitude between the different plasmids

The magnitude of luminescent intensity was determined for the three plasmids
(pCMV, pCMVe and pMHC). We observed that pCMV peaked at day 3. pMHC showed
maximum expression on day 7 and continued for 30 days. The αMHC promoter had a
smaller magnitude of luciferase expression when compared to CMV promoters.
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Compared to pCMV, the RU5 translational enhancer in the CMV plasmid (pCMVe)
increased peak expression almost 10-fold. The pMHCe plasmid also improved peak
magnitude as compared to pMHC plasmid to almost 10 fold. (Figure 4-5)

Figure 4-5 : Expression profile between various plasmid designs in vivo
Animals were injected with the four different plasmids and the gene expression was
monitored by quantifying the chemiluminescence intensity emitted. αMHC pBS Luc had
the longest expression time, 32 days, and KCPIR Luc had the maximum peak expression,
2.7x107.

4.3.6

Role of promoters and backbones in plasmid design

The vectors backbones used were pcDNA 3.1, which is a standard vector used in
most studies. pBS is the smallest vector and therefore provides greater uptake into the
cells. pKCPIR is a modified pcDNA 3.1 backbone which has a transcriptional enhancer
and an intron/exon unit inserted into the pcDNA backbone, and a modified pBS plasmid
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with the enhancer elements. On comparing pCMV backbones, pMHC backbones,
pCMVe backbones, and the pMHCe backbones, we observed the longest expressions
were obtained by using either the pBS backbone used in the pMHC and the pMHCe
plasmid. The length of plasmid expression is determined by the backbone and does not
change significantly with the use of a translational enhancer element added to this. (Table
4-1).

4.3.7

Role of Transcriptional Enhancers in plasmid design

On comparing the overall magnitudes between plasmids, it can be seen that the role
of transcriptional enhancers is to boost the magnitude of expression. Translational
enhancers slow down ribosomal units so that the chance of the occurrence of translation
is increased. Between the pCMV and pCMVe plasmids, the expression was enhanced by
more than 6 fold. Similarly the use of enhancer elements in the pMHC plasmid boosted
the expression by more than twice. (Figure 4-6)
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Figure 4-6 : Peak expression profile between various plasmids in vivo
Overall peak magnitudes describe the amount of gene expression collected over the time
course of the expression period. Enhanced CMV plasmids exhibited the largest amount of
expressions collected overall.

4.4

Discussion

The use of gene therapy to deliver therapeutic proteins has been utilized for
providing cardiac benefit to ischemic myocardium. However, the use of viral vectors
poses a threat to the host due to immunological responses and toxic concerns. The use of
non viral gene therapy for the delivery of proteins is becoming an attractive option to
reduce immunological responses and eliminate toxic concerns. The limitation of low
transfection efficiencies, associated with non viral mediated gene transfer can be
overcome with the use of translational enhancers. The need to determine the expression
of a gene in vivo, without the excision of the tissue, to provide real time, accurate data
has become necessary and optical imaging with the help of biofluorescence quantification
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provides the tools to do so. In addition, optical imaging allows for data to be collected
from the same animal over time thus reducing the number of animals required for the
study, and eliminating variations between animals.170

To date, no study has been performed with optical imaging as a means to understand
gene expressions. Our expression studies demonstrated that expression of the pCMV
plasmid peaked at day 2 post gene transfer and decreased over the following two weeks.
These findings are consistent with previous literature showing a peak in CMV-driven
gene expression, 2 days after injection in the rat heart.169,174 Peak expression in the
presence of the RU5 element (pCMVe) was 10-fold greater than that seen in the nonenhanced CMV plasmid (pCMV).

It is noteworthy that direct injection of plasmids into the infarct border zone led to
the transfection of cardiac myocytes. In our studies with plasmid delivery restricted to
cardiac myocytes, using the cardiac specific αMHC promoter, there was a delay of 4 days
after plasmid injection, prior to any evidence of significant expression. Furthermore, the
magnitude of expression was 10-fold less than that observed with the pCMV. Although
the signal was low, expression persisted for 32 days. Combining the αMHC promoter
with the RU5 translational enhancer results in significant plasmid expression for up to 1
month post-injection. Replacing the biofluorescent gene to a therapeutic gene, in the
same plasmids will be able to provide expression similar to the expression observed here,
thus optical imaging proves to be a useful tool for gene expression profiling.
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CHAPTER V

STROMAL DERIVED CELL FACTOR-1 GENE TRANSFER FOR
HEART FAILURE

5

5.1

SDF-1 GENE TRANSFER FOR HEART FAILURE

Introduction

We previously identified Stromal cell-Derived Factor-1 (SDF-1, a.k.a. CXCL12) as a
chemokine that is transiently expressed post-tissue injury to promote stem cell homing to
the myocardium.69 SDF-1 enhances tissue repair by preventing cell death and recruiting
blood borne and tissue specific stem cells to the damaged region.69 SDF-1 is a naturallyoccurring chemokine that is rapidly increased after myocardial infarction for a period of
4-5 days.69,175 SDF-1 triggers a number of protective molecular cascades that are both
anti-inflammatory81 and anti-apoptotic to preserve cardiac tissue after injury.176
Furthermore, SDF-1 is a strong chemoattractant of stem cells and progenitor cells that
promote tissue preservation and blood vessel development. The tissue-preserving and
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reparative effects of SDF-1 led us to investigate the potential role of SDF-1 in treating
ischemic cardiovascular disease.

More recently, we have demonstrated that the over-expression of SDF-1 in
myocardial tissue leads to recruitment of endogenous cardiac stem cells to the infarct
border zone.61 Since our original findings several groups have expanded the molecular
mechanisms by which myocardial expression of SDF-1 or its receptor CXCR4 leads to
preservation of cardiac myocytes and improvement in cardiac function in an acute
myocardial infarction setting.74,177 The benefit from adult stem cell therapy, for
preventing and treating cardiac dysfunction, is due to paracrine factors; therefore, the
results of cell therapy can be achieved by gene transfer.

We hypothesized that re-establishing stem cell homing by increasing SDF-1
expression via non-viral gene transfer into the peri-infarct tissue, late after myocardial
infarction, would re-establish myocardial healing through recruitment of bone marrow
derived stem cells and lead to increases in vascular density and cardiac function.69 To
date, we have re-established SDF-1 expression through a cell-based gene transfer
approach using stably transfected fibroblasts,69 mesenchymal stem cells,35 or skeletal
myoblasts transfected with an adenovirus encoding SDF-1 ex vivo.66, 178 SDF-1 protein,
in combination with a slow release matrix, has been shown to improve cardiac function in
a model of ischemic cardiomyopathy.179 While these data would suggest that SDF-1
alone may be sufficient to improve cardiac function, such a conclusion is premature,
since matrix alone has been shown to induce ventricular remodeling.180, 181 The goal of
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this study was to determine if re-establishing myocardial SDF-1 expression without the
concomitant delivery of cells is a viable strategy for increasing myocardial vascular
density and cardiac function in the setting of ischemic cardiomyopathy.

In order to deliver SDF-1 to the myocardium, we injected naked plasmid DNA
encoding hSDF-1 into the infarct border zone. In prior studies, this strategy has proven
to be safe and non-toxic, and is not associated with the toxicities and loss of function that
have been observed with adenoviral injection in the infarct border zone.182 We
characterized plasmid expression in cardiac tissue using a luciferase bioluminescence
reporter system,109 since previous non viral gene transfer studies demonstrated low
transfection efficiency with this approach. We tested plasmid dose, effect of transcription
enhancers, and ubiquitous versus cardiac-specific promoters to increase expression of this
therapeutic gene. We identified an optimal plasmid formulation, using a biofluorescence
reporter and used a similar design for this gene as well. We injected plasmid encoding
SDF-1 into the heart one month after myocardial infarction. This led to a significant
increase in cardiac function four weeks post-injection that could be attributed to
significant increase in vessel density and a trend towards reduction in scar tissue. The
degree of functional improvement correlated with the level of vector expression.
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5.2

Methods:

5.2.1

Experimental Plan

Rats are infarcted
via LAD ligation

1 month CHF

Hearts characterized with
H&E staining and antibody
staining

Chest is reopened,
plasmid is injected
100µg/site * 4 sites
In the border zone

SDF-1plasmid

Echo at baseline,
4 and 8 weeks
Hearts are
harvested

Rats were infarcted via LAD ligation, and the hearts were allowed to modify to a
chronic heart failure stage. 4 weeks after LAD ligation, the chests were re-opened in
order to inject the hSDF-1 plasmid into the border zone of the left ventricle dissolved in
100µg/100µl of PBS, at 4 sites spanning the infarct. Rats were imaged using the
ultrasound echocardiography, before the injections, and 2 weeks, 4 weeks and 8 weeks
post treatment. Hearts were then excised and characterized for vessel density, and fibrosis
extent, via histochemistry studies.

5.2.2

Plasmids Used

The pCMV, pCMVe and pMHC plasmids expressing the hSDF-1 gene was used for
this study. Detailed descriptions of these plasmids are described above. (Chapter 3)
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5.2.3

Intramyocardial Gene Delivery

8 week old male Lewis rats weighing 225-250 grams underwent LAD ligation, as
previously described. To inject the DNA, the chest was reopened four weeks post MI,
applying the same procedure as above. 100 µg of DNA solution in 100 µl of saline per
injection site was injected using a 30 gauge needle, for a total of 4 injection sites around
the border zone. The border zone was identified by the blanched region around the LAD
identified by dyskinetic motion of the anterior wall. The DNA was injected into the wall
and distention of the tissue was observed when the DNA was injected. The chest was
closed as mentioned above for the LAD ligation.

5.2.4

Echocardiographic Analysis

We routinely perform 2D-echocardiography on rats, pre injection, 2 weeks, 4 weeks
and 8 weeks post injection, using a 15-MHz linear array transducer interfaced with a
Acuson Sequoia C256 (Siemens, Munich, Germany). The animals were sedated with
ketamine, the chest was shaved, and the sedated animal maintained in a supine position.
For quantification of LV dimensions and wall thickness, we digitally record 2D clips and
m-mode images in a short axis view from the mid-LV just below the papillary muscles.
This anatomical location was chosen to consistently obtain measurements from the same
anatomical location in different mice. Measurements were made offline using ProSolv
(Indianapolis, IN).

Each measurement in each animal was made 6 times, from 3
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randomly chosen m-mode clips out of 5. As a measure of left ventricular functions,
shortening fractions was calculated from M mode studies.

5.2.5

Immunohistochemistry

8 weeks after the injection of the plasmid, the animals were perfused with saline and
histochoice and the hearts were harvested. Tissues were fixed in histochoice and
embedded in paraffin blocks according to established protocols. Antigen retrieval was
performed using 10 mM sodium citrate buffer (pH 6.0) and heat at 95°C for 5 min. The
buffer was replaced with fresh buffer and reheated for an additional 5 min, then cooled
for 20 min. The slides were washed in deionized water three times for 2 min each.
Specimens were then incubated with 1% normal blocking serum with goat and donkey
serum in PBS for 60 min to suppress nonspecific binding of IgG. Slides were then
incubated for 60 min with rabbit polyclonal von Willebrand factor (Abcam Cambridge,
MA) at 1:100 dilutions in blocking buffer with serum. Myosin was stained with mouse
monoclonal left ventricular myosin (Millipore, Billerica MA) at a dilution of 1:10 in
blocking buffer with serum. Optimal antibody concentration was determined by titration.
Slides were then washed with phosphate-buffered saline (PBS) and incubated for 45 min,
with IgG donkey anti-rabbit Alexa fluor 594 (Molecular Probes, Invitrogen, Carlsbad,
CA) at 1:800 dilution in blocking buffer with serum and IgG goat anti-mouse Alexa Fluor
488 (Molecular Probes, Invitrogen, Carlsbad CA) at 1:800 dilution in blocking buffer
with serum respectively in a dark chamber. After washing extensively with PBS,
coverslips were mounted with aqueous mounting medium. (Vectashield Mounting
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Medium with DAPI, H-1200; Vector Laboratories, Burlingame, CA, USA). For arteriole
imaging, a mouse monoclonal α-sarcomeric actin antibody was used at a 1:200 dilution
(Sigma).

5.2.6

Masson’s Trichrome Staining

8 weeks after the injection of the plasmid, the animals were perfused with saline and
histochoice and the hearts were harvested. The hearts were fixed in histochoice for 7 days
and then embedded in paraffin. Hearts were then sectioned and stained with Masson’s
Trichrome staining for identifying the infarct. Mason’s trichrome was used to quantitate
the collagen content. Fibrosis size or scar tissue was deduced by the percentage of area
with collagen as compared to the total area.

5.3

Results:

5.3.1

Intra-myocardial injection of SDF-1 plasmid increased vessel density

Previous studies have shown that SDF-1 expression is increased after MI and recruits
stem and/or progenitor cells to promote tissue preservation and promote vasculogenesis.
We tested whether non-viral gene transfer of vector expressing SDF-1 would improve
vasculogenesis following myocardial infarction. As described above, rodents were
infarcted via LAD ligation and received direct injection of SDF-1 plasmid DNA one
month post myocardial infarction. Myocardial sections obtained from animals that
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received SDF-1 gene transfer, 8 weeks after injection, were stained with antibodies
against von Willebrand Factor (vWF) to assess vasculogenesis (Figure 5-1). We observed
a statistically significant increase in blood vessel density in the infarct zone in the animals
that received pCMVe-hSDF-1 and pCMV-hSDF-1, as compared to saline controls (p<0.
0001). The infarct border zone and infarct zone, on average, had a higher blood vessel
density in the pCMVe-hSDF-1 group (21 vessels/mm2) and pCMV-hSDF-1 group (17
vessels/mm2) than those in the saline group (6 vessels/mm2) (n=7 in all groups) (Figure
5-2). The vessels observed by vWF staining were also co-stained with α-smooth muscle
actin. A co-localization of endothelial cells and actin filaments was observed (Fig 5-3),
which further established the fact that the blood vessels observed were arterioles and
arteries, and not capillaries.

Interestingly, the pCMVe vector that had the highest peak expression did not induce
significantly greater vasculogenesis than the lesser expressing unenhanced pCMV vector.
This result suggests that delivering a minimum threshold amount of SDF-1 was necessary
to induce vasculogenesis but that more SDF-1 did not induce more.
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Figure 5-1: Vessel density count (vessels / mm2) in rodents that received SDF-1 gene
Double staining with von Willebrand Factor and ventricular myosin showing blood
vessels and myocytes respectively in the infarct zone after injection with saline as
control, or plasmids; CMV pcDNA SDF-1 and CMV KCPIR SDF-1 (n=7 in all groups)
are represented above. The number of arterioles observed in the SDF-1 treated groups is
significantly greater than the controls. (p<0.001)
Red: vWF; Green: Myocytes; Blue: Dapi. Magnification = 20x

Figure 5-2 : Increase in blood vessels following SDF-1 gene therapy
Vessel density was significantly increased in the SDF-1 treated animals compared to
saline controls.CMV KCPIR-SDF1, 21 ± 1.82 vessels/mm2; CMV pcDNA-SDF1 17 ±
1.48 vessels/mm2 , and PBS 6 ± 0.73 vessels/mm2. *, p<0.001.
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Figure 5-3 : Actin staining to determine the vessels to be arterioles
Immunohistochemistry with vWF and α- sarcomeric actin staining showing blood vessels
and actin staining in the infarct zone, 8 weeks after injection with CMV KCPIR SDF-1
(n=7). The positive staining identifies the blood vessels as mature arterioles and not
capillaries. Red: actin; Green: vWF for vessels, Blue: Dapi. Magnification = 20x

5.3.2

SDF-1 plasmid therapy improves ventricular function in ischemic rats

We hypothesized that the SDF-1 plasmids that induced vasculogenesis would also
improve cardiac function post-MI. To test this hypothesis, ischemic hearts were injected
with hSDF-1 pDNA vectors. Pre-injection (one month post infarct), all rats had fractional
shortening (FS) < 30%. 4 weeks post-injection, control animals had a decrease in
fractional shortening by 35.9%. In contrast, the pCMV-SDF1, and pCMVe-SDF1 groups
showed statistically significant improvements of 4.62% and 24.97% respectively, by 4
weeks, (p < 0.01) compared to control. In contrast, a cardiac-specific promoter, αMHCdriven plasmid (pMHC-hSDF1) treated animals did not improve function compared to
control animals exhibiting a decline in FS of 32.65% (Figure 5-4). Importantly, the
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improvement in cardiac function correlated with an increase in blood vessel density
strongly suggesting a link between vasculogenesis and cardiac functional improvement.
However, the greater benefit seen with the pCMVe compared to pCMV suggests that
there are other mechanisms in play as well since pCMVe did not induce significantly
greater vascular density compared to pCMV.

SDF-1 gene transfer induced cardiac

benefit was sustained at 8 weeks, as the animals that received the CMV-driven plasmids
continued to demonstrate improved cardiac function compared to saline control and
αMHC vector groups (Fig 5-5).

Other parameters of cardiac function, such as the thickening of the anterior and
posterior walls, trended toward significant improvement (i.e. an increase in wall thickness)
in the pCMVe-hSDF1 treated animals. No significant change was observed in the
pCMV-hSDF1 treated animals, the pMHC-SDF1 treated animals or the saline control
animals. There was no change in left ventricular mass in any group. (Figure 5-6). Since
the animals treated with the plasmid producing the highest peak expression had the
largest cardiac benefit, these data suggest the importance of the magnitude of hSDF-1
vector expression rather than the length of plasmid expression in determining
improvement in cardiac function.
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Figure 5-4 : Functional benefit observed in vivo with SDF-1 plasmid treatment
Pre-injection, (one month post infarct) all rats had a Fraction of Shortening % (FS%) <
30%. 4 week post injection, the control group (n=10) decreased in FS. In contrast, both
CMV-driven plasmids showed a statistically significant improvement of 5% (CMV-SDF1) (n=9) and 25% (CMVe-SDF-1) (n=10) respectively (p<0.02). The cardiac-specific
promoter plasmid (αMHC- SDF1) (n=5) did not improve function compared to control.

Figure 5-5 : Sustenance of benefit for 8 weeks post treatment
The improvement in cardiac function following plasmid injection is sustained 8 weeks
after injection. CMV driven plasmids depict an increase in cardiac function as compared
to saline controls and αMHC driven plasmids.
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Figure 5-6 : Other physiological parameters associated with benefit
Other physiological parameters such as left ventricular mass, anterior wall and posterior
wall thickening between rodents from the different treatment groups are assessed here.
These parameters are symptomatic with ventricular remodeling.

5.3.3

SDF-1 gene transfer reduced fibrotic tissue in the infarct zone

We performed Masson’s Trichrome staining to determine the infarct size,
represented by fibrotic tissue, 4 weeks after treatment with plasmids. The infarct size was
reduced in the animals that received SDF-1 plasmid when compared to the saline animals.
The fibrotic area was smaller in the pCMVe-SDF1 group (16.92%) and pCMV-SDF1
group (17.81%), than in the saline group (23.82%) (n=7 in all groups). These results
exhibit a strong trend towards reduction in cardiac fibrosis following SDF-1 treatment
(p=0.08) (Figure 5-7).
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Figure 5-7 : Masson’s Trichrome staining to determine infarct sizes in vivo
SDF-1 gene therapy reduces infarct size, 8 weeks after treatment in chronic heart failure.
The left ventricular fibrotic area was significantly smaller in the SDF1 groups (compared
to the saline group. (n=7 in all groups)

Figure 5-8 : Decrease in fibrotic scar following SDF-1 treatment
The left ventricular fibrotic area was significantly smaller in the CMV KCPIR-SDF1
(16.92 ±2.82 %) and CMV pcDNA-SDF1 groups (17.81 ±2.59 %), compared to the
saline group (23.82 ±4.47 %). (n=7 in all groups)
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5.4

Discussion

Regenerative medicine has significant potential for the treatment of ischemic cardiac
disease because, unlike current treatments that focus on either alleviating symptoms or
reducing cardiac work load, regenerative medicines provide an opportunity to repair and
retain function in degenerating organs. Non-viral gene delivery, or the application of
naked plasmid DNA to express a therapeutic protein at a specific site, is a simple delivery
method that has been tested clinically in ischemic patients for over 15 years. A
substantial body of literature, both preclinical and clinical, has demonstrated that nonviral vector delivery of therapeutic genes is safe and effective. The safety profile of nonviral gene delivery is also attractive when compared to viral vector therapy delivery
because it does not produce a significant inflammatory response that viral vector delivery
can cause; nor is there concern for antibody response to the vector due to prior viral
exposure in the patient.

Cardiovascular gene therapy has been found to be a safe strategy to obtain transient
protein expression in the heart. Skeletal and cardiac muscle have been shown to take up
and express plasmid encoded genes as well as transgenes incorporated into viral
vectors.183, 184 While viral vectors yield increased transfection efficiencies compared to
non-viral strategies, they induce inflammatory responses that may result in unwanted side
effects and preclude repeat administrations.185 In vitro and in vivo studies have shown
that despite lower gene transfer efficiency with non-viral methods, site-specific
administration of the gene still results in physiological effects within the tissue.186, 187
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Some advantages of non-viral gene transfer are the ability for repeat administration of
therapy and the potential for transient protein expression. Several clinical trials have
demonstrated safety and efficacy for non-viral gene therapy in ischemic cardiovascular
disease.110

We previously identified Stromal cell-Derived Factor-1, or SDF-1, as a naturallyoccurring protein that is rapidly produced in response to ischemic tissue injury.175 SDF-1
induction stimulates a number of protective anti-inflammatory pathways, is increased in
the myocardium after a heart attack, but only lasts for a matter of days, and therefore the
protective response quickly fades. This short duration of SDF-1 action reduces the
potential for tissue repair. A non-viral plasmid producing SDF-1 for treatment of heart
failure provides a potentially safe means through which to obtain longer, albeit transient
(< 15 day) therapeutic protein production in the heart while allowing for the possibility of
repeat injections.

In this study, we have demonstrated that the delivery of SDF-1 plasmid to the infarct
border zone, 1 month after myocardial infarction, led to an increase in vascular density
and improvement in cardiac function that was sustained 8 to 10 weeks after gene transfer.
Our expression studies demonstrated that expression of our optimized plasmid peaked at
day 2 post gene transfer and decreased over the following two weeks. These findings are
consistent with previous literature showing a peak in CMV-driven gene expression, 2
days after injection in the rat heart.169, 174 Peak expression in the presence of the RU5
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element (pCMVe) was 10-fold greater than that seen in the non-enhanced CMV plasmid
(pCMV).

The degree of functional changes with any given plasmid encoding hSDF-1
correlated with the level of luciferase expression achieved with that plasmid construct.
We observed continued decline in cardiac function in the animals that received saline or
the low expressing αMHC plasmid (pMHC). Four weeks after plasmid injection (8
weeks after MI) there was a decline in cardiac function in both these groups, which
correlated with low expression profiles. Both CMV vectors resulted in an increase in
cardiac vascular density. However, the animals that received the CMV plasmid with
enhancer elements (pCMVe) increased cardiac function to a greater extent than those
animals that received the CMV plasmid alone (pCMV).

Increased SDF-1 expression in the infarct border zone also led to a decrease in
myocardial fibrosis at 8 to 10 weeks after plasmid injection. Similar to the change in
vascular density, there was an inverse correlation between the degree of myocardial
fibrosis and SDF-1 expression, suggesting that the mechanisms behind scar remodeling
may be crucial to the understanding of the therapeutic response to SDF-1. These data
suggest that SDF-1 treatment attenuates the progression of chronic ischemic heart failure
and may partially reverse manifestations of the disease by increasing vasculogenesis,
reducing scar formation and attenuating pathological cardiac remodeling after MI.
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CHAPTER VI

IDENTIFICATION OF TARGETING PEPTIDES

6

6.1

IDENTIFICATION OF TARGETING PEPTIDES

Introduction

Gene therapy has evolved as a viable therapeutic option for treating patients with
chronic conditions. We have optimized and established a vector system for delivering
plasmid hSDF-1 to the myocardium in order to provide significant cardiac benefit, due to
improved angiogenesis in the cardiac tissue. However, we injected this plasmid into the
myocardial wall, thus requiring an invasive procedure in order to deliver the therapeutic
gene. Injecting the plasmid directly into the myocardium, ensures maximum efficacy of
the therapeutic gene, as it is delivered into the micro environment associated with the
damaged tissue, therefore, improving the chances of the gene being taken up by these
cells. However, delivery of naked plasmid into the tissues, increases the probability of
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being subject to endosomal degradation. Therefore, only a smaller portion of the plasmid
injected is taken up by the cells and then translated to the therapeutic protein. In order to
protect the genes from degradation, scientists have studied various techniques to package
the plasmid and safely deliver it to organs.188,189 However, although this technique
protects the DNA from being degraded, it does not eliminate the need for invasive
surgery.

Systemic delivery of the plasmid, packaged into safe compartments is an optimal
solution. Recent advances in identifying various polymeric carriers capable of
encapsulating the DNA safely have spurred research into identifying efficient targeting
ligands to direct the polymeric vectors to the organs of interest.

Phage libraries are able to provide a comprehensive list of peptide sequences that
specifically bind to particular molecules. A large number of phage particles
(approximately 1010-12) are exposed to a specific molecule, a certain organic compound,
sugar molecule, or even cells in culture, to identify the few that bind to them.160 An
extension of this technique, is in vivo phage panning, where a similar number of phage
particles are infused via a vein into an animal, to identify the few ones that specifically
bind to the targeted organ.158 These have shown to traverse intestinal mucosal layers, skin
layers to target cells within them.152 They have been used to identify targets for tumor
cells, identify targets to the brain via an intra nasal pathway, and reach amyloid plaques
with the help of antibodies.150, 153, 155, 190 Infusion of phage display libraries within M13
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bacteriophage may be useful in identifying specific ligands in the infarct region of the
heart.

In this study, we hypothesized that delivering a large number of phage particles, with
multiple copies of various peptides in the library, can lead us to one or a few targets to
the infarcted zone in the heart. The main focus was to identify one or a few ligands that
have a high affinity for infarct tissue and are specific to the heart. This can then be used
to tag polymeric devices, or the naked plasmids to infuse therapeutic genes to the
ischemic myocardium.

We infused the circular C7C peptide library in M13bacteriophages into rodents that
exhibited chronic heart failure. 1.5 hours post infusion we removed the heart, separated
the infarcted and border region, and eluted the phages in this region of the heart. This was
amplified and panned for a second round. After 3 rounds of panning and sequencing of
the peptides with affinity to the infarcted region of the heart, we identified the sequence
to be a 7 peptide sequence of RQPRMKR (RR peptide) flanked on either sides by
cysteines to provide a circular CRQPRMKRC ligand with selective affinity to the heart.
On infusing this peptide tagged with a fluorescent label, we confirmed the targeting
nature of this peptide with immunohistochemistry studies.
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6.1.1

Mechanism of phage panning

The Ph.D. C7C library consists of random 7-mer peptides flanked by cysteines in
order to conserve the 7-mer peptide by giving it a circular conformation. The cysteine
residues are oxidized during phage assembly, and thus allow for a di-sulfide link that
brings the 7-mer peptide to a circular construct, conserving its sequence. These 7-mer
peptides are fused to the minor coat protein of the M13 bacteriophage via a linker
sequence Gly-Gly-Gly-Ser. These variant libraries are expressed on the outside of the
phage, while the genetic material encoding the 7 mer is inside the phage particle. The
presence of the peptide on the surface, bound to the phage, creates a link that can bind the
phage to selective targets, antibodies, receptors enzymes etc.

In vitro phage panning is carried out when multiple copies of each variant peptide is
exposed to a surface antigen, the unbound phage is washed away and the resulting phage
is eluted, amplified and exposed to a second surface with the antigen. Each such round is
called panning. After 3 to 4 rounds of panning, an exclusive sequence is identified by
DNA sequencing and ELISA, which binds to the antigen.132, 150, 151

In vivo phage panning refers to an extension of the in vitro phage panning, to identify
potential ligands that bind to organs. Phage with its variant libraries is circulated through
an animal, following infusion via a vein. The organs are harvested and the bound phage is
eluted, amplified and identified.155
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Figure 6-1 : Mechanism of in vivo phage panning technique in rodents.
Adapted from Nature Reviews Cancer 2, 83-90 (February 2002)

6.2

Methods:

6.2.1

Phage Panning

M13 phage library Ph.D.-7 (M13-based, complexity

2.8×109 transformants; New

England BioLabs, Schwalbach, Germany) which displays random 7-mer peptides at the
N-terminus of the pIII protein (high stringency: only 3–5 copies per phage particle) was
used. 1.2×1011 pfu of phage library in 200 µl saline was delivered to three anesthetized
Lewis rats (8–12 weeks old), one month post infarction via LAD ligation. LAD ligation is
described above. These animals were sacrificed 1.5 hours post infusion. Following
careful dissection to avoid any possible puncture of gastro-intestinal tract and
exsanguinations by cutting jugular veins, the rats were perfused through the heart with
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120 ml of saline to remove all blood. The hearts were removed and washed in ice cold
saline. Tissues were weighed and, homogenized in 2 ml of tissue suspension buffer
(DMEM, with 1% BSA and 10% protease inhibitors). Bound phage was eluted from this
with glycine and stabilized with Tris. This was amplified with E Coli. 1.2×1011 pfu of
amplified phage was re-infused via tail veins. This process was repeated three times. At
the end of the 3rd round, eluted phage was sequenced and identified.

6.2.2

Peptide Synthesis and Analysis

The RQPRMKR peptide was synthesized by the Protein Core lab at the Cleveland
Clinic and confirmed by mass spectrometry. This peptide was tagged with a His tag. A 6His peptide was attached to the N terminal end, thus synthesizing a 6-His-RQPRMKR
peptide (RR peptide).

Rats were infarcted via LAD ligation, as described before. One month post ligation,
the RR peptide was infused via the tail vein. 1.5 hours later, the animal was sacrificed
and the heart, lung, liver, spleen and kidney was excised, and washed in ice cold PBS.

6.2.3

Immunohistochemistry

Organs were embedded in OCT compound and were frozen immediately. The tissue
samples were stored for long periods of time at -80°C. Frozen samples were cut in a
cryotome at 5micron thickness and mounted on slides. Tissue specimens were fixed with
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paraformaldehyde and incubated with 1% normal blocking serum with goat and donkey
serum in PBS for 60 min to suppress nonspecific binding of IgG. Slides were then
incubated for 60 min with mouse monoclonal anti His antibody (Abcam Cambridge, MA)
at 1:200 dilutions in blocking buffer with serum. Slides were then washed with
phosphate-buffered saline (PBS) and incubated for 45 min, with IgG goat anti-mouse
Alexa fluor 488 (Molecular Probes, Invitrogen, Carlsbad, CA) at 1:800 dilution in
blocking buffer with serum in a dark chamber. After washing extensively with PBS,
coverslips were mounted with aqueous mounting medium. (Vectashield Mounting
Medium with DAPI H-1200; Vector Laboratories, Burlingame, CA, USA).

6.3

Results

6.3.1

Identification of targeting peptide

In vivo phage panning was performed in rats with LAD ligation, one month post
infraction. Infarction in the hearts was confirmed by echocardiography. 1.2x1012 particles
was infused via the tail vein. 1.5 hours later, when the particles have had enough time to
circulate through the body, hearts were excised. The blanched region was identified as
the infarct zone. The region in between this zone and the healthy tissue is termed the
border zone. Tissue sections were washed in ice cold saline, and the blanched region was
sectioned out. Tissues were homogenized and the phage was eluted. Phage was
sequenced using primers provided in the kit. Three colonies were picked after each round
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of panning. After three rounds of panning, a common sequence of Arg-Glu-Pro-Arg-MetLys-Arg (RQPRMKR) was identified. (Figure 6-2)

Figure 6-2 : Phage panning to determine a targeting sequence to the ischemic heart
Colonies obtained from rodents (n=3) after each panning cycle were sequenced to
identify the phage that bound to the ischemic hearts in their respective cycles. The first
pan identified multiple sequences but after the third round a common sequence was
identified.

6.3.2

Synthetic Peptide Formulation and Analysis

This peptide was synthesized at the CC Proteomics Core lab. The peptides were
synthesized with a fluorescent tag attached to one end. A (His)6 – RQPRMKR peptide
was synthesized and the purity was checked by reverse phase liquid chromatography. The
mass was determined using a mass spectrometer and was recorded at 1794.60 units using
a 4700 Reflector Spectrometer.
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6.3.3

In Vivo Expression Profile of the RR peptide

The RR peptide tagged with His was infused at 200 µg of peptide in 200 µl of PBS
into tail veins in rodents, one month after LAD ligation. Prior to infusion, rats hearts were
imaged via echocardiography to ensure an akinetic wall motion and a loss in fractional
shortening (<30%). The rats were then perfused with saline, and the organs were excised
and embedded in OCT compound. Sections were made and the tissue samples were
stained with fluorescent antibody markers against His and Dapi for nuclear detection.
Heart sections were stained positive against the His antibody, thereby confirming the
presence of the (His)6 – RR peptide. All other organs, lungs, spleen, liver and kidney
were stained negative for His, thus confirming the absence of this peptide in all other
organs. (Figure 6-3)

The RR peptide specifically targets the heart tissues and has high affinity to the
infarct region. This peptide may be used as a targeting molecule to direct therapeutic
drugs and genes to the infarct region.
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Figure 6-3 : Specificity of peptide interaction with heart tissues
Rodent hearts were frozen and then stained for His antibody. A “His” tag was attached to
the peptide sequence thus a positive His stain correlated with a positive peptide
identification. Peptides were infused via the tail vein and translocated to the heart tissue
specifically.

6.3.4

BLAST Analysis of the targeting peptide

The RQPRMKR sequence with the genomic code of agg cag ccg cgc atg aag cgg
was compared against all the known sequences n the rat genome using the BLAST
software. There were some similarities in the sequence code with other known protein
sequences such as FAS Associated Factor -1 (FAF-1) which has the sequence
qiverqprmldfrveyrdrn and another protein, Sodium-dependent phosphate transporter 1 or
Solute carrier family 20 member 1 a.k.a. Phosphate transporter 1 (PiT-1) which has a
sequence wffvcprmkrkierevkssp. But neither of these sequences possesses all the 7-mer
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sequence, therefore a conclusive evidence of either of these two proteins is lacking.
(Figure 6-4)

Figure 6-4 : BLAST Analysis of the peptide sequence with other known proteins
BLAST analysis provides a comparison between a known peptide sequence to the whole
genome to identify potential peptide targets or proteins associated with the peptide.
Analyzing the targeting peptide against the rat genome using the BLAST software
provided two potential protein targets, FAF-1 and PiT-1.
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6.4

Discussion

Targeting peptides are an essential component in delivering genes or encapsulated
drugs to the organ of interest. There has been a growing body of researchers trying to
develop micro particles, and other polymeric compounds to devise novel means to
encapsulate genes and drugs to protect their safety from degradation.191 However, on the
other hand, research involving the identification of targeting ligands has been slow to
progress. This is partly due to the lack of effective libraries required for screening of
ligands. Previously, researchers studied various angiogenic and inflammatory pathways
that were triggered during injury to build a library of possible ligands and then screened
them to identify effective ones. This poses a problem with missing out on ligands that
were not included as part of the list.159

The PhD library, using phages has revolutionized the screening for target compounds
to complex diseases, such as cancer.155 The PhD libraries provide every possible
combination of the whole genome, and thus are useful in identifying ligands that may be
involved in targeting.150 However, the repeated panning cycles, are responsible for the
high selectivity in this process. The prepared libraries have sufficient complexity to
produce multiple DNA sequences encoding the same consensus peptide motifs. These
libraries are used for various purposes, ranging from epitope mapping, material-specific
peptide identification, in vitro testing and identification, small molecule discoveries,
enzyme substrates and various in vivo applications.148, 149, 151, 154, 160 The Ph.D. libraries
have been used extensively for discovery of peptide antagonists of VEGF-mediated
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angiogenesis, trans-dermal trafficking and trans-intestinal trafficking peptides, and cell
targeting peptides.151, 152, 155

In our study we have identified and confirmed a peptide sequence of RQPRMKR,
with some unknown binding sites that may relate to the FAF-1 peptide or the PiT-1
peptide. This sequence was identified after three different panning rounds. This peptide
was synthetically made and tagged with a fluorescent label of 6-His. This peptide
sequence was specific among 1.2x1011 pfu of phage and demonstrated specificity to the
heart tissue as compared to the various other organs. When used as a tagging peptide to
nanocarriers, this peptide will be capable of transporting the carriers to the heart alone,
and thus reduce risks of secondary organ complications.

This study now opens the doors towards the application of this targeting peptide in
multiple applications involving the failed heart, thus providing the solution to systemic
delivery of drugs for patients, who are incapable of undergoing a surgical procedure.
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CHAPTER VII

ENGINEERED NANOPARTICLES AS CARRIERS FOR SYSTEMIC
DELIVERY

7

7.1

NANOPARTICLES AS CARRIERS FOR SYSTEMIC DELIVERY

Introduction

Gene therapy has evolved as a promising option to deliver pro-angiogenic proteins to
infarct zones, thus providing cardiac benefit. We have identified a gene design without
viral promoters, using the ubiquitously-expressing CMV promoter and transcription
enhancers, to improve the length and magnitude of gene expression as compared to
traditional naked plasmid deliveries. Using this design we delivered therapeutic levels of
Stromal Derived Cell Factor-1 (SDF-1) (which is pro-angiogenic) in rodents and pigs
with chronic heart failure, by direct injection in the border zone, thereby improving
cardiac function. To target cardiac myocytes in the infarct zone, we also generated a
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vector with a cardiac-specific αMHC promoter. On assessing the gene expression, in vivo,
we observed that non-enhanced αMHC driven plasmids have low magnitudes of
expression which could be increased 10-fold, to therapeutic levels, with transcriptional
enhancers. This therapy is safe, effective, and the benefits can last long after the
expression of the gene is lost. We have also studied and identified targeting peptides that
allow for systemic targeting to the heart.

However, the need for improving penetration of the genes into the cells has long
been a challenge. Studies with cell penetrating peptides, such as TAT, VP22, etc have
shown improvements in cell penetration of therapeutic drugs.192-195 Encapsulations of
drugs and plasmids within polymeric devices have been studied extensively. The need for
biodegradable particles, to encapsulate drugs, and deliver them safely to injured tissue, in
an active form, has been the reason for the development and growth of nanoparticulate
systems. PLGA (poly lactide co glycolide) is a poly ester with growing interest due to its
stability, ability to bind targeting ligands to the surface, regulated control of release of the
encapsulated plasmid in the cytoplasm, ability to be degraded in vivo, following the
release of the plasmid, and approval for use in human trials by the FDA.114, 118 Our focus
was to engineer a polymeric carrier that is capable of targeting the ischemic myocardium
and delivering therapeutic drugs to it. PLGA polymeric devices may be able to
encapsulate therapeutic genes and deliver them safely to tissues via the systemic
circulation.
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We hypothesized that encapsulating the gene of interest into PLGA polymeric
particles, tagged with the RQPRMKR (RR) peptide will be able to provide a targeting
encapsulated drug capable of homing to the ischemic myocardium via systemic delivery.
The targeting peptide, RR, when tagged to the polymeric complex, will be viable and in
its active form, and will be able to direct the polymeric complex to the injured
myocardium. The PLGA polymer will then be able to release the encapsulated material
into the area of injury.

To understand the behavior of encapsulated drugs in vivo, and to determine the
efficacy of this system, various strategies have been studied in the past. Fluorescent
nanoparticles with polystyrene have been used as models to understand tissue uptake and
trafficking.196 Other strategies have employed gold colloidal particles that can be viewed
by transmission electron microscopy due to its dense matter.197 6 Coumarin (6C) is a
lipophilic fluorescent dye that can be viewed by confocal microscopy, and its
fluorescence activity can be accurately measured by High Performance Liquid
Chromatography (HPLC) analysis.127,198 Our focus was to design a nanoparticulate
carrier capable of encapsulating 6C, a fluorescent dye, and delivering it to the
myocardium, with the help of a tagging peptide. The uptake and in vivo trafficking would
then be monitored to determine the dose, time, and other aspects associated with this
delivery system.

In order to determine the release and uptake of nanoparticles in vitro, we added
nanoparticles with or without the homing peptide to cardiac fibroblasts seeded on 6 well
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plates. As expected, we did not see a difference in fluorescence between the two groups.
The uptake took place in about 30 minutes and stayed for more than 24 hours. In vivo, we
observed a greater uptake of nanoparticles, as determined by the amount of fluorescence
in various organs, in the injured myocardium, as opposed to the healthy myocardium. RR
peptide helps target the encapsulated material to the injured myocardium.

On replacing the 6C dye with a therapeutic gene, such as SDF-1 we may be able to
show improved cardiac benefit via systemic delivery, capable of translating this complex,
to patients with chronic heart failure.

7.2

Methods

7.2.1

Materials

BSA (Fraction V) and PVA (average molecular weight, 30,000–70,000) were
purchased from Sigma (St. Louis, MO). 6-Coumarin was purchased from Polysciences
(Warrington, PA). PLGA (50:50 lactide–glycolide ratio, 143,000 Da, viscosity 0.87dl/g)
was purchased from Birmingham Polymers (Birmingham, AL). RR-peptide of the
sequence (His)6 - Arg-Glu-Pro-Arg-Met-Lys-Arg (molecular weight 1784) was custom
synthesized by Cleveland Clinic Proteomics Core(Cleveland, OH). Denacol_ EX-521
(Pentaepoxy, molecular weight 742) was a gift from Nagase Chemicals Ltd (Tokyo,
Japan). Zinc tetrahydrofluroborate hydrate, poly(vinyl alcohol) (PVA, average molecular
weight 30,000–70,000), dextran, boric acid, and ethanol were obtained from Sigma
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Chemical Co. (St. Louis, MO). Chloroform was obtained from Fisher Scientific
(Pittsburgh, PA).

7.2.2

Formulation of 6C loaded PLGA nanoparticles

Nanoparticles containing BSA and 6-coumarin were formulated using a double
emulsion-solvent evaporation technique as described previously. An aqueous solution of
BSA (60 mg/ml, 1 ml) was emulsified in a PLGA solution (180 mg in 6ml chloroform)
containing 6-coumarin (100µg) using a probe sonicator (55W for 2 min) (Sonicator® XL,
Misonix, NY). The water-in-oil emulsion formed was further emulsified into 50 ml of
2.5% w/v aqueous solution of PVA by sonication (55W for 5 min) to form a multiple
water-in-oil-in-water emulsion. The multiple emulsion was stirred for ~18 h at room
temperature followed by for 1 h in a desiccator under vacuum to remove the residual
chloroform. Nanoparticles were recovered by ultracentrifugation (35,000 rpm for 20 min
at 4 °C, OptimaTM LE-80K, Beckman, Palo Alta, CA), washed two times with distilled
water to remove PVA, unentrapped BSA and 6-coumarin, and then lyophilized (−80 °C
and <10_m mercury pressure, SentryTM, Virtis, Gardiner, NY) for 48 h to obtain a dry
powder. Dry lyophilized nanoparticle samples were stored in a desiccator at 4°C and
were reconstituted in a suitable medium (buffer or cell culture medium) prior to an
experiment.
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7.2.3

Conjugation of targeting peptide:

The peptide to be conjugated is the RQPRMKR peptide, identified via phage
panning experiments. Prior to conjugation, the peptide is tagged with (His)6 residues in
its N terminal. The peptide was conjugated to the nanoparticles in two steps.

Step 1: Surface activation step: nanoparticles were suspended in borate buffer
(50mM, pH 5.0) by sonication for 30 sec on an ice bath. This is followed by the addition
of Denacol (40 mg), an epoxy that helps conjugation of the peptide on the surface and the
catalyst zinc tetrahydrofluroborate hydrate (50 mg) also dissolved in an equal volume of
buffer to the NP solution. This mixture was stirred gently for 30 minutes at 37C. NPs
were separated by ultracentrifugation at 30000 rpm for 20 minutes at 4C. Any unreacted
Denacol is removed by multiple wash steps.

Step 2 : Conjugation of peptide: Surface activated NPs were suspended in borate
buffer (4 ml) and stirred into a solution containing three different initial amounts of
peptides; 250ug, 500ug and 1 mg in borate buffer. This reaction is carried out for 2 hours
at 37C. The unreacted peptide was removed by ultracentrifugation and the final
nanoparticles suspension was lyophilized for 48 hours.

115

7.2.4

Nanoparticle characterization

Particle size and surface charge (zeta potential).

Particle size and size distribution were determined by photon correlation
spectroscopy (PCS) using quasi-elastic light scattering equipment (ZetaPlusTM equipped
with particle sizing mode, Brookhaven Instrument Crop., Holtsville, NY). A dilute
suspension (100µg/ml) of nanoparticles was prepared in double distilled water and
sonicated on an ice bath for 30 s. The sample was subjected to particle size analysis. Zeta
potential of nanoparticles in 0.001M double distilled water, was determined using
ZetaPlusTM in the zeta potential analysis mode.

7.2.5

In vitro expression and uptake of 6-coumarin

Rat cardiac fibroblasts (abbreviated as rCFs,) cultured in DMEM Medium with 10%
fetal bovine serum (Gibco, NY) and 1% penicillin G and streptomycin (Gibco BRL,
Grand Island, NY), were used for all the cell culture studies. The cells were seeded at
200,000 cells per well/1 ml (50% confluency) in a 6-well plate and allowed to attach
overnight. Nanoparticles were added at different doses in 1 ml of the medium and
incubated for 2 days. Untreated cells (plain medium) were used as a control. At the end of
the incubation period, cells were washed twice with phosphate buffered saline (PBS, pH
7.4) to remove nanoparticles and 1 ml of fresh medium was added to each well. The
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uptake of the nanoparticles in the cells was determined using optical microscopy studies,
and high performance liquid chromatography (HPLC) analysis

7.2.6

Extraction and quantitation of 6C fluorescence in cells

Cells were washed with PBS three times and were solubilized in 1% Triton X 100
solution. This suspension was stored at -80°C overnight and lyophilized for 48 hours.
Lyophilized cell lysates were reconstituted in methanol (500ul) and incubated at 37°C for
18 hours to extract the dye. Samples were centrifuged at 14000 rpm for 10 minutes at 4°C
to remove cell debris. Supernatants were collected for HPLC analysis. A standard curve
is obtained by adding 8 µg to 40 µg of nanoparticles in Triton X 100 solution and
lyophilized as the cell samples.

7.2.7

Confocal Microscopy Analysis

rCFs were plated on coverslips in 6 well plates at 50,000 cells per well (50%
confluency) in 1 ml of culture medium and allowed to attach for 24 h. Cells were then
incubated with 6-coumarin loaded nanoparticle suspension (200µg/ml) in growth medium
for 60 min. Cells were then washed twice with PBS and visualized with a Zeiss Confocal
LSM410 microscope equipped with 488 nm excitation laser (Carl Zeiss Microimaging,
Inc., Thornwood, NY).
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7.2.8

In vivo Expression Analysis

Rats were infarcted via LAD ligation, as described above. 4 weeks post infarction,
nanoparticles with or without the tagging peptide was infused via the tail vein at 200 µg
of particles per animal in 200µl of PBS. The nanoparticles were allowed to circulate
overnight, after which the animals were sacrificed by de-sanguination by perfusion with
saline, and the organs (heart and liver) were excised. Heart tissues were divided based on
the region of infarct or the healthy region. The wet weight of the tissues was recorded.
Samples were homogenized in 2 ml of distilled water using a tissue homogenizer. The
homogenized samples were then lyophilized for 48 hours. The 6C dye from the
homogenized tissue was extracted by shaking with 5 ml of methanol at 37°C for 24 hours
at 100 rpm using an Environ orbital shaker. Standard curve was obtained by samples
varying from 8 µg to 40µg of the nanoparticles in methanol. Tissue extracts were
centrifuged at 14000 rpm for 10 minutes to remove cell debris. The supernatant was
collected and this was used for HPLC analysis.

7.2.9

HPLC Analysis

A Shimadzu HPLC system (Shimadzu Scientific Instruments, Columbia, MO) fitted
with an SCL-10A system controller, an SIL-10A auto-injector, LC-10AT pump, a RF10A XL

fluorescence detector, and Class VP chromatography data system software

version 4.2 was used. A Nova pak C-8 column with spherical particles (4 mm) and pore
size of 60A ° (Waters, Milford, MA) and the mobile phase consisting of acetonitrile
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/water (65:35) containing 5mM sodium salt of 1-heptane sulfonic acid (Aldrich,
Milwaukee, WI) set at a flow rate of 0.8 ml/min were used to resolve the dye peak.
Excitation and emission wavelengths were 450 and 490 nm respectively. A 20 ml aliquot
of each sample was injected into HPLC. The retention time of 6-coumarin was 2.6 min.
The amount of nanoparticles in different tissue samples was determined from a
calibration curve plotted between the fluorescent intensity and the amount of
fluorescently labeled nanoparticles that were treated similar to the tissue samples. There
was no background peak for the control tissue (without nanoparticles). The assay is
sensitive enough to detect as low as 5 ng nanoparticles in the tissue samples.

7.3

Results

7.3.1

Formulation of Nanoparticles

Nanoparticles with 6 Coumarin as a fluorescent marker and BSA as a model protein
were formulated. Nanoparticles had a typical protein loading of 20% (w/w). As in, 20 mg
of BSA was present in 100 mg of nanoparticles.

7.3.2

Particle Size Analysis and Zeta Potential

Particle size distribution was analyzed by dynamic light scattering technique. The
size of the unconjugated PLGA polymer encapsulating the 6C dye in BSA was found to
be 0.095 microns or 95 ±12.3 nm. The conjugated PLGA polymer with the tagging
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peptide on the surface had an average size of 103 ± 11 nm indicating uniform particle
size distribution. When these particle sizes were analyzed before sonicating them, the
mean particle size was 600 ± 350 nm indicating the importance of sonicating on these
particles.

The zeta potential, corresponding to the surface charge was recorded at -14.72 ± 0.95
mV for the unconjugated particles and -11.04 ± 6.22 mV for the conjugated particles.

Nanoparticles were resuspended easily after lyophilization to form a stable colloidal
dispersion without any change in size or content. In previous studies, it has been shown
that 99.4% of the entrapped dye remains associated with the nanoparticles even after 48 h
of in vitro release study under constant conditions. 199Therefore, these nanoparticles serve
as a good model formulation to study the tissue uptake in vivo in acute experiments.
Furthermore, one can use these nanoparticles to quantitate the uptake as well as to study
their localization in the cells/tissue by fluorescence microscopy

7.3.3

In vitro Expression Analysis

Dose Analysis

Rat cardiac fibroblasts were cultured in DMEM Medium with 10% fetal bovine
serum and 1% penicillin and streptomycin. The cells were seeded at 50,000 cells per well
in 1 ml of culture medium (50% confluency) in a 6-well plate and allowed to attach
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overnight. Nanoparticles with the conjugated peptides were added at different doses
ranging between 10 µg of nanoparticles to 1 mg of nanoparticles per well in 1 ml of the
medium and incubated overnight. At the end of the incubation period, cells were washed
twice with phosphate buffered saline (PBS, pH 7.4) to remove nanoparticles and 1 ml of
fresh medium was added to each well. The cells were then viewed using optical
microscopy (Figure 7-1).

When less than 100 µg of particles were added to the wells, the signal obtained was
almost inconceivable. On the other hand a strong signal was observed at 500 µg of
particles and 1 mg of particles per well. A minimum of 200 µg per well of particles are
required for an observable signal. For future studies 200 µg of particles per well was used.

Figure 7-1 : Dose response with un-conjugated nanoparticles encapsulating 6C
Cardiac fibroblasts were cultured and nanoparticles encapsulating a fluorescent dye, 6C,
were added to this in varying doses. The signal obtained correlates to the amount of 6C
that released inside the cells. A 200µg dose was used for future studies.
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7.3.4

Time for Uptake

Rat cardiac fibroblasts were cultured in DME Medium with 10% fetal bovine serum
and 1% penicillin and streptomycin. The cells were seeded at 50,000 cells per well / 1 ml
of culture medium (50% confluency) in a 6-well plate and allowed to attach overnight.
Nanoparticles with and without the conjugated peptides were added at 200 µg of
nanoparticles per well in 1 ml of the medium and incubated for varying lengths of time
varying between 30 minutes and 24 hours to determine the optimum time for uptake.
Unconjugated nanoparticles were used as controls. At the end of the incubation period,
cells were washed twice with phosphate buffered saline (PBS, pH 7.4) to remove
nanoparticles and 1 ml of fresh medium was added to each well. The cells were then
viewed using optical microscopy

When the cells were analyzed at 30 minutes or less, no significant signal was
observed. However, after 1 hour there was an observable signal that increased for upto 3
hours, following which the signal remained constant for up to 24 hours. For future in
vitro studies, nanoparticles will be added for a period of 2 hours before it is washed away.
(Figure 7-2)
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Figure 7-2 : Time response with un-conjugated nanoparticles encapsulating 6C
Rat cardiac fibroblasts were cultured onto 6 well plated and 200µg of nanoparticles
without any targeting peptide were added to this. The time taken for release of the
nanoparticles into the cells and the endocytosis was determined by imaging cells ant
various time points following the addition of nanoparticles. 6C signal was obtained 1
hour following the addition and lasted for more than 24 hours.

As expected, there was no significant difference in signal between the two
nanoparticles types, whether conjugated or un-conjugated. Particles were added to the
wells and did not have to target any specific cell type. In fact, there seemed to be a slight
increase in particle uptake with un-conjugated particles. (Figure 7-3) Therefore in order
to address this, a quantitative study was performed with conjugated and un-conjugated
particles, at 200 µg of particles per well following 2 hours of uptake.
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Figure 7-3 : Time response of nanoparticles with 6C conjugated with RR peptide
Rat cardiac fibroblasts were cultured onto 6 well plated and 200µg of nanoparticles with
targeting peptide were added to this. On imaging these cells at various time points, 6C
signal was obtained 1 hour following the addition and lasted for more than 24 hours
similar to the results obtained from un-conjugated nanoparticles

7.3.5

HPLC Analysis with in vitro particle study

Rat cardiac fibroblasts were cultured in the appropriate medium at 50,000 cells per
well/1 ml of culture medium (50% confluency) in a 6-well plate and allowed to attach
overnight. Nanoparticles with and without the conjugated peptides were added at 200 µg
of nanoparticles per well in 1 ml of the medium and incubated 2 hours. Unconjugated
nanoparticles were used as controls. At the end of the incubation period, cells were
washed twice with phosphate buffered saline (PBS, pH 7.4) to remove nanoparticles and
1 ml of fresh medium was added to each well and were solubilized in 1% Triton X 100
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solution. This solution was lyophilized for 48 hours, and cell lysates were reconstituted in
methanol (500ul) and incubated at 37°C for 18 hours to extract the dye. Samples were
centrifuged at 14000 rpm for 10 minutes at 4°C to remove cell debris. Supernatants were
collected for HPLC analysis. A Standard curve was obtained by adding 8 µg to 40 µg of
nanoparticles in Triton X 100 solution and lyophilized as with the cell samples.

Following the HPLC analysis, the amount of fluorescent dye extracted from the unconjugated particles was 14.89 ±2.1 µg per well and the amount of 6C dye extracted from
conjugated nanoparticles was 11.97 ± 3.24 µg per well. There is a slight decrease in the
loading of conjugated particles that may be attributed to the slightly smaller sizes as
compared to the un-conjugated particles. However, this difference is not significant.
However, when unsonicated 6C unconjugated nanoparticles were used, this uptake
dropped to almost half, indicating the importance of particle size on uptake. (Figure 7-4)

Figure 7-4 : In vitro HPLC analysis to determine amount of 6C in cardiac
fibroblasts
Both conjugated and unconjugated nanoparticles had similar sizes. A quantitative
analysis between the unconjugated and conjugated nanoparticles revealed similar
amounts of nanoparticles being taken up by cardiac fibroblasts in culture. However,
unsonicated nanoparticles that had a larger size exhibited lower uptake.
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7.3.6

In vivo nanoparticle uptake in rodents

4 weeks post infarction via LAD ligation in rodents, nanoparticles with or without
the tagging peptide was infused via the tail vein at 200 µg of particles per animal in
200µl of PBS. The nanoparticles were allowed to circulate overnight, and the organs
(heart and liver) were excised. Heart tissues were divided between infarcted and healthy
regions. The wet weight of the tissues was recorded. Samples were homogenized,
lyophilized and the 6C dye from the homogenized tissue was extracted by shaking with 5
ml of methanol at 37°C for 24 hours at 100 rpm. Tissue extracts were centrifuged at
14000 rpm for 10 minutes to remove cell debris. The supernatant was collected and this
was used for HPLC analysis. Standard curve was obtained by samples varying from 8 µg
to 40µg of the nanoparticles in methanol.

On analyzing the HPLC results, it was observed that infarcted tissue regions had
more 6 C extracted from them, as compared to healthy tissues (n=3) (Figure 7-5). Also,
the amount of fluorescence intensity observed in the infarcted region of the heart
increased when nanoparticles with the homing peptide were infused as compared to when
nanoparticles alone were used. This increase in fluorescence intensity was significant,
with a p value of < 0.01 (Figure 7-6). When particles were conjugated with the ischemic
heart targeting peptide, they travelled to the infarcted region of the heart.

126

*

Figure 7-5 : In vivo HPLC analysis between infarct and healthy regions of the heart
On comparing infarcted tissue and healthy tissue for the amount of nanoparticles that
released the fluorescent dye, 6C in them, we observed a greater amount of nanoparticles
that targeted the infarct heart as compared to the healthy heart when a targeting peptide
was used to conjugate the nanoparticles.

Figure 7-6 : Difference in uptake in infarcted tissue with conjugation of
nanoparticles
A greater number of nanoparticles targeted the infarct heart when a targeting peptide was
conjugated to the surface of the PLGA polymer. (n=5), p<0.05
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7.4

Discussion

Regenerative medicine aims to repair and retain the function of cardiac tissues
following ischemia. The most viable of these therapeutic options is the use of genes that
can trigger various other pathways responsible for alleviating the symptoms of cardiac
failure. The use of non viral gene therapy is a safe and non toxic method of providing
these genes to injured tissues, allowing them to repair and regenerate the tissue to
mediate benefit in function. However, although non viral naked gene therapy may be a
viable option in vitro, it is subject to degradation in vivo, by lysosomes in the
cytoplasm.109 DNA plasmids have a polynucleotide structure and thus are negatively
charged and hydrophobic in nature. This poses a challenge for traversing the tissue layers,
and they are easily degraded in the system.191 In order to overcome this, genes need to be
properly condensed to a size that can be taken up by cells. The encapsulation of these
genes within polymeric carriers may provide an efficient, non toxic, yet safe delivery
mechanism for sustained intra cellular delivery of these therapeutic agents. However this
delivery platform has some limitations as the plasmid needs to be condensed to allow
encapsulation within the nanoparticle. Following that, the whole assembly needs to be
stable during formulation and in vivo. This complex should be capable of being targeted
to the tissue or cells of choice by either a surface ligand or by possessing a specific
promoter element in the plasmid, or both. And lastly, following intra cellular delivery,
these encapsulated particles need to be released in their viable form else they will be
sequestered and exited from the cells by lysosomal endosmosis.114
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PLGA offers a viable, effective and safe delivery of therapeutic agents; drugs and
genes, due to its capability release the encapsulated material intra cellular. Also, it is
capable of attaching surface ligands and can thus be modified for specific tissue
targeting.114,118 We wanted to test the efficacy and safety of PLGA polymers in being
able to deliver a fluorescent dye within ischemic heart tissue and thus develop a model
capable of delivering therapeutic genes responsible for cardiac regeneration.

In this study we formulated PLGA nanoparticles via the double emulsion process
and encapsulated a fluorescent dye, 6C that can be viewed via optical microscopy
analysis. This dye is capable of being excited and emitted at certain wavelengths
therefore the amount can be quantitated by using HPLC analysis. The surface of these
particles was activated with PVA thus making it hydrophilic and being capable of
attaching to surface ligands. We previously identified a peptide sequence RQPRMKR
which is a specific ligand to ischemic cardiac tissues via phage panning studies. We
tagged the surface of the PLGA nanoparticles with this ligand in order to mediate its
delivery specifically to the ischemic heart.

Intracellular levels of nanoparticles increased with dose and time, and an optimum
200 µg of particles per well for a mean incubation time of 2 hours was selected for our
study. In vitro studies with and without the surface ligands demonstrated that the size of
the particles and not the ligands associated on its surface mediates the uptake into cells.
The uptake of nanoparticles was proportional to the size of the particles, however, there
was no significant difference between the particle uptake as the size between the
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conjugated and un-conjugated particles was not very different from each other with
average sizes around 100 nms.119 When un-sonicated particles, of an average size of 500
nm were used the uptake changed dramatically, with the amount of extracted 6C from
these cells reducing to more than half of the sonicated particles.

In vivo studies with PLGA nanoparticles demonstrated the selective targeting of
conjugated nanoparticles to the ischemic heart specifically, as compared to the healthy
heart or the liver as a response to the targeting ligand on the surface. Un-conjugated
particles did not get taken up by the heart tissues and instead were found to be flushed
into the liver.

This study provides a viable option for the encapsulation of a fluorescent agent and
has demonstrated the intracellular characteristics, in vitro and in vivo associated with this.
This can be used as a model for future studies, as a mechanism for the delivery and
uptake of other genetic or drug therapies responsible for mediating benefit to the cardiac
tissue.
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CHAPTER VIII

IDENTIFICATION OF NOVEL CARDIAC PATHWAYS IN
REVERSE VENTRICULAR REMODELING FOLLOWING STEM
CELL THERAPY

8

IDENTIFYING

CARDIAC
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INVOLVED

IN

REVERSE

VENTRICULAR REMODELING

8.1

Introduction

Cell therapy, especially stem cell therapy has emerged as a promising method for the
repair and/or regeneration of ischemic myocardium following myocardial infarct. This
includes the use of Hematopoietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs),
and Multipotent Adult Progenitor Cells (MAPCs).31,36,37,200 MSCs have been extensively
tested for the repair of diseases involved in the heart, brain, liver and the skin.13,48,201-204
Various mechanisms have been demonstrated for cardiac repair mediated by MSCs,
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some of which include differentiation of recruited or cardiac stem cells, fusion between
host and recruited stem cells, promotion of angiogenesis and thus improved tissue
perfusion.31,46,200,205 In the past, MSCs have been shown to differentiate to cells of the
endothelial lineage providing for angiogenesis and thus improvement in micro
circulation.205 Also, functional recovery of cardiac tissue following MSC engraftment has
shown to be coupled with increase in various other paracrine factors, including Vascular
Endothelial Growth Factor (VEGF), basic Fibroblast Growth Factor (bFGF), and
Angiopoietin-I which induces the growth of blood vessels.34,49,53 However, due to the
complexity involved in the mechanism of repair followed by mesenchymal stem cell
therapy, the exact pathways that determine this change in functional improvement is not
yet determined.

Similar results obtained from the varied stem cell sources combined with limited
evidence that these different cell types actually differentiate into cardiac myocytes has led
to the conclusion that the majority of the improvement observed is not due to the
regeneration of cardiac myocytes, but rather due to the paracrine factors released by the
engrafted stem cells.52, 206

Consistent with this hypothesis are our recent studies demonstrating that the benefit
of MSC therapy is increased by the over-expression of specific factors, namely Stromal
Cell Derived Factor -1 (SDF-1)35 and Monocyte Chemoattractant Protein-3 (MCP-3).52
Studies in our laboratory have demonstrated that MSC home to myocardial tissue in
response to MCP-3, and that re-establishment of MCP-3 weeks after Acute Myocardial
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Infarction (AMI) re-establishes MSC homing to the heart leading to improved cardiac
function. The expression of MCP-3 in the absence of MSC infusion had no effect.
Interestingly, unlike virtually all preclinical cell transplantation studies published to date,
the improvement in LV dimensions and function was achieved in the absence of
neovascularization or an increase in vascular density.52 These observations suggest that
the MCP-3 based recruitment of MSC late after AMI leads to the expression of as yet
undefined paracrine factors that are able to reverse LV remodeling without inducing
vessel development or growth.

We thus hypothesize that this MSC-MCP3 mediated improvement in ventricular
function is attributed to reverse ventricular remodeling. Also, this reverse ventricular
remodeling is ascribed to paracrine factors secreted in the microenvironment.

The main focus of this aim was to identify key pathways and candidate proteins that
are modified as a result of the improvement in cardiac function when MCP-3 is expressed
followed by MSC infusions, in chronic heart failure hearts. Whole genome analysis
provides a comprehensive list of information on all genes in the genome that are affected
as a result of the application of therapy. Therefore this would be a viable option to
identify these proteins and the pathways associated in the changes that lead to functional
improvement.

The primary focus is to identify candidates associated with reversing ventricular
remodeling, following therapy with mesenchymal stem cells. To understand and identify
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these proteins we employed whole genome analysis studied pathways upregulated
following treatments with MSC therapy. Important aspects of genome wide experiments
are the large number of genes and their associated pathways assessed and the high
sensitivity of this approach. We investigated secreted proteins, and thus were able to
eliminate specific genes associated with the respective tissue types either host or
engrafted. Moreover, we looked specifically for pathways associated with the cardiac
lineage and the changes mediated in the cardiac tissue.

8.2

8.2.1

Methods

Experimental Plan

Group 1

MCP-3 transfected cardiac fibroblasts MSC x 6 doses

Group 2 (control)

MCP-3 transfected cardiac fibroblasts Saline

Group 3 (control)

Cardiac fibroblasts

MSC x 6 doses

Group 4 (control)

Cardiac Fibroblasts

Saline

Group 5 (control)

Saline

MSC x 6 dose

Group 6 (control)

Saline

Saline

Table 8-1 : Animal groups involved in stem cell therapy
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8.2.2

Isolation of MSCs

Rat bone marrow was isolated by flushing rat femurs and tibias with 0.6 ml DMEM
repeatedly till all of it is extracted. Clumps of bone marrow were gently minced using a
20 gauge needle and a 10 ml syringe. Cells were then be removed by Percoll density
gradient. This bone marrow was washed with PBS three times to remove all debris and
then plated in a dish with MSC media, comprising 10% FBS and 1% antibiotic in low
glucose DMEM, and incubated at 37ºC for three days. The mesenchymal stem cells
adhere to the plate leaving the endothelial cells in suspension. The media was changed in
order to obtain a pure population of MSC cells. This culture is then sorted negatively
after 4 passages for CD45 and CD34, by magnetic cell sorting techniques in order to
obtain a double purified and pure population of MSCs.

8.2.3

Isolation of Cardiac Fibroblasts

The left ventricles of 3 to 5 rats were pooled together, minced and placed in 100
U/ml of collagenase XI and trypsin at 37 ºC for 10 minutes in a shaking incubator. The
cell suspension was filtered out using gauze filtration and minced tissue was collected.
The cell suspension was centrifuged at 2000 rpm for 10 minutes to sediment the cells.
The cells were seeded in Ham’s modified DME medium supplemented with 10 % FBS
and 1% antibiotic containing Penicillin and Streptomycin. Non adherent cells were
removed after 2 hours of incubation and the adherent cells were washed twice with
phosphate buffered solution (PBS). The resulting adherent fibroblasts were cultured in
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Ham’s modified DMEM medium supplemented with 10% FBS and 1% antibiotic
containing Penicillin and Streptomycin on T75 flasks and incubated in 37ºC and 5% CO2.

8.2.4

Transfection of Cardiac Fibroblasts with MCP-3

MCP-3 from total RNA was cloned into expression vector pcDNA3.1 and a MYC
TAG was attached in order to detect the gene. The cardiac fibroblast culture dish was
treated with the MCP-3 encoding expression vector, or the control pcDNA vector
overnight in the presence of FUGENE. MCP-3 expression was selected by neomycin by
the addition of Geneticin to the media for two weeks. The surviving cells were expanded
and used for the experiment.

8.2.5

Experimental animals

We used male Lewis rats (Jackson Laboratories) for the chronic heart failure study.
All animals were 8 week old weighing 200-225 grams. There were 5 animals in each
group involved in the study (Table 8-1).

8.2.6

Intramyocardial Cardiac Fibroblast delivery

To inject the cardiac fibroblasts, the chest will be reopened two weeks post MI,
applying the same procedure as above, and using a 30 gauge needle, 100µl of DNA
solution will be injected per injection site. There will be 4 injection sites in all, around the
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border zone. The border zone will be identified by the blanched region around the LAD.
The DNA will be injected into the wall and blanching will be observed when the DNA is
injected. The chest will be closed as mentioned above for the LAD ligation.

8.2.7

Infusion of Mesenchymal Stem Cells

Mesenchymal stem cells will be infused via the tail vein using a 30 gauge needle.
The needle will be inserted and blood will be drawn from the vein to ensure the site of
injection. 2 million MSCs in 100 µl volume will be injected over a period of 1 minute to
avoid any emboli formation.

8.2.8

Isolation of total RNA

RNA from tissue samples will be isolated using the Trizol reagents. Briefly, the
tissues are homogenized in Trizol in dry ice and chloroform is added to this. The aqueous
phase obtained is collected and mixed with isopropanol and centrifuged to collect the
samples. RNAgents denaturing solution (from Qiagen) is then added to this to dissolve
the pellet. Samples are again collected with isopropanol and are centrifuged to collect the
samples at the bottom. This sample is not treated with 75% ethanol and again centrifuged
to collect samples. The supernatant is again discarded without disturbing the pellet and
the pellet is dissolved in DEPC water for future use. Further clean up of the RNA will be
done with the use of the Qiagen kit as per the manufacturer’s instructions.
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8.2.9

Preparation of cRNA

First-strand cDNA was synthesized using Oligo dT and Superscript II RT (Invitrogen,
Grand Island, NY). Alternatively, cDNA will be prepared using OVATION RNA
Amplification System (NuGen Technologies, Inc., San Carlos, CA). cDNA amplification
products will then be fragmented and chemically-labeled with biotin to generate
biotinylated cDNA targets. Each Affymetrix gene chip for rat genome will be hybridized
with fragmented and biotin-labeled target (2.5 μg) in 200 μl of hybridization cocktail.
Target denaturation is performed at 99°C for 2 minutes, followed by hybridization for 18
hours. Arrays then will be washed and stained using Genechip Fluidic Station 450, and
hybridization signals will be amplified using antibody amplification with goat IgG
(Sigma-Aldrich) and anti-streptavidin biotinylated antibody (Vector Laboratories,
Burlingame, CA).

8.2.10 Affymetrix Analysis

Eight micrograms of total RNA from rats treated with MSC and MCP-3 and control
rats with MCP-3 without MSCs was tested. Affymetrix GeneChip Rat Exon Arrays 1.0,
which allow analysis of >23,000 transcripts, was performed in triplicates and analyzed
with Affymetrix Microarray Suite (MAS 5.0). All possible comparisons Comparison
between MSC-MCP-3 treated animals vs. Saline MCP-3 treated control animals was
tested. Chips were scanned on a Affymetrix Gene Chip Scanner 3000, using GeneChip
Operating Software (GCOS) version 3.0. Background correction and normalization was

138

done using Robust Multichip Average (RMA) with GeneSpring V 7.3.1 software (Silicon
Genetics, Redwood City, CA). Volcano plots were used to identify differentially
expressed genes using the parametric testing assuming variances are equal (filters based
on the results of a Student's two-sample t-test for two groups or a one-way analysis of
variance (ANOVA) for multiple groups) and no multiple testing correction. Comparisons
were done between MSC MCP-3 treated group and the Saline MCP-3 treated control
group. The differentially expressed gene list was loaded into IPA 5.0 software
(www.ingenuity.com) to perform biological network and functional analyses.

8.3

Results

8.3.1

Stem cell therapy improves cardiac function in chronic heart failure

8 week old rats were infarcted via LAD ligation. 4 weeks post ligation, all rats had a
diminished fractional shortening of < 30%. The chests were re opened and cardiac
fibroblasts were transplanted into the heart wall at 2 million cells per animal. Cardiac
fibroblasts were modified to secrete increased levels of MCP-3 or were used as is, as
controls. One day post transplantation, 2 million mesenchymal stem cells were infused
via the tail vein, 6 times in a period of 12 days. 3 days after the last infusion, rats were
analyzed for cardiac function, via echocardiographic analysis.

Pre injection all rats had a fractional shortening less than 30%. Rats that received
mesenchymal stem cells showed increase in cardiac function, immediately post stem cell
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therapy, as compared to the rats that did not receive stem cell therapy. Among the ones
that received stem cell therapy, rodents with boosted MCP-3 activity showed the
maximum benefit as compared to the all other groups. (Figure 8-1)

Figure 8-1 : Change in cardiac function with MSC therapy in vivo
Ischemic rat hearts were injected with cardiac fibroblasts overexpressing the homing
factor for mesenchymal stem cells, MCP-3 and infused with mesenchymal stem cells.
Animals that received both treatments showed an improvement in cardiac function, 3
days post treatment, as compared to the ones that did not receive mesenchymal stem
cells. (n=5)

8.3.2

Identification of pathways and genes involved in cardiac repair

Among all the groups, the RNA from the group with MSC and MCP-3 treatment and
the animals from the MCP-3 with saline group were sent for whole genome analysis. The
results from the whole genome analysis were sorted in order to identify a sub set of genes
that were maximally affected by the therapy, thus leading to improved cardiac
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functioning, via reverse ventricular remodeling. The gene expression results were
supplied by whole genome analysis. Gene profiling were conducted with RNA isolated
from the left ventricles of treated and control rats.

Microarray analysis was performed on RNA isolated from each group to identify
differentially expressed genes, using the Affymetrix Rat exon 2.0 array. Signals were
loaded into Gene Chip Operating Software (GCOS) and normalized using the Robust
Multichip Average (RMA) algorithm. The normalized set was further sorted to provide a
more ideal normalization with the GC-RMA software. Instead of eliminating the
mismatch genes, as provided by RMA analysis, the GC RMA, supplies a graded average
for each gene, with a simulated number for the mismatch, as provided by the number of
G and C rich regions in the probe. This subset of genes was then sorted based on
Significance of Microarray studies, to remove false positives for p values with a False
Detection Rate of 20%. The expressed genes were finally sorted based on p values (<0.05)
and fold changes.

To provide a more specific subset of differentially expressed genes, with a p value of
0.05 and a Fold change of 2, these genes were subject to ANOVA to determine the
number of genes that are expressed differentially. Following these sorting measures a
small subset of secreted genes were identified, based on their locations in the cell either
in the cytoplasm, the cell wall, or extra cellular matrix. (Table 8-2). Among these genes,
some were upregulated and some were down regulated. PSG-19 and LIF were
upregulated and our focus was on these genes.
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Gene ID

Gene Name

Function

PSG-18
LIF
Downregulated Genes

Pregnancy Specific Glycoprotein 18
Leukemia Inhibitory factor

Induces IL10
Proliferation of cells

CTF1
SERPINH1
MIP/CCL3
VCAN
REG3A

Cardiotrophin 1
Serpin Peptidase Inhibitor
Macrophage Inflammatory Protein
Versican
Regenerating Islet-Derived 3 alpha

cardioprotective
Cell survival
Pro-inflammation
Macrophage adhesion
Pancreatitis associated
protein

Upregulated Genes

Table 8-2 : Genes of secreted proteins involved in cardiac repair with MSC therapy

8.3.3

RT PCR Analysis for individual paracrine factors

RT-PCR analysis was carried out with primers specific for the PSG-19 gens with the
RNA isolated from the tissues of all animal groups. Primers were designed with the
software provided in the NCBI website. For RT-PCR analysis, forward primer of
GAGCCTTGTTGGAGCTGAAG and reverse primer of AGGGCTACACCCTGA
ACAGA were used. However, there was no difference between the amount of this
protein expressed by the various groups.
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8.3.4

Pathway Analysis with Ingenuity Pathway Analysis Software

Pathway analysis provides highly sophisticated information on the interactions
between genes and the relationship between one another, with respect to various
functions. The various analyses were performed as described above. Briefly, the results
from the Affymetrix data analysis was subject to normalization software with GC-RMA,
and sorted based on p values. This data set is referred to as the reference set. Instead of
using all the genes in the rat genome as the reference set, this subset of affected and
normalized genes was used as the reference. This data set was further subject to a 20%
false detection rate in the SAM analysis, to identify and eliminate false p-values. The
following subset that ensued was the data set for the pathway analysis. This data set was
analyzed to determine the interactions between these differentially significant genes.

Pathway analysis was able to provide us with information regarding specific genes
(either up or down regulated) that was associated with cardiovascular functions, including
development and disorder. These genes were then sorted into a subset that can provide
leads into factors that may affect ventricular remodeling. (Table 8-3)
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Symbol

Gene Name

Fold Change

Location

Type(s)

Upregulated genes
MIF

macrophage migration
inhibitory factor
(glycosylationinhibiting factor)
leukemia inhibitory
factor (cholinergic
differentiation factor)
secreted frizzledrelated protein 4

2.84

Extracellular
Space

cytokine

2.27

Extracellular
Space

cytokine

2.27

troponin I type 3
(cardiac)
myocyte enhancer
factor 2B
apolipoprotein H
(beta-2-glycoprotein I)
follicle stimulating
hormone, beta
polypeptide
urotensin 2

2.24

Plasma Membrane Transmembrane
receptor
Cytoplasm
transporter

2.24

Nucleus

2.21

Extracellular
Space
Extracellular
Space

CYSLTR2 cysteinyl leukotriene
receptor 2
DRD1
dopamine receptor D1
HCN2
hyperpolarization
activated cyclic
nucleotide-gated
potassium channel 2
C-type lectin domain
CLEC11A family 11, member A
GLRX3
glutaredoxin 3
VEGFA
vascular endothelial
growth factor A
GRIN2A glutamate receptor,
ionotropic, N-methyl
D-aspartate 2A
MAX
MYC associated factor
X
ES22
esterase 22
EGF
epidermal growth
factor
GHR
growth hormone

LIF

SFRP4

TNNI3
MEF2B
APOH
FSHB

UTS2

2.19

2.18

transcription
regulator
transporter
other

other

2.14

Extracellular
Space
Plasma Membrane

2.13
2.12

Plasma Membrane
Plasma Membrane

GPCR
ion channel

2.12

2.10

Extracellular
growth
Space
factor
Cytoplasm
enzyme
Extracellular
growth
Space
factor
Plasma Membrane ion channel

2.09

Nucleus

2.08
2.07

Cytoplasm
Extracellular
Space
Plasma Membrane

2.12
2.10

2.07
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GPCR

transcription
regulator
enzyme
growth
factor

receptor
MAPT
GRM5
AGTR1B
PIK3C2G

IFNG
KRT1
CSF3
CAV3
NOS2
GRIA2
AMPD1

PDGFA

ATP2B3

AACS
CEBPA

microtubule-associated
protein tau
glutamate receptor,
metabotropic 5
angiotensin II
receptor, type 1b
phosphoinositide-3kinase, class 2, gamma
polypeptide
interferon, gamma

2.05

Cytoplasm

transmembra
ne receptor
other

2.05

Plasma Membrane

GPCR

2.05

Plasma Membrane

GPCR

2.04

Cytoplasm

kinase

2.03

cytokine

keratin 1
colony stimulating
factor 3 (granulocyte)
caveolin 3
nitric oxide synthase 2,
inducible
glutamate receptor,
ionotropic, AMPA 2
adenosine
monophosphate
deaminase 1
platelet-derived
growth factor alpha
polypeptide
ATPase, Ca++
transporting, plasma
membrane 3
acetoacetyl-CoA
synthetase
CCAAT/enhancer
binding protein
(C/EBP), alpha

2.03
2.02
2.02
2.02

Extracellular
Space
Cytoplasm
Extracellular
Space
Plasma Membrane
Cytoplasm

2.02

Plasma Membrane

ion channel

2.01

unknown

enzyme

2.01

Extracellular
Space

growth
factor

2.01

Plasma Membrane

transporter

2.00

Cytoplasm

enzyme

2.00

Nucleus

transcription
regulator

Extracellular
Space
Plasma
Membrane
Extracellular
Space
Plasma
Membrane

other

Downregulated genes
TIMP1
TIMP metallopeptidase
inhibitor 1
FN1
fibronectin 1

-3.99
-3.74

VCAN

versican

-3.54

C3AR1

complement component 3a
receptor 1

-3.45
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other
cytokine
enzyme
enzyme

enzyme
other
GPCR

CXCL13

chemokine (C-X-C motif)
ligand 13
serpin peptidase inhibitor,
clade A member 3
potassium inwardlyrectifying channel,
subfamily J, member 2
serpin peptidase inhibitor,
clade E
chemokine (C-C motif)
receptor 5
vascular cell adhesion
molecule 1
heat shock 27kDa protein 1
lysyl oxidase

-3.43

-2.99

ANXA2

chemokine (C-C motif)
receptor 2
chemokine (C-C motif)
ligand 13
nephroblastoma
overexpressed gene
5-hydroxytryptamine
(serotonin) receptor 1B
annexin A2

THY1

Thy-1 cell surface antigen

-2.85

ANPEP

-2.85

MSLN

alanyl (membrane)
aminopeptidase
met proto-oncogene
(hepatocyte growth factor
receptor)
ectonucleotide
pyrophosphatase/phosphod
iesterase 3
mesothelin

CP

ceruloplasmin (ferroxidase)

-2.79

SIRPA

signal-regulatory protein
alpha
integrin, alpha M
(complement component 3
receptor 3 subunit)
neural cell adhesion

-2.77

SERPINA3
KCNJ2

SERPINE1
CCR5
VCAM1
HSPB1
LOX
CCR2
CCL13
NOV
HTR1B

MET

ENPP3

ITGAM

NCAM1

Extracellular
Space
Extracellular
Space
Plasma
Membrane

cytokine

Extracellular
Space
Plasma
Membrane
Plasma
Membrane
Cytoplasm
Extracellular
Space
Plasma
Membrane
Extracellular
Space
Extracellular
Space
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane

other

-2.82

Plasma
Membrane

enzyme

-2.80

Extracellular
Space
Extracellular
Space
Plasma
Membrane
Plasma
Membrane

other

Plasma

other

-3.23
-3.19

-3.18
-3.17
-3.16
-3.11
-3.03

-2.98
-2.97
-2.91
-2.86

-2.84

-2.76

-2.75
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other
ion channel

GPCR
other
other
enzyme
GPCR
cytokine
growth factor
GPCR
other
other
peptidase
kinase

enzyme
phosphatase
other

SELE

molecule 1
cytochrome b-245, beta
polypeptide
selectin E

MMP2

matrix metallopeptidase 2

-2.73

FZD2

frizzled homolog 2
(Drosophila)
c-fos induced growth factor
(vascular endothelial
growth factor D)
protein tyrosine
phosphatase, receptor type,
C
CD14 molecule

-2.71

CYBB

FIGF

PTPRC

CD14

RRAD

-2.75
-2.74

Membrane
Cytoplasm

enzyme

Plasma
Membrane
Extracellular
Space
Plasma
Membrane
Extracellular
Space

other

-2.69

Plasma
Membrane

phosphatase

-2.69

Plasma
Membrane

-2.69

peptidase
GPCR
growth factor

transmembran
e receptor
enzyme

Ras-related associated with
diabetes
lectin, galactoside-binding,
soluble, 3
deleted in malignant brain
tumors 1

-2.68

Cytoplasm

-2.66

Extracellular
Space
Plasma
Membrane

RPS6
UTS2R

ribosomal protein S6
urotensin 2 receptor

-2.65
-2.65

S100A4

-2.63
-2.63

Cytoplasm

enzyme

APLNR

S100 calcium binding
protein A4
UDP-glucose ceramide
glucosyltransferase
apelin receptor

Cytoplasm
Plasma
Membrane
Cytoplasm

-2.62

GPCR

CD53

CD53 molecule

-2.62

TGFB2

transforming growth factor,
beta 2
actinin, alpha 1
transglutaminase 2
paired related homeobox 1

-2.62

Plasma
Membrane
Plasma
Membrane
Extracellular
Space
Cytoplasm
Cytoplasm
Nucleus

thyrotropin-releasing
hormone
peripheral myelin protein
22

-2.59

LGALS3
DMBT1

UGCG

ACTN1
TGM2
PRRX1
TRH
PMP22

-2.65

-2.61
-2.60
-2.59

-2.58
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Extracellular
Space
Plasma
Membrane

other

transmembran
e receptor
other
GPCR
other

other
growth factor
other
enzyme
transcription
regulator
other
other

IGF1

insulin-like growth factor 1

-2.57

TGFBR2

transforming growth factor,
beta receptor II
Janus kinase 2
CD44 molecule (Indian
blood group)
Cbp/p300-interacting
transactivator
epithelial membrane
protein 1
disabled homolog 2,
mitogen-responsive
phosphoprotein
carnitine
palmitoyltransferase 1A
(liver)
heat shock 70kDa protein 5
(glucose-regulated protein,
78kDa)
protein tyrosine
phosphatase, non-receptor
type 6
fibrinogen gamma chain

-2.57

adducin 3 (gamma)
cathepsin B
hypoxia inducible factor 1,
alpha subunit
synuclein, gamma (breast
cancer-specific protein 1)
5-hydroxytryptamine
(serotonin) receptor 2A
adaptor-related protein
complex 2, alpha 2 subunit
early growth response 1

JAK2
CD44
CITED2
EMP1
DAB2

CPT1A

HSPA5

PTPN6

FGG
ADD3
CTSB
HIF1A
SNCG
HTR2A
AP2A2
EGR1
MAGED1
APP
GRN
BMP2
EDNRA

-2.56
-2.55
-2.55
-2.55
-2.55

Extracellular
Space
Plasma
Membrane
Cytoplasm
Plasma
Membrane
Nucleus
Plasma
Membrane
Plasma
Membrane

growth factor
kinase
kinase
other
transcription
regulator
other
other

-2.55

Cytoplasm

enzyme

-2.55

Cytoplasm

other

-2.54

Cytoplasm

phosphatase

-2.54

other

-2.54
-2.54
-2.53

Extracellular
Space
Cytoplasm
Cytoplasm
Nucleus

-2.53

Cytoplasm

-2.52

GPCR

-2.51

Plasma
Membrane
Cytoplasm

-2.51

Nucleus

melanoma antigen family
D, 1
amyloid beta (A4)
precursor protein
granulin

-2.51

bone morphogenetic
protein 2
endothelin receptor type A

-2.49

Plasma
Membrane
Plasma
Membrane
Extracellular
Space
Extracellular
Space
Plasma

transcription
regulator
transcription
regulator
other

-2.50
-2.50

-2.49
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other
peptidase
transcription
regulator
other

transporter

growth factor
growth factor

Membrane
TP53

tumor protein p53

-2.49

Nucleus

AXL

AXL receptor tyrosine
kinase
caspase 3, apoptosisrelated cysteine peptidase
transforming growth factor,
beta 1
Rho GDP dissociation
inhibitor (GDI) beta
selectin P (granule
membrane protein 140kDa,
antigen CD62)
integrin, beta 1

-2.49

Plasma
Membrane
Cytoplasm

CASP3
TGFB1
ARHGDIB
SELP

ITGB1

HBEGF
OLR1

JUP

heparin-binding EGF-like
growth factor
oxidized low density
lipoprotein (lectin-like)
receptor 1
junction plakoglobin

GJA1

gap junction protein, alpha
1, 43kDa
SERPINF1 serpin peptidase inhibitor,
clade F
TNFRSF1A tumor necrosis factor
receptor superfamily,
member 1A
PDGFC
platelet derived growth
factor C
TLR2
toll-like receptor 2

GSK3B
PTGS1
CYB5R3
SCAMP2
JAG1

glycogen synthase kinase 3
beta
prostaglandinendoperoxide synthase 1
cytochrome b5 reductase 3
secretory carrier membrane
protein 2
jagged 1 (Alagille
syndrome)

-2.49
-2.49

transmembran
e receptor
transcription
regulator
kinase
peptidase

Extracellular
Space
Cytoplasm

growth factor

-2.48

Plasma
Membrane

other

-2.48

Plasma
Membrane

-2.48

-2.48
-2.48

-2.47
-2.47
-2.47
-2.47

-2.46
-2.46

Extracellular
Space
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Extracellular
Space
Plasma
Membrane
Extracellular
Space
Plasma
Membrane

other

transmembran
e receptor
growth factor

transmembran
e receptor
other
transporter
other

transmembran
e receptor
growth factor

-2.45

Nucleus

transmembran
e receptor
kinase

-2.45

Cytoplasm

enzyme

-2.45
-2.44

Cytoplasm
Cytoplasm

enzyme
transporter

-2.44

Extracellular
Space

growth factor
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GPAM

glycerol-3-phosphate
acyltransferase,
mitochondrial
interleukin 6 signal
transducer

-2.44

Cytoplasm

-2.44

Plasma
Membrane

-2.43

Cytoplasm

-2.43

Nucleus

-2.43
-2.43

-2.42

Cytoplasm
Extracellular
Space
Plasma
Membrane
Plasma
Membrane
Cytoplasm

-2.42

Cytoplasm

transporter

-2.41
-2.41

Cytoplasm
Plasma
Membrane

other
transporter

-2.41

Cytoplasm

enzyme

DMD

v-yes-1 Yamaguchi
sarcoma viral related
oncogene homolog
signal transducer and
activator of transcription 3
exostoses (multiple)-like 3
natriuretic peptide
precursor A
lysophosphatidic acid
receptor 1
Notch homolog 2
(Drosophila)
prolyl 4-hydroxylase, beta
polypeptide
ATPase, H+ transporting,
lysosomal accessory
protein 1
tropomyosin 2 (beta)
ATPase, Ca++
transporting, plasma
membrane 4
myosin VA (heavy chain
12, myoxin)
dystrophin

-2.40

other

CLU

clusterin

-2.40

FSTL1

follistatin-like 1

-2.40

OGG1

-2.40
-2.40

Nucleus

transcription
regulator

-2.40

Plasma
Membrane

enzyme

PSEN1

8-oxoguanine DNA
glycosylase
catenin (cadherinassociated protein), beta 1,
88kDa
guanine nucleotide binding
protein (G protein), beta
polypeptide 1
presenilin 1

Plasma
Membrane
Extracellular
Space
Extracellular
Space
Nucleus

-2.40

peptidase

NCSTN

nicastrin

-2.39

Plasma
Membrane
Plasma

IL6ST

LYN

STAT3
EXTL3
NPPA
LPAR1
NOTCH2
P4HB
ATP6AP1

TPM2
ATP2B4

MYO5A

CTNNB1

GNB1

-2.42
-2.42
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enzyme

transmembran
e receptor
kinase

transcription
regulator
enzyme
other
GPCR
transcription
regulator
enzyme

other
other
enzyme

peptidase

VIM
TAGLN
CD81

vimentin
transgelin
CD81 molecule

-2.39
-2.38
-2.38

CSPG4

-2.38

ACVR1B

chondroitin sulfate
proteoglycan 4
neuroblastoma RAS viral
(v-ras) oncogene homolog
actinin, alpha 4
serine
hydroxymethyltransferase
2 (mitochondrial)
activin A receptor, type IB

ADORA1

adenosine A1 receptor

-2.37

IL1R1

interleukin 1 receptor, I

-2.37

EPHA7

EPH receptor A7

-2.37

HCN4

hyperpolarization activated
cyclic nucleotide-gated
potassium channel 4
ornithine decarboxylase 1
lipocalin 2

-2.37

lipase, hormone-sensitive
protein tyrosine
phosphatase, receptor, F
retinoid X receptor, alpha
calcium channel, voltagedependent, T type, alpha
1G subunit
caspase 2, apoptosisrelated cysteine peptidase
endothelin converting
enzyme 1
CREB binding protein

-2.36
-2.36

NRAS
ACTN4
SHMT2

ODC1
LCN2
LIPE
PTPRF
RXRA
CACNA1G

CASP2
ECE1
CREBBP
LIPA
CD47
GJB6

-2.38
-2.37
-2.37

-2.37

-2.37
-2.36

-2.36
-2.36

Membrane
Cytoplasm
Cytoplasm
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Cytoplasm
Cytoplasm

Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Cytoplasm
Extracellular
Space
Cytoplasm
Plasma
Membrane
Nucleus
Plasma
Membrane

other
other
other
other
enzyme
other
enzyme

kinase
GPCR
transmembran
e receptor
kinase
ion channel

enzyme
transporter
enzyme
phosphatase
receptor
ion channel

-2.36

Cytoplasm

peptidase

-2.36

peptidase

-2.36

Plasma
Membrane
Nucleus

lipase A, lysosomal acid,
cholesterol esterase
CD47 molecule

-2.36

Cytoplasm

-2.35

gap junction protein, beta
6, 30kDa

-2.35

Plasma
Membrane
Plasma
Membrane
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transcription
regulator
enzyme
other
transporter

MCM7

TIMP2
DYNC1H1
GAB2
PDPK1
TGIF1
TRPC6

IGF1R

GRIA3
VEGFC
REST
GALR2
ICAM1
IRS1
LXN
GPI
AMPD3
FST
NOTCH3
JAK1
ADM
CDS2
DUSP5

minichromosome
maintenance complex
component 7
TIMP metallopeptidase
inhibitor 2
dynein, cytoplasmic 1,
heavy chain 1
GRB2-associated binding
protein 2
3-phosphoinositide
dependent protein kinase-1
TGFB-induced factor
homeobox 1
transient receptor potential
cation channel, subfamily
C, member 6
insulin-like growth factor 1
receptor

-2.35

Nucleus

enzyme

-2.35

other

-2.34

Extracellular
Space
Cytoplasm

-2.34

Cytoplasm

other

-2.34

Cytoplasm

kinase

-2.34

Nucleus

-2.34

Plasma
Membrane

transcription
regulator
ion channel

-2.34

Plasma
Membrane

glutamate receptor,
ionotrophic, AMPA 3
vascular endothelial growth
factor C
RE1-silencing transcription
factor
galanin receptor 2

-2.33

Plasma
Membrane
Extracellular
Space
Nucleus

intercellular adhesion
molecule 1
insulin receptor substrate 1
latexin
glucose-6-phosphate
isomerase
adenosine monophosphate
deaminase 3
follistatin

-2.33

Notch homolog 3
(Drosophila)
Janus kinase 1
adrenomedullin

-2.32

CDP-diacylglycerol
synthase
dual specificity
phosphatase 5

-2.33
-2.33
-2.33

-2.33
-2.33
-2.32
-2.32
-2.32

Plasma
Membrane
Plasma
Membrane
Cytoplasm
Cytoplasm
Extracellular
Space
unknown

peptidase

Transmembrane
receptor
ion channel
growth factor
transcription
regulator
GPCR
transmembran
e receptor
other
other
enzyme
enzyme

transcription
regulator
kinase
other

-2.31

Extracellular
Space
Plasma
Membrane
Cytoplasm
Extracellular
Space
Cytoplasm

-2.31

Nucleus

phosphatase

-2.31
-2.31
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other

enzyme

SCARB2
APAF1
CLTC
MAP3K1
OGT

DYNLT1
ITGA1
STXBP1
CCND2
DIO2
HNRNPD
HYOU1
IGF2
PLD2
DIO3
AGRN
ATP6V0C

CXCR3
MYD88
NRP1

ADAM17
CAPN1
CXCR4
FYN

scavenger receptor class B,
member 2
apoptotic peptidase
activating factor 1
clathrin, heavy chain (Hc)

-2.31

mitogen-activated protein
kinase kinase kinase 1
O-linked Nacetylglucosamine
(GlcNAc) transferase
dynein, light chain, Tctextype 1
integrin, alpha 1
syntaxin binding protein 1
cyclin D2
deiodinase, iodothyronine,
type II
heterogeneous nuclear
ribonucleoprotein D
hypoxia up-regulated 1
insulin-like growth factor 2
(somatomedin A)
phospholipase D2
deiodinase, iodothyronine,
type III
agrin
ATPase, H+ transporting,
lysosomal 16kDa, V0
subunit c
chemokine (C-X-C motif)
receptor 3
myeloid differentiation
primary response gene (88)
neuropilin 1

-2.29

ADAM metallopeptidase
domain 17
calpain 1, (mu/I) large
subunit
chemokine (C-X-C motif)
receptor 4
FYN oncogene related to

Plasma
Membrane
Cytoplasm

other

other

-2.31

Plasma
Membrane
Cytoplasm

-2.31

Cytoplasm

enzyme

-2.30

Cytoplasm

other

-2.30

other

-2.30
-2.30
-2.30

Plasma
Membrane
Cytoplasm
Nucleus
Cytoplasm

-2.30

Nucleus

-2.30
-2.30

Cytoplasm
Extracellular
Space
Cytoplasm
Plasma
Membrane
Plasma
Membrane
Cytoplasm

transcription
regulator
other
growth factor

-2.31
-2.31

-2.30
-2.30
-2.29

-2.29
-2.29
-2.29

-2.29
-2.29
-2.28
-2.28
153

Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Plasma
Membrane
Cytoplasm
Plasma
Membrane
Plasma

other

kinase

transporter
other
enzyme

enzyme
enzyme
other
transporter

GPCR
other

transmembran
e receptor
peptidase
peptidase
GPCR
kinase

PDE3A
SMPD1

STEAP3
ITPR1
SMAD1
CDH2
CDK9
EGFR
APC
CXCL2
MAP3K11
PDE5A
PPP1R12A

CCND1
CDH13
ITSN1
MYO9B
HTT
TSC2
ERBB2

NSF
VLDLR
PSEN2
CXCL12

SRC, FGR, YES
phosphodiesterase 3A,
cGMP-inhibited
sphingomyelin
phosphodiesterase 1, acid
lysosomal
STEAP family member 3
inositol 1,4,5-triphosphate
receptor, type 1
SMAD family member 1

-2.28

Membrane
Cytoplasm

enzyme

-2.28

Cytoplasm

enzyme

-2.28
-2.28

Cytoplasm
Cytoplasm

transporter
ion channel

-2.28

Nucleus

cadherin 2, type 1, Ncadherin (neuronal)
cyclin-dependent kinase 9
epidermal growth factor
receptor
adenomatous polyposis coli
chemokine (C-X-C motif)
ligand 2
mitogen-activated protein
kinase kinase kinase 11
phosphodiesterase 5A,
cGMP-specific
protein phosphatase 1,
regulatory (inhibitor)
subunit 12A
cyclin D1
cadherin 13, H-cadherin
(heart)
intersectin 1 (SH3 domain
protein)
myosin IXB
huntingtin

-2.28

-2.27

Plasma
Membrane
Nucleus
Plasma
Membrane
Nucleus
Extracellular
Space
Cytoplasm

transcription
regulator
other

-2.27

Cytoplasm

enzyme

-2.27

Cytoplasm

phosphatase

-2.27
-2.27

other
other

-2.27

Nucleus
Plasma
Membrane
Cytoplasm

-2.27
-2.26

Cytoplasm
Cytoplasm

tuberous sclerosis 2
v-erb-b2 erythroblastic
leukemia viral oncogene
homolog 2,
N-ethylmaleimide-sensitive
factor
very low density
lipoprotein receptor
presenilin 2 (Alzheimer
disease 4)
chemokine (C-X-C motif)
ligand 12

-2.26
-2.26

Cytoplasm
Plasma
Membrane

enzyme
transcription
regulator
other
kinase

-2.26

Cytoplasm

transporter

-2.26

Plasma
Membrane
Cytoplasm

transporter

Extracellular
Space

cytokine

-2.28
-2.28
-2.27
-2.27

-2.26
-2.25
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kinase
kinase
enzyme
cytokine
kinase

other

peptidase

BID

BH3 interacting domain
death agonist
PRKCD
protein kinase C, delta
IKBKB
inhibitor of kappa light
polypeptide gene enhancer
in B-cells, kinase beta
ITPKB
inositol 1,4,5-trisphosphate
3-kinase B
Rho GTPase activating
ARHGAP20 protein 20
CACNA1C calcium channel, voltagedependent, L type, alpha
1C subunit
ERBB3
v-erb-b2 erythroblastic
leukemia viral oncogene
homolog 3 (avian)
PLAU
plasminogen activator,
urokinase
MMP9
matrix metallopeptidase 9

-2.25

Cytoplasm

other

-2.25
-2.25

Cytoplasm
Cytoplasm

kinase
kinase

-2.25

Cytoplasm

kinase

-2.25

unknown

other

-2.24

Plasma
Membrane

ion channel

-2.24

Plasma
Membrane

kinase

-2.24

peptidase

BIN1
GATA4

bridging integrator 1
GATA binding protein 4

-2.23
-2.23

Extracellular
Space
Extracellular
Space
Nucleus
Nucleus

ETS1

v-ets erythroblastosis virus
E26 oncogene homolog 1
(avian)
E1A binding protein p300

-2.23

Nucleus

-2.23

Nucleus

MAP-kinase activating
death domain
adrenergic, alpha-1A-,
receptor
mechanistic target of
rapamycin
(serine/threonine kinase)
apolipoprotein E

-2.22

Cytoplasm

-2.22

Plasma
Membrane
Nucleus

GPCR

transporter

-2.22

-2.22

Cytoplasm

kinase

SF1

guanine nucleotide binding
protein (G protein), beta
polypeptide 2-like 1
v-src sarcoma (SchmidtRuppin A-2) viral
oncogene homolog (avian)
splicing factor 1

Extracellular
Space
Cytoplasm

-2.21

Nucleus

AXIN1

axin 1

-2.20

Cytoplasm

transcription
regulator
other

EP300
MADD
ADRA1A
MTOR

APOE
GNB2L1

SRC

-2.24

-2.22

-2.22
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peptidase
other
transcription
regulator
transcription
regulator
transcription
regulator
other

kinase

enzyme

DNM1
CXCL1
ARHGEF7
ATG7
CTF1
DCTN1
KHSRP
GRB2
APH1A
CASP9
CABIN1
MAPK1
SMAD3
GIT1

CDK5
SNAP29
DLG4
PDE3B
PPP1CC

NOS3
PTEN
IL4
PTK2

dynamin 1
chemokine (C-X-C motif)
ligand 1
Rho guanine nucleotide
exchange factor (GEF) 7
ATG7 autophagy related 7
homolog (S. cerevisiae)
cardiotrophin 1

-2.20
-2.20

enzyme
cytokine

-2.20

Cytoplasm
Extracellular
Space
Cytoplasm

-2.19

Cytoplasm

enzyme

-2.19

cytokine

-2.19

Extracellular
Space
Cytoplasm

dynactin 1 (p150, glued
homolog, Drosophila)
KH-type splicing
regulatory protein
growth factor receptorbound protein 2
anterior pharynx defective
1a homolog (C. elegans)
caspase 9, apoptosisrelated cysteine peptidase
calcineurin binding protein
1
mitogen-activated protein
kinase 1
SMAD family member 3

-2.19

Nucleus

enzyme

-2.18

Cytoplasm

other

-2.18

Cytoplasm

peptidase

-2.18

Cytoplasm

peptidase

-2.18

Nucleus

other

-2.18

Cytoplasm

kinase

-2.18

Nucleus

G protein-coupled receptor
kinase interacting ArfGAP
1
cyclin-dependent kinase 5
synaptosomal-associated
protein, 29kDa
discs, large homolog 4
(Drosophila)
phosphodiesterase 3B,
cGMP-inhibited
protein phosphatase 1,
catalytic subunit, gamma
isozyme
nitric oxide synthase 3
(endothelial cell)
phosphatase and tensin
homolog
interleukin 4

-2.17

Nucleus

transcription
regulator
other

-2.16
-2.16

Nucleus
Cytoplasm

kinase
transporter

-2.15

kinase

-2.15

Plasma
Membrane
Cytoplasm

-2.15

Cytoplasm

phosphatase

-2.14

Cytoplasm

enzyme

-2.14

Cytoplasm

phosphatase

-2.14

cytokine

PTK2 protein tyrosine
kinase 2

-2.14

Extracellular
Space
Cytoplasm
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other

other

enzyme

kinase

CLIP2

-2.13

Cytoplasm

-2.13

Cytoplasm

transcription
regulator
kinase

-2.13

Cytoplasm

peptidase

PRL

CAP-GLY domain
containing linker protein 2
mitogen-activated protein
kinase 3
caspase 4, apoptosisrelated cysteine peptidase
prolactin

-2.11

cytokine

ZNF423

zinc finger protein 423

-2.10

Extracellular
Space
Nucleus

NFKB2

nuclear factor of kappa
light polypeptide gene
enhancer in B-cells 2
cAMP responsive element
binding protein 1
CD2-associated protein
natriuretic peptide
precursor B
paxillin
crystallin, alpha B
vascular endothelial growth
factor B

-2.10

Nucleus

-2.10

Nucleus

-2.09
-2.09

Cytoplasm
Extracellular
Space
Cytoplasm
Nucleus
Extracellular
Space

tumor necrosis factor

-2.08

angiotensinogen (serpin
peptidase inhibitor, clade
A, member 8)
dynactin 2 (p50)
wingless-type MMTV
integration site family,
member 4
sonic hedgehog homolog
(Drosophila)
adrenergic, beta-2-,
receptor, surface
B-cell CLL/lymphoma 2
glutamate receptor,
ionotropic, N-methyl Daspartate 2B
peroxisome proliferatoractivated receptor gamma

-2.07

Notch homolog 4
(Drosophila)

MAPK3
CASP4

CREB1
CD2AP
NPPB
PXN
CRYAB
VEGFB
(includes
EG:89811)
TNF
AGT

DCTN2
WNT4

SHH
ADRB2
BCL2
GRIN2B

PPARG

NOTCH4

-2.09
-2.08
-2.08

transcription
regulator
transcription
regulator
transcription
regulator
other
other
other
other
other

Extracellular
Space
Extracellular
Space

cytokine

-2.07
-2.06

Cytoplasm
Extracellular
Space

other
other

-2.05

Extracellular
Space
Plasma
Membrane
Cytoplasm
Plasma
Membrane

peptidase

-2.03

Nucleus

-2.02

Plasma
Membrane

liganddependent
nuclear
receptor
transcription
regulator

-2.04
-2.03
-2.03
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other

GPCR
other
ion channel

GRIN1

GRM1
FSHR
PKIG

CDK5R1
REN

glutamate receptor,
ionotropic, N-methyl Daspartate 1
glutamate receptor,
metabotropic 1
follicle stimulating
hormone receptor
protein kinase (cAMPdependent, catalytic)
inhibitor gamma
cyclin-dependent kinase 5,
regulatory subunit 1 (p35)
renin

-2.01

Plasma
Membrane

ion channel

-2.01

GPCR

-2.01

Plasma
Membrane
Plasma
Membrane
unknown

-2.01

Nucleus

kinase

-2.01

Extracellular
Space

peptidase

-2.01

GPCR
other

Table 8-3 : Genes associated with cardiac function
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Discussion

The repair of ventricular tissues, following ischemia can lead to an improvement in
the quality of life in patients suffering from chronic heart failure. Various studies have
focused on the need for angiogenesis in ischemic tissue, in order to stimulate hibernating
myocardium and provide for cardiac functional benefit.12,34,48 However, the application of
mesenchymal stem cells delivered peri infarct, as a response to the MSC homing factor,
monocyte chemoattractant protein-3 (MCP-3) led to a significant improvement in cardiac
benefit, without any improvement in angiogenesis, or the differentiation of MSCs to
cardiac myocytes in the infarct tissue.52 Therefore, in order to understand the molecular
mechanisms involved, and to identify lead paracrine factors responsible for reverse
ventricular remodeling, we analyzed these tissues for all up and down regulated genes,
following MSC therapy, using microarray studies.
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We approached the microarray

analysis data with two different aspects, one primarily to look for secreted proteins in the
tissue based on fold changes and p-values, and another to look for specific proteins
associated with cardiovascular functions, based on p values and interactions between the
differentially expressed genes.

Secreted proteins in the treated group were based on the location of these proteins, in
the extra cellular space. We identified 6 secreted proteins that were differentially
expressed with a fold change of greater than 2. Among these proteins, two were
upregulated, and we looked at these 2 genes, Leukemia inhibitory factor, is a gene that
promotes proliferation of cells, but there hasn’t been any studies to see its effect on
cardiac benefit. However, PSG-18 (pregnancy specific glycoprotein 18) has been shown
to induce a cardioprotective protein IL10.207 IL10 has been implicated in heart failure to
promote cardiac functional benefit, by preventing the infiltration of macrophages.208,209
However, on studying the expression of PSG-19 based on RT PCR analysis between all
the groups, we did not obtain any conclusive evidence of this being a differentially
expressed gene between all the groups.

Differentially expressed genes, associated with cardiovascular functions, were then
analyzed based on pathway analysis networks. Network studies allow us to understand
the interactions between the various genes and the role they play within the various
pathways that they are involved in.165, 166 This data is provided by literature from previous
studies performed and uploaded onto the software. However, the lack of a complete
library does not provide accurate and updated information, but can still provide various
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leads that can be pursued in order to understand the molecular pathways associated with
reverse ventricular remodeling.147 A list of the complete genes, as obtained from the
pathway analysis software has been provided. Some of the upregulated genes have been
shown to provide cardiac benefit and some have been shown to increase the risk involved
with the disease, and circulating levels of these proteins are used as diagnostic markers
for the disease. Some proteins, such as macrophage migration inhibition factor (MIF),
and interferon gamma (IFNg) have been shown to increase the risk for heart failure.210, 211
Other proteins such as SFRP-4 (secreted frizzled receptor protein 4) promotes cardiac
protection by reducing fibrosis size in ischemic models,54, 212 MEF2b (myocyte enhancer
protein 2b) is essential for heart development,213 CLEC11A, also known as SCGF (Stem
cell growth factor) is secreted and is required by an autocrine process responsible for the
proliferation of hematopoietic stem cells,214 VEGf (Vascular endothelial growth factor) is
responsible for angiogenesis in infarct tissues,215 GLRX3 (glutaredoxin 3) reduces the
risks involved with cardiac failure in diabetic mice,
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and CAV3 (caveolin 3)

overexpression has been studied as a means to provide cardiac protection.217 Taking cue
from the various studies performed earlier, and correlating them to this cardiovascular
gene list provided by this study, we are able to identify novel molecular mechanisms
involved in reverse ventricular remodeling.

This study paves the way for future studies, where these specific genes can be
focused on for ventricular repair, and can be validated by protein and RT PCR analysis.
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CHAPTER IX

SUMMARY AND CONCLUSIONS
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SUMMARY AND CONCLUSIONS

Overall, we have developed and designed a gene drug that can provide significant
improvements in cardiac function, capable of translating to a clinical setting. We have
engineered a delivery package, using nanoparticlulate carriers with homing ligands,
capable of targeting the polymeric carrier to ischemic tissues. We have analyzed
pathways responsible for reverse ventricular leads and have paved the way for future
research responsible for improving the quality of life in patients, by inducing the reversal
of ventricular remodeling. The conclusions and outcomes, based on in vivo and in vitro
studies, as elucidated by previous chapters above, are outlined here.

We investigated the use of optical imaging as a tool for detecting gene expression
studies. We used a Luciferase gene, one that emits chemiluminescence in the presence of
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an i.p. injection of luciferin, as our gene of interest for the bioluminescence studies in
chronic heart failure rodent models. The chemiluminescence emitted was quantified and
analyzed in order to understand the genetic profile of this plasmid.

We noticed the changes in expression profiles, with the use of enhancer elements in
the gene design, thus correlating to the boosts in gene expression. Utilizing a cooled
camera to detect bioluminescence can help understand the genetic profile in gene therapy
and eliminate the need for complicated bioassays.

We designed a gene vector with enhancer elements, supported from the expression
data collected by the bioluminescence studies and used this vector to now express the
hSDF-1 gene, responsible for providing cardiac benefit in ischemic myocardium

We observed the improvements in cardiac function, in vivo and its correlation to the
expression profiles, and were able to design a gene vector, capable of delivering the SDF1 gene to ischemic myocardiums and provide sustained benefit, lasting up to 2 months
following therapy.

We investigated the mechanism by which SDF-1 gene transfer provides cardiac
benefit and attributed that to improved angiogenesis in the infarcted region of the cardiac
tissue. We also observed a reduction in fibrosis area, but this did not correspond to the
amount of benefit.
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Employing phage panning techniques, we identified a targeting ligand out of
millions of peptides that is specific to the infarcted region of the heart. This ligand was
determined to be a 7 mer sequence of RQPRMKR.

We synthesized this peptide and tagged it with a fluorescent tag, to be able to view it
with optical microscopy. This peptide is specific to the heart and not other organs.

We engineered nanoparticles made with polymeric PLGA and investigated the
distribution patterns, uptake and release, in vitro, in cardiac fibroblasts and in vivo in
chronic heart failure rodents. We identified the uptake to happen in the first one hour
after the addition of particles, and continued release for up to 24 hours post addition, in
culture dishes.

The role of the size of particles was determined, when we observed that size and
uptake was inversely co related. The addition of larger particles (un sonicated ones)
mediated lower uptake than sonicated, smaller sized particles.

The presence of targeting peptides did not affect the amount of uptake in cells
growing on culture plates specifying its role in targeting of the particles, and not in cell
penetration.

In vivo studies with nanoparticles, in rodents with chronic heart failure, determined
the role of targeting peptides. More particles, with targeting peptides, released the dye in
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the infarcted region as compared to particles without the targeting peptide. The non
targeting particles were found flushed away from circulation, into the liver.

To determine novel pathways responsible for ventricular remodeling, we
investigated the role of mesenchymal stem cells with whole genome analysis. Whole
genome analysis was able to provide accurate and detailed information, regarding all the
pathways and nodal genes, up regulated due to stem cell therapy.

The recruitment of mesenchymal stem cells by monocyte chemoattractant protein-3,
late after acute myocardial infarction, was able to provide cardiac benefit in function, due
to paracrine effects.

We identified a list of differentially expressed genes responsible for ventricular
remodeling. Some of these genes have been studied to provide cardiac benefit.

Overall, we have developed a non viral gene therapy based delivery of h-Stromal
derived cell factor -1 plasmid to benefit regeneration of cardiac myocardium due to
improved angiogenesis. We have developed a carrier system, capable of transporting this
gene, via the circulation, to the area of injury, in the heart, and deliver the drug gene. We
have paved the way for new research in cardiac regeneration by identifying novel
pathways responsible for reverse ventricular regeneration.
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Significance and Clinical Impact

This study has identified a key gene drug responsible for providing benefit to the
myocardium. On the other hand, we have designed and optimized this drug to sustain
long enough and translate clinically viable quantities of protein in order to provide
significant benefit long after the loss of gene expression. We have been able to able to
verify our findings, and develop a method for improvement in cardiac function without
the use of any cell types, or viral particles involved. This principle and gene and vector
design can now be extended to larger animals and clinical populations towards AMI
leading to CHF patients.

As mentioned above, over 10% of the US population over the age of 65 years has the
diagnosis of congestive heart failure (CHF). The majority of the patients have CHF due
to a history MI. These findings could be particularly useful in treating these patients.

Apart from the drug design we have identified a nanoparticulate carrier system,
capable of encapsulating this drug. If we are able to verify these findings and extend this
system towards targeted and effective drug delivery to ischemic cardiac tissue, this will
eliminate the need for painful surgeries and will provide an easier yet effective strategy to
treat the older populations, for whom, surgery may be a cause for risk.
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Future Directions

This study has provided an extensive insight into the design and delivery of gene
drugs to the myocardium. However, we anticipate that the future studies will be in many
aspects. One will bring about extensive research in utilizing gene therapy without the use
of viral or cellular delivery methods not only for cardiovascular but in all areas of gene
therapy.

Another aspect will be to utilize this novel engineered nanoparticle delivery
mechanism for any delivery of drug or gene to an ischemic myocardium. This will pave
the way for future studies of taking these findings of this experiment into studies
involving larger animals and into the clinical populations.

A third aspect will be to study defined cardiac pathways and genes identified by the
microarray study and launch into a series of experiments involving animal studies and
protein analysis to identify nodal proteins responsible for reverse ventricular remodeling.
These proteins can then be packaged into the nanocarriers identified above, in a vector
design as constructed above, in order to come up with more effective strategies for the
repair of cardiac tissue following ischemic damage.
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